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Genetics of Cerebral Small Vessel Disease  -  Rhea Yan Ying Tan 
Cerebral small vessel disease (SVD) is a leading cause of stroke and vascular dementia. The 
majority of cases are sporadic, occurring in the elderly hypertensive population. However, 
there also exist patients with familial disease. The most common form is Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), caused 
by mutations in the NOTCH3 gene. In recent years, other genes have also been found to cause 
familial SVD, such as COL4A1/A2, HTRA1, FOXC1 and TREX1. Genome wide association studies 
(GWAS) have also revealed loci associated with sporadic SVD strokes and its related features. 
This thesis explores the genetic basis of SVD primarily from the angle of the ‘one gene, one 
disease’ hypothesis. We explore the phenotype of familial SVD using CADASIL as a prototype. 
We next adopt a candidate gene approach to rare variant discovery using high throughput 
sequencing (HTS) techniques in two forms: 1) a multi-gene sequencing panel to examine the 
presence of rare variants in a cohort of 993 presumed-sporadic, early-onset SVD stroke 
patients, and 2) whole genome sequencing in 118 pedigrees with suspected familial SVD. We 
also evaluate the prevalence of known disease-causing mutations in the general population 
using a cohort of whole genome sequenced non-SVD patients, and other control databases. 
We demonstrate that a few presumed-sporadic SVD stroke patients may in fact have familial 
disease that was not previously diagnosed. We show that known and novel rare variants in 
candidate genes are found in our cohort of familial SVD patients, and suggest a possible role 
for rare variants in genes associated with related phenotypes and sporadic disease in this 
cohort. Finally, we identify known disease-causing variants in relatively high frequencies in 
the population, and show that conclusions on the pathogenicity of variants based on allele 
frequency and functional analyses may sometimes be misguided, thus highlighting the 
current limitations we face in the clinical interpretation of variants identified on HTS.  
In recent years genetic studies have revealed that pathways in different familial diseases are 
likely to converge in the pathogenesis of sporadic disease. Further uncovering the genetic 
basis of undiagnosed cases of familial SVD may shed light on the mechanisms underlying the 
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Cerebral small vessel disease is an umbrella term which broadly describes the disease of small 
blood vessels in the brain. It encompasses two categories of disease: arteriosclerotic SVD 
arising mainly from hypertension and other cardiovascular risk factors, and cerebral amyloid 
angiopathy (CAA). Arteriosclerotic SVD, which is the focus of this thesis, is a major cause of 
ischaemic stroke and vascular dementia.  
Among the subtypes of stroke, the mechanisms of SVD are perhaps the least understood. 
Genetic studies of SVD, as well as the study of inherited forms of SVD, are beginning to give 
us insights into possible mechanisms that underlie the disease in general. This thesis aims to 
contribute to our understanding of the underlying pathophysiology of SVD by exploring the 
genetic basis of the disease. 
The following chapters will examine the genetics of SVD by considering the role of single genes. 
Beginning with a monogenic disease, Cerebral Autosomal Dominant Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a ‘model’ of SVD, it goes on to 
examine rare variants in multiple candidate genes in patients with presumed ‘sporadic’ SVD. 
Finally, it explores the role of rare variants in candidate genes in families with suspected 
familial SVD, and investigates the presence of known monogenic disease mutations in the 
general population.  
The chapters are briefly summarised as follows:  
Chapter 1: Introduction. This chapter is a review of the monogenic causes of SVD and the 
overlapping mechanisms underlying these diseases. This review brings together recent data 
from studies in monogenic SVD and genetic studies in ‘sporadic’ SVD. It aims to show how 
these provide new insights into the pathogenesis of SVD, and highlights the possible 
convergence of disease mechanisms in monogenic and sporadic SVD.  
Chapter 2: Materials and Methods 
Chapter 3: Migraine, encephalopathy and stroke and their inter-relationships in CADASIL. 
This is a cross-sectional study of a cohort of patients diagnosed with CADASIL.  
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Chapter 4: A candidate gene study in presumed sporadic SVD. This chapter explores the 
hypothesis that monogenic disease genes also have a role in sporadic SVD strokes, using a 
next generation sequencing platform.  
Chapter 5: Rare variants in suspected familial SVD: a candidate gene approach using whole 
genome sequencing. This chapter examines the prevalence of rare variants in known SVD 
genes, and other candidate genes associated with related phenotypes such as leukodystrophy, 
familial hemiplegic migraine, connective tissue disease and cerebral amyloid angiopathy in a 
cohort of patients who are suspected to have monogenic SVD.  
Chapter 6: Frequency of known disease-causing mutations in control populations. In a 
population of unrelated controls, the prevalence of known disease-causing mutations is 
evaluated using whole genome sequencing. This section explores the question of whether 
known ‘mutations’ are truly fully penetrant disease-causing variants, or are part of a 
‘background carrier rate’, and in fact require other genetic or environmental factors in order 
to cause disease.  




1.2. Stroke and Cerebral SVD 
A stroke is defined as the acute onset of focal neurological disturbance arising due to a 
cerebrovascular cause, either confirmed on histology or on imaging, where other causes have 
been excluded.1 Although historically understood to be a single entity, it is now recognised 
that stroke is a broad term describing the acute culmination of multiple disease processes, 
each of which can lead to either ischaemic (80%) or haemorrhagic (20%) events.2  
The three most common causes of ischaemic strokes are large vessel atherosclerotic disease 
(LVD), cerebral small vessel disease (SVD) and cardioembolic causes. Other rare causes 
include cervical artery dissection or vertebral artery dissection, while up to a quarter of 
ischaemic strokes may remain cryptogenic with no underlying cause identified3 Haemorrhagic 
strokes are typically classified according to their location in the brain, with subcortical or deep 
haemorrhages arising due to hypertensive cerebral small vessel disease, and lobar or cortical 
bleeds arising due to cerebral amyloid angiopathy (see 1.2.2) or cerebrovascular 
abnormalities such as arteriovenous malformations.  
1.2.1. Arteriosclerotic SVD 
SVD arising from arteriosclerosis of the small perforating arteries supplying the white matter 
and deep grey matter of the brain accounts for up to a fifth of ischaemic strokes, and is also 
an important cause of haemorrhages occurring in the subcortical or deep regions of the brain 
(deep intracerebral haemorrhage, ICH). It is also the most common cause of vascular cognitive 
impairment and vascular dementia, which is the second most common cause of dementia.4   
This type of SVD is characterised radiologically by the following features best seen on MRI: 
lacunar infarcts of presumed ischaemic origin, symptomatic subcortical haemorrhage, white 
matter hyperintensities (WMH) on T2-weighted/FLAIR MRI, which also corresponds to low 
signal on CT described as leukoaraiosis, cerebral microbleeds on gradient echo MRI, dilated 
perivascular spaces and brain atrophy.5  On histopathological examination the deep 
perforating arteries in non-amyloid SVD show features of focal atherosclerosis both at the 
origin of and within the proximal perforating arteries, as well as diffuse abnormalities in the 
small perforating vessels. These include fibrinoid necrosis and lipohyalinosis, where the 
smooth muscle cells are replaced with collagen, amyloid and other hyaline material, leading 
to narrowing of the vessel lumen.4,6  
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The majority of SVD strokes are thought to be sporadic, occurring in the elderly population 
with hypertension being the major risk factor. Despite its prevalence, the pathogenesis of SVD 
is poorly understood in comparison with the other types of ischaemic stroke. It is 
hypothesized that the histopathological changes of the small blood vessels as described 
above result in reduced cerebral blood flow7 and cerebral autoregulation,8 which in turn 
cause hypoperfusion, and this has been demonstrated on imaging studies. Endothelial 
dysfunction has also been found to feature early in the disease, and this may contribute to 
the impairment of cerebral autoregulation.9 
More recently it has been proposed that increased Blood Brain Barrier (BBB) permeability 
may play an important role in the development of SVD.10 Neuropathological studies have 
shown the presence of plasma proteins such as fibrinogen in the brain parenchyma, 
suggesting that there had been extravasation of these proteins across a transiently open 
BBB.11,12 Evidence of previous BBB disruption is also provided by cerebrospinal fluid (CSF) 
studies showing the presence of plasma proteins in the CSF.13 Further support is provided by 
recent MRI studies demonstrating leakage of contrast agents such as gadolinium across the 
BBB.14 It is likely that both hypoperfusion and increased BBB permeability interact, and 
endothelial dysfunction and activation could contribute to both. 
1.2.2. Cerebral amyloid angiopathy 
Cerebral amyloid angiopathy (CAA) is a term used to describe a number of cerebral 
vasculopathies which involve the deposition of amyloid fibrils in the walls of the small or 
medium cerebral blood vessels, as well as the capillaries of the brain parenchyma and 
leptomeninges.15 These depositions are altered proteins which have adopted a β-pleated 
sheet conformation. CAA is classically characterised by large lobar (cortical) haemorrhages, 
but can also cause transient behavioural changes, seizures and cognitive impairment leading 
to dementia. On MRI, patients often have a distinctive distribution of classical SVD features, 
such as WMH with a predominant posterior distribution, and cerebral microbleeds in the 
lobar regions as visualised on gradient-echo MR imaging.16 They may also have cortical 
superficial siderosis, a marker also used in the radiological diagnosis of CAA.17  Possible or 
probable CAA can be diagnosed in life based on the clinical syndrome and imaging features 
with the aid of the modified Boston criteria, and a definitive diagnosis can be made with the 
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demonstration of amyloid fibril deposition on post-mortem histopathological analysis.17 More 
recently, the Edinburgh criteria which uses CT and apolipoprotein Ɛ (APOE) genotyping to 
estimate the probability of CAA has also been proposed.18  
1.3. Genetics of Stroke 
The majority of strokes in general, and SVD strokes in particular, are thought to be ‘sporadic’, 
resulting from the interaction of multiple genetic and environmental factors. Early studies in 
animals,19 twins, affected sibling-pairs 20,21 and of familial aggregation of strokes suggested 
that stroke is highly heritable. These findings were also supported by findings from 
epidemiological studies looking at the family history of stroke 22 and genome-wide complex 
trait analysis studies using genome-wide data, which also showed that younger-onset strokes 
have a higher heritability23,24. Most of the variants identified in genome-wide association 
studies (GWAS) of ischaemic stroke have also been found to be specific to one subtype of 
stroke, providing further evidence that each subtype of stroke has a different aetiology and 
genetic background.23–26 For example, a locus at chromosome 7p21, in the region of the 
histone deacetylase 9 (HDAC9) gene was found to be associated with LVD stroke, and PITX2 
and ZFHX3 were identified in cardioembolic stroke.23  GWAS studies have also identified 
susceptibility loci for intracerebral haemorrhage (ICH), however these early studies in stroke 
did not identify genome-wide significant loci for SVD.27  
A growing body of evidence now suggests that genetic susceptibility is particularly important 
in ‘sporadic’ SVD. This includes epidemiological data showing that family history of stroke is a 
risk factor for SVD,28 and recent genome-wide association study (GWAS) data demonstrating 
a significant heritability for ‘sporadic’ SVD of the predominant lacunar ischaemic stroke sub-
phenotype.29 More recent GWAS findings in SVD are discussed in sections 1.4 and 1.6. 
There are also both hereditary and sporadic forms of CAA. CAA also typically occurs as a 
sporadic disease in the elderly population, with the deposition of amyloid beta (Aβ) protein 
in the walls of the blood vessels being the most common form. It is thus commonly associated 
with parenchymal Aβ plaques and Alzheimer’s disease.30 Like Alzheimer’s disease, the APOE 
genotype is a risk factor for sporadic CAA and CAA-related intracerebral haemorrhage (ICH). 
The Ɛ2 genotype is associated with the presence of CAA, and both the Ɛ2 and Ɛ4 genotypes 
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are associated with an increased risk of lobar ICH, recurrent lobar ICH and an earlier age at 
onset of lobar ICH.31 
1.3.1. Monogenic causes of stroke 
Strokes may also present as a feature of monogenic disease. Most inherited forms of stroke 
cause a specific stroke syndrome due to a single mechanism, however some syndromes may 
lead to strokes through more than one mechanism. Tables 1-1 and 1-2 summarise the known 




Table 1-1: Monogenic disorders causing ischaemic stroke, classified according to the stroke subtype 
they result in. The list is not exhaustive but includes examples of the major stroke subtypes.  












Retinal Vasculopathy with Cerebral 







COL4A1/A2 –related small vessel arteriopathy with 







Cerebral microangiopathy, leukoencephalopathy 
with calcifications and cysts (LCC) 
 
#614561 






























































Stroke subtype Monogenic disorders OMIM 
Cardioembolism Familial cardiomyopathies 
Familial arrhythmias 
 
>40 different types 





Factor V Leiden 
 
#612309 
Prothrombin (F2), Protein S (PROS1), Protein C 








Mitochondrial myopathy, Encephalopathy, Lactic 







Table 1-2: Monogenic disorders causing haemorrhagic strokes.  
Stroke subtype Monogenic disorders OMIM 
Small vessel 
disease 














































• Hereditary haemorrhagic telangiectasia 
 
#187300 














Syndromes marked with a * predominantly cause haemorrhagic strokes, but may also cause ischaemic 
strokes. 
1.3.2. Monogenic causes of SVD 
1.3.2.1. Monogenic diseases which cause ischaemic stroke 
SVD is the subtype of stroke that is most likely to present as a familial disease.4  There are 
several monogenic forms of SVD, which not only recapitulate the clinical, radiological and 
histopathological features of classical sporadic SVD, but may also have other distinctive 
neurological or non-neurological features. (Table 1-3 and Table 1-4) Although rare, these 
extremes in phenotype share both clinical and radiological features with sporadic SVD, and 







Table 1-3: Monogenic disorders with strokes arising from SVD as a major clinical feature 
Disease (OMIM #) Gene(s) and 
chromosome 
Gene products and 
function 
Key clinical features Inheritance mode, 
mutations 

















• Migraine with aura 
• Subcortical ischaemic stroke 
• Psychiatric disturbance 








in exons 2 – 24 
• WMH involve anterior temporal 
poles and external capsules 
• Granular Osmiophilic Material 
(GOM) surrounding smooth 
muscle cells of systemic small 
vessels  
• Diagnosis with skin biopsy or 















factor β pathway33 
 
• Subcortical ischaemic strokes 
• Cognitive impairment 
• Early-onset diffuse alopecia 
• Degenerative disc disease 
Autosomal recessive 
and dominant missense 
and nonsense 
mutations 
Diagnosis on molecular genetic testing 
CARASAL: Cathepsin A 





Cathepsin A. Has 








regulates a lysosomal 








• Subcortical ischaemic and haemorrhagic 
strokes 
• Dry mouth, difficulty swallowing, dry 
eyes, muscle cramps 
• Cognitive impairment 











Disease (OMIM #) Gene(s) and 
chromosome 
Gene products and 
function 
Key clinical features Inheritance mode, 
mutations 
Key diagnostic or radiological features 





Alpha 1 and Alpha 2 
chains of collagen IV. 
Encode α1 and α2 
collagen chains, 
which are the most 
abundant 





• Infantile hemiparesis 
• Developmental delay 
Adult: 
• Subcortical ischaemic and haemorrhagic 
strokes 
• Cognitive impairment 
• Retinal small vessel abnormalities 
Systemic: 
• Renal cysts, haematuria 
• Muscle cramps with raised creatine 
kinase 
• Cerebral aneurysms 
 
Autosomal dominant 
and recessive missense 
and nonsense 
mutations, most 
commonly affecting Gly 
in Gly-X-Y repeats 
• Significant subcortical 
microbleeds on MRI 
• Periventricular cysts 









Three prime repair 
exonuclease. 
Encodes DNase III 
(Three prime repair 
exonuclease), which 
has roles in DNA 
repair 36 
 
• Visual loss 
• Migraines 
• Subcortical ischaemic and haemorrhagic 
strokes  
• Cognitive impairment 
• [Hereditary systemic angiopathy in some 
patients: Raynaud’s phenomenon, 




frameshift mutations in 
C-terminus 
• Subcortical ‘pseudotumours’ – 
contrast-enhancing mass lesions 
with surrounding oedema 
• Diagnosis on molecular genetic 
testing 












right asymmetry of 
internal organs 38 
 
• Subcortical infarcts 
• Axenfeld Rieger Syndrome 
• Cerebellar malformations 
• Hearing impairment 
Autosomal dominant or 
de novo 6p25 deletions 
or duplications 







Disease (OMIM #) Gene(s) and 
chromosome 
Gene products and 
function 
Key clinical features Inheritance mode, 
mutations 
Key diagnostic or radiological features 
Cerebral microangiopathy, 
leukoencephalopathy with 
calcifications and cysts 
(LCC) and Coats plus 
syndrome (Coats disease + 
LCC) 
SNORD118 in 




(and not in 
LCC) 
Box C/D snoRNA U8. 






component 1. Has 
roles in maintaining 
telomere ends.  
LCC- exclusively neurological:  
• Seizures 
• Dystonia, spasticity, ataxia 
• Hemiplegia 
• Cognitive delay 
 
Coats plus– multisystem: 
• Features of LCC 
• Sparse pale hair 
• Skin depigmentation 
• Dysplastic nails 
• Intrauterine growth retardation 
• Retinal telangiectasias and exudates 








and complete gene 
deletion  
Leukoencephalopathy, calcification 
and cysts seen in LCC and Coats plus, 
but not Coats disease. 
 
Cysts not seen in all LCC patients 
 
Angiomatous blood vessels, gliosis and 
Rosenthal fibres in white matter 
Deficiency of ADA2 
(DADA2) 
CECR1 Adenosine 








• Intermittent fevers 
• Small subcortical ischaemic and 
haemorrhagic strokes 
• Raised acute phase proteins 








White matter relatively spared. 
Skin biopsies show neutrophils and 
macrophages in interstitium with 













Table 1-4: Monogenic disorders with strokes arising from both small and large artery disease as a clinical feature 
Disease (OMIM #) Gene(s) and 
chromosome 
Gene products Key clinical features Inheritance mode, 
mutations 









• Acute pain crises (small fibre peripheral 
neuropathy) 
• Ischaemic and haemorrhagic strokes 
• Renal failure 
• Angiokeratomas 
• Tortuous retinal vessels, whorl keratopathy on slit-
lamp exam 
• Dolichoectasia of intracranial arteries 
• Cardiomyopathy, hypertension  
• Lipid staining may show Gb3 ‘zebra bodies’ in 




• Biochemical diagnosis with 
low α-galactosidase in plasma 
and peripheral leukocytes 
(males) 











• Angina, hypertension, intermittent claudication, 
restrictive cardiomyopathy, mitral valve prolapse 
• GIT bleeding 
• Ischaemic strokes 
• Yellow popular skin lesions 
• Visual impairment, peau d’orange changes, angioid 
streaks on retina, neovascularisation and retinal 
haemorrhages 






Diagnosis only by molecular 





Neurofibromin • Neurofibromas, café-au-lait spots, freckling 
• Lisch nodules 
• Neurofibromas, Schwannomas 
• Dural ectasia 












The most common familial form of SVD is Cerebral Autosomal Dominant Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy (CADASIL), caused by mutations in the NOTCH3 
gene.39  These are cysteine-altering mutations (either a gain or loss of a cysteine residue) in 
the epidermal growth factor-like repeat (EGFr) domains encoded by exons 2 to 24 of the 
NOTCH3 gene.39 CADASIL is the most common inherited form of stroke, with an estimated 
population prevalence in the UK of about 2 to 4 per 100 000.40,41 A study of 994 apparently 
sporadic lacunar stroke patients aged ≤70 years found CADASIL mutations in 0.5%; this was 
higher (1.5%) in patients with confluent leukoaraiosis on MRI.42 
CADASIL is typically characterised by exclusively neurological features, the most prominent 
being migraine, subcortical ischaemic lacunar infarcts and cognitive impairment. Migraine, 
usually with aura, is the first symptom in 60-75% of patients, and usually arises in the second 
to third decade. The aura is typically visual or sensory, but can also be dysphasic. Confusion is 
not an uncommon aura, and may form one end of a spectrum with the encephalopathic 
presentation (further discussed in Chapter 3). The subcortical strokes tend to be ischaemic 
lacunar infarcts, with a mean age at onset of 47 years in a recent study, although the first 
stroke can occur as late as in the 70s.43  
Psychiatric disturbances, particularly depression and apathy, but also anxiety, are common, 
and depression often precedes other symptoms. Cognitive impairment, with early 
involvement of selective executive dysfunction and impaired processing speed is common in 
the fourth and fifth decades, and may progress to dementia.44 Some patients may present 
with dementia and without symptomatic strokes.45 Seizures, both focal and generalised, are 
rare but well described.44 
Patients may experience encephalopathic episodes (also known as a ‘CADASIL coma’), a 
reversible acute confusion or coma often with seizures usually developing from a migraine 
and lasting as long as 7 – 14 days.43 These may be susceptible to hormonal influences, 
occurring frequently around the puerperium.46 Spinal cord involvement is very rare but a few 
cases have been reported.47 A number of reports have also documented the occurrence of 
ocular involvement defined by retinal arteriolar narrowing on fundoscopy or fluorescence 




The earliest radiological features are patchy T2 white matter hyperintensities (WMH) up to 
15 years prior to the onset of symptoms, with patients typically having an abnormal MRI by 
age 35.51 As symptoms develop, this progresses to confluent WMH with characteristic 
involvement of the anterior temporal pole. (Figure 1-1) This feature is rare in sporadic SVD, 
but has been shown to have high sensitivity and specificity in CADASIL.52 Other MRI markers 
are seen in sporadic SVD, such as subcortical lacunar infarcts, microbleeds and dilated 
perivascular spaces, and cerebral atrophy.53 
Although commonly described as an exclusively neurological disease, a few case reports have 
documented co-existing renal abnormalities.54,55 The systemic small blood vessels also show 
distinctive histopathological features seen electron microscopy, with granular osmiophilic 
material (GOM) accumulating around the smooth muscle cells of blood vessels. GOM 
deposition gradually replaces the vascular smooth muscle cells, and occurs in both peripheral 
and CNS arteries, primarily in the leptomeningeal and small penetrating arteries.56 Electron 
microscopy for GOM in skin and muscle biopsies has been used in the diagnosis of CADASIL, 
in particular where patients have not tested positive on a screen for NOTCH3 mutation.56 
Patients can vary markedly in terms of the type of clinical features, their severity and the ages 
at onset, both between and within families.44,45,57 Disease severity is not thought to relate to 
mutation site,58 although a recent study in Dutch CADASIL patients has suggested the 
possibility of a more severe phenotype arising with mutations in EGFr domains 1 – 6, and a 
milder phenotype with mutations in other EGFr domains.59 Family-based studies suggest that 
other genetic factors may influence disease severity. Both hypertension and smoking have 
been associated with an earlier age at onset of stroke in CADASIL, while higher blood pressure 





Figure 1-1: Radiological features of CADASIL on MRI. White matter hyperintensities (WMH) involving 
the anterior temporal pole (A) and external capsules (B) are seen on T2/FLAIR MRI sequences. (C) 
Subcortical cerebral microbleeds can be seen in some patients on T2* Gradient Recalled Echo (T2* 
GRE) sequences.  
CARASIL 
An autosomal recessive form of familial SVD has also been described in consanguineous 
Japanese and Chinese families, and has been attributed to mutations in the HTRA1 gene.61 
This disease is known as Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts 
and Leukoencephalopathy (CARASIL), and is caused by the inheritance of a missense or 
nonsense mutation in each copy of the HTRA1 allele.62 It has been described in around 50 
individuals in Japanese and Chinese pedigrees showing consanguinity,62–64 and recently cases 
have also been described in Europeans with compound heterozygous or homozygous HTRA1 
mutations.65,66 A less severe form of the disease due to heterozygous mutations in the same 
gene has been described in Caucasian and Japanese populations.67,68 
Patients with CARASIL also develop SVD manifesting as recurrent subcortical ischaemic 
lacunar stroke, progressive cognitive and motor impairment, seizures and psychiatric 
disturbances including personality changes, emotional lability, abulia and apallic syndrome.62 
Unlike CADASIL, these patients also develop non-neurological symptoms including early-
onset diffuse alopecia and degenerative disc disease resulting in acute middle to lower back 
pain. Patients with CARASIL have a more rapid progression of symptoms, developing 
dementia and becoming bedridden by around 40 years.62 
On MRI, confluent hyperintensities in the deep white matter (WMH) and periventricular 




involvement of the anterior temporal poles and external capsules has also been documented 
in some patients.63 Histopathological features of CARASIL are similar to those seen in sporadic 
SVD, such as arteriopathy (loss of vascular muscle cells) arteriosclerosis (hyaline degeneration 
of the media), non-occlusive fibrous thickening of the intima, and fragmentation of the 
internal elastic lamina. No GOM deposits have been found.63,70–72 
RVCL-S 
Retinal vasculopathy with cerebral leukodystrophy and systemic manifestations (RVCL-S) is 
an autosomal dominant disease of the cerebral small vessels caused by frameshift mutations 
in the C-terminus of the TREX1 gene.73 RVCL-S was previously described as a number of 
discrete syndromes, which are now understood to have a common genetic aetiology and 
overlapping phenotypes: cerebroretinal vasculopathy (CRV),74,75 hereditary endotheliopathy, 
retinopathy, nephropathy and stroke (HERNS)75,76 and hereditary vascular retinopathy 
(HVR).73,75,77 
RVCL-S typically presents with progressive visual impairment in the fourth to fifth decades, 
secondary to retinal vasculopathy, neovascularization of the optic disc, retinal haemorrhages, 
macular oedema, microaneurysms and capillary obliteration. Fluorescein angiograms show 
telangiectatic capillaries and avascular areas in the retina.75 
Patients subsequently develop neurological features in the form of subcortical ischaemic 
strokes, TIAs, migraine, cognitive impairment, psychiatric abnormalities (such as personality 
disorders, depression and anxiety) and seizures, with a progressive decline to death around 5 
to 10 years after the onset of symptoms.75 
Some patients may also have systemic features, and this disease variant was initially 
described as hereditary systemic angiopathy (HSA). These patients develop systemic small 
vessel vasculopathy resulting in the premature infarction and necrosis of tissue, manifesting 
as Raynaud’s phenomenon, hepatic micronodular cirrhosis, renal dysfunction and 
osteonecrosis.78,79 
In addition to typical MRI features of SVD, some of these patients were also reported to have 
contrast-enhancing mass lesions in the deep white matter of the cerebrum and cerebellum. 
Also known as pseudotumours, these masses are associated with surrounding vasogenic 




is not sensitive for RVCL.80 Histopathologically these tumours are found to have areas of 
coagulative necrosis secondary to obliterative vasculopathy.73 These areas are surrounded by 
oedematous white matter with prominent reactive astrogliosis similar to that seen in 
radiation necrosis. The small vessels are often occluded by fibrin thrombi, with thickened 
fibrotic walls and a distinctive multilamellar subendothelial basement membrane.73 
COL4A1/A2 related arteriopathy 
A spectrum of conditions with both paediatric and adult onset of neurological and systemic 
features has previously been described as four separate syndromes: autosomal dominant 
Type I Porencephaly brain SVD with haemorrhage, brain SVD with Axenfeld-Rieger Anomaly 
and Hereditary Angiopathy with Nephropathy, Aneurysms and muscle Cramps (HANAC 
syndrome). (Table 1-5) These were later found to be attributable to mutations in the same 
gene, COL4A1, which encodes the Type IV collagen α1 chain.81  
COL4A1 arteriopathy was first described in infants with porencephaly, infantile hemiparesis 
and developmental delay, as well as intracerebral haemorrhages associated with trauma and 
anticoagulation.82 A mouse model of COL4A1 mutations developed intracerebral 
haemorrhages during birth, which was avoided by caesarean section, lending support to the 
suggested association between haemorrhage and head trauma in the perinatal period.83 
More recently, it has been recognised that COL4A1 mutation carriers may present for the first 
time in adulthood with subcortical intracerebral haemorrhages and ischaemic lacunar infarcts, 
as well as WMH on MRI and microbleeds on T2* sequences.82 (Figure 1-2) Other neurological 
features include seizures, cognitive impairment progressing to dementia and visual loss. 
Patients with visual loss also show marked tortuosity of the medium and small retinal 
arterioles and venules alongside retinal ischaemic changes.84 Systemic involvement has also 
been described, such as renal agenesis, muscle and cardiac symptoms as well as Raynaud’s 
phenomenon.81 The phenotypes seen in COL4A1 angiopathy vary widely, and the age at onset 
and phenotype can vary markedly between members of the same family.81  
On neuroimaging, patients may have periventricular fluid-filled cysts involving subcortical 
structures in the brain (porencephaly).82 Aneurysms may also be seen at the intracranial 
portions of the internal carotid artery.82 WMH are also found in the posterior periventricular, 




spaces are mainly seen in the basal ganglia, while microbleeds are prominent and found both 
in the subcortical region and cortical-subcortical junction.82 On post-mortem examination 
these patients had thickening and focal disruptions of capillary basement membranes, and 
dissociated smooth muscle fibres with abnormal spreading of the basement membrane at the 
dermo-epithelial junction and kidney tubules.85 
Mutations in the COL4A2 gene at the same chromosomal locus have also been found to cause 
a similar phenotype of cerebral SVD manifesting as recurrent intracerebral haemorrhage, 
infantile porencephaly, congenital hemiplegia, intracranial aneurysms, nephropathy and 








Table 1-5: Clinical syndromes in COL4A1-related SVD.  
 Autosomal Dominant Type I 
Porencephaly  
HANAC Syndrome Brain SVD with haemorrhage Brain SVD with Axenfeld 
Rieger anomaly 
Walker Warburg Syndrome 
Inheritance Autosomal dominant Autosomal dominant 
 
Autosomal dominant Autosomal dominant Autosomal recessive 
Clinical 
features  
• Perinatal haemorrhage with 
porencephaly 
• Renal – microscopic or 
gross haematuria, renal 
cysts, mild renal failure 
• Muscle cramps –raised CK 
• Visual loss – retinal artery 
tortuosity or haemorrhage  
• Raynaud’s phenomenon 
• Supraventricular 
arrhythmia 




• Intellectual disability 
leading to dementia 
• Dystonia 
• Strokes and TIAs  
• Migraine 
• Ocular involvement: 
retinal arteriolar 
tortuosity, cataracts, 
glaucoma, ocular anterior 
segment dysgenesis 
(Axenfeld Rieger anomaly) 
• Muscle cramps 
• Raynaud’s phenomenon 
• Kidney defects 
• Cardiac arrhythmia 
• Ocular dysgenesis 
• Neuronal migration 
defects 
• Congenital muscular 
dystrophy – hypotonia or 
severe myopathy leading 
to fatal respiratory 
insufficiency 




Small vessel disease • Small vessel disease 
(usually asymptomatic) 
• Large artery disease – 
unruptured intracranial 
aneurysms of carotid 
siphon (usually 
asymptomatic) 
Small vessel disease • Large vessel disease – 
aneurysms of intracranial 
segment of internal 
carotid artery 
• Small vessel disease 










• Diffuse white matter 
hyperintensities 
• White matter 
abnormalities sparing 
temporal lobe and arcuate 
fibres 
• Single or multiple 
aneurysms localized on 
carotid siphon  











• Thickening of basement 
membrane of capillaries  
• Abnormal thickening, 
multilamination and focal 
disruption of basement 
membranes in kidney and 
skin  
• Dissociation of vascular 
smooth muscle cells 
  Cerebral cortical malformation 









Figure 1-2: MRI appearances in two patients (A-C and D-F) with COL4A1 mutations. T2/FLAIR 
sequences show confluent white matter hyperintensities (A,B,D). T2* GRE sequences show cortical-
subcortical microbleeds (C,F) and a previous haemorrhage (E,F)  
 
FOXC1-PITX2 deletion or -duplication related SVD 
The forkhead box transcription factor 1 (FOXC1) gene on chromosome 6p25 encodes a 
member of the winged/helix forkhead family of transcription factors. FOXC1 was initially 
identified as the causative gene for Axenfeld-Rieger Syndrome (ARS) and cerebellar 
malformations in patients with chromosome 6p25 copy number variations.88 Patients with 
ARS present with ocular abnormalities such as anterior segment dysgenesis and early-onset 
glaucoma, as well as non-ocular features such as systemic dysmorphisms and dental and 
umbilical abnormalities.88 This often overlaps with another phenotype known as the Dandy 





In multiple case reports of patients with 6p25 deletions, individuals with ARS and other 
developmental abnormalities were also found to have WMH from as early as 18 months of 
age.90 A meta-analysis and study of expression quantitative trait loci (eQTL) in GWAS data 
from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
Consortium later demonstrated that three single nucleotide polymorphisms (SNPs) 
associated with WMH strongly influenced FOXC1 transcript levels, and that 18 out of 18 
patients with FOXC1-related ARS also showed MRI evidence of SVD.91 Experimental 
overexpression and suppression of the FOXC1 gene in zebrafish also led to cerebral 
haemorrhage, lending further support for the gene’s independent involvement in 
cerebrovascular disease.91 
FOXC1 interacts with paired-like homeodomain transcription factor 2 or pituitary homeobox 
2 (PITX2) a developmental transcription factor expressed in the neural crest. Mutant forms of 
PITX2 also cause ARS, and ARS patients with PITX2 mutations have also shown features of SVD 
on brain imaging.91  
Deficiency of ADA2 (DADA2)  
Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease first 
described in children aged 3 to 6 years old. These children presented with intermittent fevers, 
recurrent strokes, elevated levels of acute phase reactants, livedoid rash, 
hepatosplenomegaly and hypogammaglobulinaemia – a syndrome not unlike that seen in the 
sporadic autoimmune vasculitic disease described as Sneddon syndrome.92 
These patients all suffered small subcortical ischaemic or haemorrhagic strokes before the 
age of 5 during acute episodes of inflammation, with or without fever. On MRI these strokes 
were found to involve the subcortical white matter, brain stem, basal ganglia and thalamus, 
however there was no evidence of WMH. Skin biopsies showed a predominance of 
neutrophils and macrophages in the interstitium with perivascular T lymphocytes and no 
overt vasculitis.  
Whole exome sequencing on 9 patients and their unaffected parents was performed and a 
candidate gene was identified under a recessive model of inheritance – the Cats Eye 
Syndrome Chromosome Region Candidate 1 (CECR1) gene encoding adenosine deaminase 2. 




CECR1 gene, and were demonstrated to have a deficiency of the ADA2 enzyme.92 
Haematopoietic stem cell transplantation has been suggested as a possible therapeutic 
option, showing success in at least one patient.93  
Cerebral microangiopathy, leukoencephalopathy with calcifications and cysts (LCC) 
Cerebral microangiopathy, leukoencephalopathy with calcifications and cysts (LCC) was first 
described in children presenting with neurological features such as dystonia, ataxia, spasticity, 
hemiplegia and cognitive delay. These patients were found to have cerebral white matter 
disease, intracranial calcifications in the white matter, basal ganglia and thalamus, as well as 
cysts within the hemispheres, basal ganglia or thalamus, some of which resulted in 
obstructive hydrocephalus.94 Subsequently, similar features were reported in adults.95,96  
Histopathological features of LCC include the small, tortuous ‘angiomatous’ appearance of 
small cerebral blood vessels, together with glial changes, Rosenthal fibres, microcalcifications 
and microhaemorrhages.97  
A study of 40 patients with LCC, mostly of European ancestry, found homozygous or 
compound heterozygous mutations in the SNORD118 gene in 33 of these pedigrees. The 
SNORD118 gene encodes a non-protein-coding RNA involved in ribosome biogenesis, Box C/D 
small nuclear RNA (snoRNA) U8. 
There is significant phenotypic overlap between LCC and Coats disease, a multisystem 
disorder which typically presents with non-neurological features such as skin depigmentation, 
dysplastic nails, sparse pale hair and intrauterine growth retardation. Classic features of Coats 
disease are retinal telangiectasias and exudates. Patients with features of both Coats disease 
and LCC have been described as having ‘Coats plus’ syndrome or Cerebroretinal 
Microangiopathy with Calcifications and Cysts 1 (CRMCC1),98 although LCC and CRMCC1 are 
considered distinct diseases with different genetic aetiologies,99 with mutations in the CST 





1.3.2.2. Monogenic diseases which cause haemorrhagic stroke 
COL4A1/A2-related arteriopathy (as described above), and cerebral amyloid angiopathy (CAA) 
may present with intracerebral haemorrhage. Haemorrhagic strokes in COL4A1/A2-related 
disease typically occur in the subcortical areas (deep intracerebral haemorrhage), while 
haemorrhages arising due to CAA tend to be in the cortex (‘lobar’).  
Hereditary cerebral amyloid angiopathy 
Several large founder families have been identified as having a hereditary form of CAA, with 
an autosomal dominant pattern of inheritance. The majority of cases are due to the 
deposition of amyloid beta (Aβ), derived from the amyloid precursor protein (APP), which is 
encoded on chromosome 21.101 Aβ- and non-Aβ-type hereditary CAA may also co-occur in 
familial Alzheimer’s disease caused by mutations in APP, PSEN1 (Presenilin1) and PSEN2 
(Presenilin2) genes.102  
Different forms of hereditary CAA have been described, and these have overlapping clinical 
features. A common feature of most hereditary CAA cases is cerebral SVD resulting in small 
cortical infarcts and recurrent lobar intracerebral haemorrhages. Patients also tend to 
develop cognitive decline progressing to dementia. Some patients may also experience 
movement disorders. The key clinical features described, and genes implicated in different 







Table 1-6: Genes and key clinical features in hereditary cerebral amyloid angiopathy (CAA) and related amyloid disorders 







Clinical and pathological features References 
APP HCHWA-Dutch 605714 c.693G>C Amyloid beta 
(Aβ) 
• Haemorrhagic strokes 
• Ischaemic strokes 
• Expressive dysphasia 
• Personality changes 
• Myoclonic jerks 
• Cognitive impairment leading to dementia 
• Seizures 
• Parenchymal plaques 












HCHWA-Iowa c.694G>A 107 
HCHWA-Arctic c.693A>G 108 
CST3 HCHWA-
Icelandic 





• Haemorrhagic strokes 
• Dementia 
• Involvement of leptomeninges, cerebral cortex, basal ganglia, brainstem, cerebellum 
• Peripheral tissue involvement: lymphoid organs, skin 
109 
ITM2B (BRI2) Familial British 
Dementia 





• Ischaemic and haemorrhagic strokes 
• Spastic tetraparesis 
• Dementia 
• Parenchymal amyloid and preamyloid plaques 
• Involvement of leptomeninges, cortical, subcortical regions, brainstem, cerebellum and 














• Ischaemic and haemorrhagic strokes 
• Cerebellar ataxia 
• Paranoid psychosis leading to dementia 
• Cataracts 
• Deafness 
• Parenchymal plaques with co-deposition of Aβ 
• Involvement of leptomeninges, cortical and subcortical regions, brainstem, cerebellum 



























• Sensorimotor and autonomic polyneuropathy 
• Intracerebral haemorrhage 
• Dementia 
• Psychosis 
• Visual impairment 
• Motor paresis or ataxia 
• Deposition of ATTR in vitreous, leptomeninges, meningeal blood vessels 
 
112 


















• Corneal lattice dystrophy 
• Polyneuropathy (cranial and peripheral nerves) 
• Autonomic dysfunction 
• Dermatologic features e.g. cutis laxa 
• Renal involvement 













• Parenchymal perivascular PrP deposition 





1.4. The role of the extracellular matrix in the pathogenesis of SVD: 
insights from monogenic SVD 
Recent data from genetic studies in both monogenic and ‘sporadic’ SVD are beginning to shed 
light on possible shared molecular mechanisms that may be important in the disease, 
including a key role for abnormalities in the extracellular matrix (ECM), or ‘matrisome’ 
proteins in the pathogenesis of the disease. The ECM is the non-cellular component of tissues 
made up of water, proteins and polysaccharides. It provides scaffolding for cellular 
components by producing fibrous proteins such as collagen, laminin and elastin, and is also 
biochemically active, providing signals which contribute to tissue function and homeostasis. 
The ECM binds to and serves as a reservoir for many other biochemically active molecules.115 
The matrisome is thus defined as the ensemble of nearly 300 proteins which make up the 
ECM (core matrisome), or are  associated with the ECM (matrisome-associated proteins), and 
have been characterised by bioinformatics and proteomic methods. 116  
In the blood vessels, the ECM interacts with other vascular cells to influence vascular 
development and remodelling. The blood vessels have ECM components in each of its three 
layers. The innermost layer (tunica intima) is lined with endothelial cells on a basement 
membrane comprising of matrisome proteins such as type IV collagen; the tunica media 
contains sheets of smooth muscle cells separated by ECM, while the outermost tunica 
adventitia contains myofibroblast cells and is rich in type I and III collagen in addition to many 
other matrisome proteins.117 A recent review by Joutel et al discusses the role of the 
matrisome in the small vessels, and the evidence for the alteration of matrisome function in 
SVD in greater depth.118 
1.4.1. Matrisome involvement in CADASIL 
The involvement of the matrisome in different monogenic forms of SVD suggests that the 
ECM may be the basis of shared molecular pathways in SVD. This has been illustrated in 
CADASIL, where the basis of ECM involvement has now been characterised at several stages 
- from histopathological studies in post-mortem analysis,119 to a direct link to cerebral 




Post-mortem studies in patients with CADASIL have shown a possible aggregation cascade of 
matrisome proteins. The basis of this arose from the fact that a pathognomonic feature of 
CADASIL is the deposition of granular osmiophilic material (GOM) in the extracellular space 
of the small blood vessels systemically,123 and the accumulation of deposits of the NOTCH3 
ectodomain (NOTCH3ECD) cleaved from the mutant NOTCH3 receptor.124 In transgenic mice 
expressing the human NOTCH3 p.R90C mutation, NOTCH3ECD accumulation and GOM 
deposits are often the earliest pathological features of the disease. 125 This is followed by a 
potassium channelopathy which precedes and results in the onset of impaired cerebral 
vasoreactivity,126 eventually leading to the development of white matter lesions. 127 
Studies in post-mortem specimens from CADASIL patients and transgenic CADASIL mouse 
models suggest that increased levels of NOTCH3ECD promote the formation of disulphide 
cross-linked aggregates in a cascade.  These aggregates sequester key matrisome proteins, 
which have roles in maintaining the integrity and function of the ECM, in the walls of the blood 
vessels.119,128 A summary of these proteins and their functions is provided in Table 1-7.  
This protein aggregation cascade demonstrated by proteomic studies shows parallels with the 
progression of features in animal models of CADASIL, suggesting that each protein’s 
involvement may contribute to different features in the disease pathway. Decreased baseline 
cerebral blood flow and cerebrovascular reactivity have been demonstrated in CADASIL 
patients, and the latter has been shown to be associated with the progression of white matter 
lesions.129 A transgenic mouse model of CADASIL has recapitulated these features, showing 
dysfunctional cerebral vasoreactivity early in disease. This was characterised by the impaired 
cerebral blood flow autoregulation in response to vasodilator stimuli (hypercapnia and 





Table 1-7: Matrisome proteins found to co-aggregate with NOTCH3 ECD.  






• Interacts with 
NOTCH3131 
• Regulates ECM assembly 





• NOTCH3ECD deposits 










• TGFβ is secreted as an 
inactive complex with 
LTBP-1 and latency 
associated peptide (LAP) 
• LTBP-1 regulates 
bioavailability of active 
TGFβ in the ECM135 
 
• NOTCH3ECD deposits 
found to co-aggregate 
with LTBP-1.128 
• CARASIL mutations 
preclude physiological 








Tissue inhibitor of 
metalloproteinase 
3 (TIMP3) 
• Regulatory function in 
ECM remodelling – 




degrades ECM. 137 
• NOTCH3 ECD forms 
complexes with TIMP3119 
• Increased TIMP3 activity 
contributes to vessel 
fibrosis, dysfunctional 
cerebral blood flow and 
myogenic responses to 
changes in neural activity, 
but is not associated with 











Vitronectin • Glycoprotein in blood 
plasma and ECM 




• NOTCH3ECD aggregation 
promotes the 
sequestration of TIMP3, 
which then promotes the 
co-aggregation of 
vitronectin.119 
• Reduced vitronectin 
levels associated with 
lower white matter 
burden in mouse model 
but not cerebral blood 














The impaired cerebral vasoreactivity in a transgenic CADASIL mouse model was later 
suggested to be due to an increase in the number of voltage-gated potassium channels in the 
membranes of the smooth muscle cells. 126 These channels oppose depolarisation due to 
pressure, and downregulation of these channels restores normal myogenic responses to 
pressure.126 
In biochemical and proteomic studies of cerebral vessels from CADASIL patients, NOTCH3ECD 
aggregation was found to induce the co-aggregation of Tissue inhibitor of metalloproteinase 
3 (TIMP3), which then promotes the sequestration of another matrisome protein, vitronectin, 
in these aggregates.  
A potential mechanistic link between increased TIMP3 activity and impaired cerebral blood 
flow regulation has recently been demonstrated. Increased TIMP3 expression in transgenic 
mice was shown to promote the upregulation of potassium channel current density in the 
cerebral arterial myocytes, and thus the reduction of myogenic tone and cerebral 
autoregulation.121,122 This process is thought to be mediated by TIMP3/ a disintegrin and 
metalloproteinase 17 (ADAM17) interactions.  
ADAM proteases cleave off the extracellular domains in the activation of membrane-bound 
proteins. In particular, ligands of the EGFR family, such as heparin-binding EGF-like growth 
factor are substrates of ADAM17.139 The ADAM17/Heparin-binding EGF-like growth factor 
(HB-EGF)/EGFR (ErbB1/ErbB4) signalling axis regulates cerebral arterial tone and cerebral 
blood flow.140 TIMP3 inhibits this signalling axis, and restoration of this axis with the delivery 
of exogenous ADAM17 or HB-EGF restores cerebral blood flow autoregulation in transgenic 
mice.122 
TIMP3 is associated with potassium channelopathy and impaired cerebrovascular reactivity 
but not white matter lesion load, while the subsequent involvement of vitronectin is 
associated with the presence of white matter lesions but not cerebral vasoreactivity 
impairment.119 The stepwise involvement of each protein in the cascade thus shows direct 
parallels with each stage of disease progression in the animal model. (Figure 1-3) 
The cascade of sequential recruitment and aggregation of matrisome proteins triggered by 
an altered NOTCH3ECD is also reminiscent of the ‘prion hypothesis’ in other neurodegenerative 




molecule acts as a ‘seed’ and triggers further misfolding and protein aggregation.141 In these 
diseases, proteins such as Aβ, tau and α-synuclein adopt β-sheet-rich conformations and self-
propagate.142 Although mutant proteins in the aggregatory process in CADASIL may not 
necessarily act in a prion-like manner – but instead promote the aggregation of different 




Figure 1-3: The involvement of matrisome proteins in the pathogenesis of CADASIL and CARASIL. 
Vitronectin and TIMP3 may serve as molecular correlates of clinical features and terminal pathways 
in the disease. Vitronectin levels are associated with white matter lesion load, while TIMP3 levels are 
associated with cerebral vasoreactivity in a transgenic CADASIL mouse model. LTBP-1, which co-
aggregates with NOTCH3ECD in CADASIL, has also been identified as the proteolytic target of HtrA1 





1.4.2. Convergence of disease mechanisms in CADASIL and CARASIL: 
relevance to sporadic SVD  
The molecular pathways in CADASIL may be particularly relevant to our understanding of the 
pathogenesis of sporadic SVD. Evidence from both CADASIL and population-based genetic 
studies suggest that the same pathways may also contribute to sporadic disease.  
While GOM deposits are pathognomonic of CADASIL, other histopathological features of 
CADASIL recapitulate those seen in sporadic disease. These include the fibrosis of the 
adventitia, and the loss of endothelial and smooth muscle cells of the perforating arteries. 
Similar features are also seen in post-mortem studies of cerebral vasculature in CARASIL, with 
fibrous intimal proliferation, hyaline degeneration of the media, loss of arterial smooth 
muscle cells and splitting of the internal elastic lamina contributing to the narrowing of the 
vessel lumen. 70,71 
Genetic studies in the population also suggest the possible involvement of monogenic disease 
genes in the pathogenesis of sporadic SVD.  In a study of 888 population-based stroke- and 
dementia-free individuals in the Austrian Stroke Prevention Study, the association between 
common single nucleotide polymorphisms (SNPs) in the NOTCH3 gene region and white 
matter hyperintensities and lacunes was investigated. Four common variants, rs1043994, 
rs10404382, rs10423702 and rs1043997, which are in strong linkage disequilibrium, were 
found to be significantly associated with both the presence and progression of WMH, with 
this effect only being present in hypertensives. This suggests that the minor alterations in 
Notch3 receptor function may act together with, or augment the effects of hypertension to 
cause this association. These results were replicated in a sample of 8545 individuals from the 
CHARGE Consortium.143 However, the association with WMH was not replicated in meta-
analyses of GWAS data sets from ischaemic stroke cohorts in 3670 cases and 7397 controls, 
and no association was found between NOTCH3 SNPs and lacunar stroke or with WMH in 
stroke patients.144 Similarly, the largest trans-ancestral meta-analysis to date, of 67,162 
stroke cases and 454,450 controls, did not show any association between NOTCH3 and 
WMH.145 Evidence for the involvement of monogenic disease genes in sporadic SVD is 







Table 1-8: Review of studies of the association between common or rare variants in Mendelian disease genes and sporadic SVD or its associated markers 









Small vessel stroke 
(ischaemic and 
haemorrhagic) 
Exome (n=368) and 
targeted gene (n=2599) 
gene sequencing 
1251 small vessel stroke 
cases <70 years 
1716 controls 
3 ischaemic and 3 haemorrhagic patients had 
CADASIL mutations  
1 small vessel ischaemic stroke patient had a 
Fabry mutation 
No significant association between rare 
variants and stroke 
• Multiple genes 
evaluated 
• Study powered only to 
detect associations with 
mutations of low 
penetrance 
146 
NOTCH3 WMH in 
community-based 
population 
Direct sequencing of all 33 
exons, promoter and 
3’UTR of NOTCH3 
Sequenced: 195 community-
based Caucasians, 82 
controls with no WMH 
Genotyped: 888 participants 
from Austrian Stroke 
Prevention Study 
4 SNPs associated with WMH presence and 





• Only candidate gene 
studied 
• Replication of 
rs10404382 in GWAS 
data from hypertensive 
stroke-free elderly 
individuals in CHARGE 
consortium (n=8545) 
143 
Ischaemic stroke Direct sequencing of all 33 
exons 
269 Caucasians with 
ischaemic stroke, 95 controls 
1 SNP associated with ischaemic stroke: 
• rs78501403(e) 
1 CADASIL mutation 
• p.R558C 
• Only candidate gene 
studied 
• Insufficient power to 
demonstrate 




lacunar stroke or 
WMH in stroke 
patients 
Meta-analysis of GWAS 
data sets 
1350 European patients with 
MRI-confirmed lacunar 
stroke 
3670 patients with ischaemic 
stroke and WMH 
7397 controls 
 
No association between NOTCH3 variants 
and lacunar stroke or WMH volume 









Gene Phenotype studied Approach No. of patients/controls Variants identified* Strength of evidence Ref 
Leukoaraiosis 
(Fazekas scale 3) 




218 patients with lacunar 
stroke (48 with leukoaraiosis)  
No association identified between common 
polymorphisms and leukoaraiosis 
1 CADASIL mutation 
• p.C697T 







PCR analysis of T6746C 
polymorphism 
235 Japanese patients with 
CT/MRI defined ischaemic 
stroke/TIA  
(142 with lacunar stroke) 
315 controls 
No association found between polymorphism 
and cerebrovascular disease or lacunar 
stroke 





Novel diagnostic array for 
known mutations and 
polymorphisms in exons 3 
and 4 of NOTCH3 
70 patients with CT/MRI 
confirmed ischaemic stroke 
and 77 patients with 
dementia 
117 controls 
No association between known 
polymorphisms and stroke or dementia.  
• Only 5 previously 
identified 





Lacunar stroke  Genome-wide genotyping 
and direct sequencing of 
GLA and NOTCH3 
994 patients with lacunar 
stroke with age at onset ≤70 
years 






No classical pathogenic Fabry mutations 
identified 
• One patient had missense p.R118C 




















Sequencing of gene in 
females. 
Plasma α-galactosidase 
activity in males, followed 
by sequencing if enzyme 
activity if low 
721 German patients with 
cryptogenic ischaemic stroke 
aged 18 to 55 
Fabry mutations identified in 21 males (4.9%) 
and 7 females (2.4%) 
• 11 males, 3 females with periventricular 
WMH 
• 18 males, 7 females with ischaemic 
stroke 
• 3 males, 0 females with haemorrhagic 
stroke 
 
• Only candidate gene 
studied 






Sequencing of gene and 
plasma α-galactosidase 
activity 
493 Portuguese patients with 
young onset stroke age 18 to 
55 
12 patients (2.4%) had GLA mutations 
• 9 ischaemic stroke, including 2 SVD 
• 2 ICH 
• 1 cerebral venous thrombosis 
• Only candidate gene 
studied 
• Aetiology of stroke 
uncertain 
153 
Stroke and white 
matter lesions 
Sequencing of gene in 
females. 
Plasma α-galactosidase 
activity in males. 
1000 patients with ischaemic 
stroke, TIA, ICH, white matter 
lesions, vertebrobasilar 
dolichoectasia 
19 males (3.5%) and 8 females (1.8%) had 
missense mutations.  
• Only candidate gene 
studied 




Ischaemic stroke Sequencing of gene in 
females. 
Plasma α-galactosidase 
activity in males, followed 
by sequencing if enzyme 
activity if low 
475 Japanese males with 
ischaemic strokes 
10 males had decreased α-Gal A activity – all 
had multiple small vessel infarcts  
5 had p.Glu66Gln mutation 









Gene Phenotype studied Approach No. of patients/controls Variants identified* Strength of evidence Ref 
COL4A1 Presumed sporadic 
ICH 
Direct sequencing of 
coding regions of COL4A1 
and flanking intronic 
regions 
48 patients with presumed 
hypertension-related deep 
ICH 
48 patients with probably 
CAA-related ICH 
145 controls 
2 rare variants associated with ICH: 
• c.C1055T (p.Pro352Leu) (e) 
• c.C1612G (p.Arg538Gly) (e) 
• Only candidate gene 
studied 
• Only rare variants 
studied – not common 
variants 
• Cellular assay of 
variants demonstrated 
















Meta-analysis of GWAS 
data sets 
1545 patients with ICH, 1485 
controls 
1854 patients with lacunar 
stroke, 2733 with ischaemic 
stroke and WMH, 9361 
controls 
3 COL4A2 SNPs associated with deep ICH 
• rs9521732 (i) 
• rs9521733 (i) 
• rs9515199 (i) 
SNPs did not reach significance threshold for 
association with lacunar stroke or with WMH 
volume 
• Both COL4A1/A2 
studied 
• No significant eQTLs 
with 3 SNPs or 5 other 
SNPs in high linkage 
disequilibrium with 
these three.  
• SNPs located in regions 
with possible regulatory 
roles 
157 
COL4A2 WMH in stroke 
patients 
Meta-analysis of GWAS 
data 
3670 stroke patients 4 novel SNPs associated with WMH, one of 
which is in COL4A2 
• rs9515201 (i) 
• SNP in strong LD with 
those previously 
identified (above) 
• SNP may have 
regulatory function 
158 
COL4A2 Presumed sporadic 
ICH 
Direct sequencing of 
coding regions of COL4A2 
and flanking intronic 
regions 
48 patients with presumed 
hypertension-related deep 
ICH 
48 patients with probable 
CAA-related ICH 
145 controls 
3 rare coding variants associated with ICH 
• c.3368A>G (p.Glu1123Gly) (e) 
• c.3448C>A (p.Gln1150Lys) (e) 
• c. 5068G>A (p.Ala1690Thr) (e) 
• Only candidate gene 
studied 
• Only rare variants 
studied, not common 
variants 
• Cellular assay 
demonstrated impaired 









Gene Phenotype studied Approach No. of patients/controls Variants identified* Strength of evidence Ref 
TREX1 Severe WMH and 
recurrent strokes 
Sequencing of TREX1 gene 100 patients with severe 
WMH and young-onset 
strokes suspicious of CADASIL 
2 patients had missense mutations 
• p.Tyr305Cys 
• p.Arg169His 










Meta-analysis of GWAS 




9361 patients in GWAS 
18 patients with FOXC1-
related ARS 
10 SNPs located in GMDS gene adjacent to 
FOXC1 
• rs12206258 (i) 
• rs12203614 (i) 
• rs12199578 (i) 
• rs12193217 (i) 
• rs10458129 (i) 
• rs12206340 (i) 
• rs12189662 (i) 
• rs6936881 (i) 
• rs7765344 (i) 
• rs7765461 (i) 
 
9 SNPs near PITX2 
• rs2129979 (ds) 
• rs11931959 (ds) 
• rs13121924 (ds) 
• rs3866831 (ig) 
• rs6533531 (ig) 
• rs13141190 (ig) 
• rs6533530 (ig) 
• rs7697491 (ig) 
• rs723363 (ig) 
 
 
• Only candidate gene 
region studied 
• 3 SNPs strongly modify 
FOXC1 transcript levels: 
rs12206258, rs6936881, 
rs7765344 
• 18 of 18 patients with 
FOXC1-related ARS have 

















WMH in stroke-free 
adults 
Meta-analysis of GWAS 
data 
84961 Europeans: 4348 with 
stroke, of which 1770 were 
non-cardioembolic ischaemic 
strokes.  
• rs12204590 near FOXF2 associated 
with all stroke and WMH burden in 
stroke-free adults 
• rs12204590 replicated in 
validation samples 
(stroke patients) 
associated with risk of all 
stroke 
• rs12200309 in complete 
LD with rs12204590, 
associated with SVD 
ischaemic stroke in 
validation samples 
• Region includes 
enhancers with 2 SNPs 
in high LD with 
rs12204590 having 




CECR1 Ischaemic lacunar 
stroke 
Examination of individual-
level whole exome data    
94 patients with late-onset 
stroke in the Siblings with 
Ischemic Stroke Study 
(SWISS) subcohort 
Two brothers with late-onset small vessel 
ischaemic strokes heterozygous for 
p.Tyr453Cys mutation. 
• Only candidate gene 
studied 
92 




1.4.3. Collagen: involvement of the most abundant matrisome protein  
Collagen is the most abundant protein in the ECM, and has a characteristic triple-stranded 
helical structure known as tropocollagen. Tropocollagen is made up of polypeptide chains 
with highly conserved repetitive three-residue sequences (Gly-X-Y). As glycine is the amino 
acid with the smallest side chain, it allows the tight assembly of each collagen strand in a helix, 
with glycine forming the core of each helix. Multiple tropocollagen molecules polymerise to 
form collagen fibrils which provide tensile strength to tissues.35 
Type IV collagen in the basement membrane is formed with α1 and α2 collagen chains in a 
2:1 ratio. These chains, encoded by the COL4A1 and COL4A2 genes respectively, are the most 
abundant proteins in basement membranes and surrounding smooth muscle cells in the 
tunica media of blood vessels.117 The relationship between collagen mutations and vessel 
fragility is well described in diseases such as osteogenesis imperfecta (COL1A1 or COL1A2 
mutations) and Ehlers-Danlos syndrome (COL3A1 mutations).   
While a precise molecular pathway in COL4A1 and A2-associated SVD has yet to be identified, 
it is likely that the impaired function of collagen in the ECM contributes to the disease process. 
The majority of reported mutations in COL4A1/A2-related SVD affect the glycine residue of 
the Gly-X-Y residues, disrupting the three-dimensional conformation of each α1 or α2 strand 
and thus impairing the formation of the resulting tropocollagen molecule.162 This is thought 
to result in the impaired synthesis of the basement membrane and thus lead to blood vessel 
fragility.83 Both human and mouse mutations in COL4A2 have been shown to cause the 
impaired secretion of both α1 and α2 chains, thus resulting in the retention of mutant α1 and 
α2 chains in the endoplasmic reticulum.159 The accumulation of mutant α1 or α2 chains 
results in endoplasmic reticulum stress, which is also thought contribute to disease.163,164  
A genotype-phenotype correlation in the subtype of COL4A1-related SVD known as HANAC 
syndrome has been suggested.165 Mutations in these patients were found to aggregate in the 
31-residue cyanogen bromide-derived fragment (CB3[IV]) region. This region of the cell 
contains integrin-binding domains, and is thought to be instrumental in integrin-mediated cell 
adhesion to the collagen molecules, 165   suggesting that abnormal interactions between type 




1.4.3.1. Role of monogenic disease genes in sporadic SVD 
Recent evidence suggests that common variants in COL4A2 are associated with sporadic SVD 
and ICH. A meta-analysis of genotype data from large GWAS studies in stroke in individuals of 
European ancestry identified three common variants (rs9521732, rs9521733, rs9515199) in 
intronic regions in COL4A2 which were significantly associated with deep ICH. There was a 
similar trend for lacunar stroke and WMH although the associations did not achieve the 
stringent significance levels set to account for the multiple comparison made.157 (Table 1-8) 
A multi-ethnic genome-wide meta-analysis of dementia- and stroke-free cohorts found a SNP 
located in an intron of the COL4A2 gene, rs9515201 which was associated with WMH in 
community populations; this SNP 158 is in strong linkage disequilibrium with SNPs that were 
previously identified to be associated with sporadic ICH.157 (Table 1-8) A further meta-analysis 
of genotype data from 19569 European stroke patients and 37853 controls suggested an 
association between a locus in COL4A2 and both lacunar ischaemic stroke (rs9515201)and 
deep ICH (rs4771674).166 In this same study, an association was found between a locus in 
HTRA1 (rs79043147)and lacunar ischaemic stroke. 166  
1.5. Other possible mechanisms of disease – insights from genetics  
1.5.1. Blood Brain Barrier development and integrity 
The FOXC1 gene codes for the forkhead box transcription factor C1 (Foxc1), which is critical 
in the development of blood vessels.167 Foxc1 originates from the neural crest and is 
expressed by brain pericytes, which are integral components of the BBB, and regulates 
vascular morphogenesis and maturation during embryological brain development.  While 
Foxc1 deletion does not preclude angiogenesis and may not affect BBB formation and 
permeability, it results in altered brain pericyte and endothelial cell proliferation, impairing 
blood vessel stability and thus predisposing these vessels to haemorrhage. 167 Hence, 
although the precise mechanisms behind FOXC1-associated SVD are not known, the 
theoretical basis of this disease suggests an impairment of the BBB.  
FOXC1 interacts with Paired-like homeodomain transcription factor 2 or Pituitary Homeobox 




of PITX2 also cause ARS.88 ARS patients with PITX2 mutations also had features of SVD on 
brain imaging.91 The similar phenotype seen with PITX2 mutations lends further support for 
the involvement of the FOXC1 pathway in the development of SVD.  
Studies in FOXC1 knockout models have led to speculation that matrisome proteins may 
mediate disease mechanisms in FOXC1-related SVD.118 The expression of matrix 
metalloproteinases (MMPs), which regulate the ECM, is increased in the cornea of global and 
neural crest-deleted Foxc1-/- mice. These MMPs regulate the bioavailability of vascular 
endothelial growth factors sequestered in the ECM. Upregulation of MMP expression leads 
to disorganisation of the ECM and excessive growth of vessels in the cornea of mutant mice.37 
Suppression of Foxc1 in zebrafish also reduced expression of platelet-derived growth factor 
(PDGF), a matrisome-associated protein integral to the development of vasculature. 
Consistent with evidence in humans that alterations in Foxc1 dosage were associated with 
SVD, zebrafish with either Foxc1 knockdown or overexpression also exhibited cerebral 
haemorrhage.91 
Adjacent to the FOXC1 gene on chromosome 6p25 is FOXF2, a gene that encodes the Foxf2 
transcription factor. Foxf2 is expressed specifically in CNS pericytes and is required for 
pericyte differentiation and BBB development. 161  FOXF2 knockout mouse embryos develop 
defects in the BBB, and FOXF2 inactivation in adult mice lead to BBB breakdown, cerebral 
infarction and microhaemorrhage. 168 
FOXF2 mutations and copy number variations have been implicated in Anterior Segment 
Dysgenesis, an ocular condition which also occurs in ARS. 169 In ARS, patients with FOXC1 and 
FOXF2 both deleted have more extensive WMH than those with deletion of only FOXC1, 
suggesting that the loss of interactions between FOXC1 and FOXF2 contribute to a shared 
disease pathway. 25 
The same forkhead box protein loci have also been implicated in sporadic SVD. (Table 1-8) A 
meta-analysis of GWA data of the FOXC1 and PITX2 gene locus identified 10 WMH-associated 
SNPs which lie in an intron of the GDP-mannose 4,6-dehydratase gene (GMDS) adjacent to 
FOXC1. Three of these SNPs have effects on FOXC1 transcript levels.91 In the PITX2 gene locus, 
nine SNPs were found to be significantly associated with WMH.91 Another recent large-scale 




SNP was also associated with WMH, suggesting that the mechanism by which disease risk is 
conferred is though SVD. 161 These converging results from sporadic and monogenic disease 
lend support to the possible roles of the FOXC1-PITX2-FOXF2 interactions and their roles in 
maintaining BBB integrity via proteins in the matrisome. 
Evidence for the involvement of the BBB in SVD is also seen in CADASIL. Histopathological 
examinations of cerebral vessels from CADASIL patients and transgenic mouse models of 
CADASIL have shown damaged pericytes.170–172 The TGFβ pathway, which has been implicated 
in both CADASIL and CARASIL (Figure 1-3), may provide a possible explanation for this process. 
In vitro studies of TGFβ1, which is the most extensively studied form of TGFβ, have shown 
that TGFβ1 reduces pericyte proliferation and elevates the expression of MMPs and other 
proinflammatory cytokines which may disrupt BBB function.173 
1.5.2. Impairment of DNA Damage Response 
RVCL-S is an autosomal dominant form of SVD caused by frameshift mutations in the TREX1 
gene.73 TREX1 codes for the most abundant DNA exonuclease in mammals, known as DNase 
III or Three prime Repair Exonuclease.73 DNase III has a role in the repair of DNA damage, and 
serves this function by translocating from the endoplasmic reticulum to the nucleus during 
oxidative DNA damage.78 DNase III enzymatically digests cytosolic single-stranded DNA to 
prevent the cell from responding to immunostimulatory DNA, such as those arising from 
pathogenic viruses.  
Dysfunctional DNase III arising from loss-of-function TREX1 mutations may thus result in the 
erroneous recognition and clearance of self-nucleic acids, resulting in autoimmune and 
inflammatory diseases such as systemic lupus erythematosus (SLE), an inherited form of SLE 
known as familial chilblain lupus, and an inflammatory early-onset encephalopathy known as 
Aicardi-Goutiéres Syndrome.174 
Functional analyses have shown that RVCL-S-causing TREX1 mutations cause cellular 
mislocalization,78 rather than a loss of enzymatic activity. The expression of DNase III with a 
truncated C-terminus and disrupted transmembrane domain impairs its cellular localisation 
in the endoplasmic reticulum.73 The nuclear target of DNase III was recently identified as 
poly(ADP-ribose) polymerase-1 (PARP1), an enzyme which repairs single stranded DNA breaks 




response.175 The disrupted localisation of DNase III may theoretically have a toxic gain-of-
function effect, or attenuate normal DNA damage responses, however the precise 
mechanisms underlying RVCL-S remain to be characterised.  
1.6. Further insights from GWAS: distinct mechanisms across the 
SVD spectrum 
Significant progress has been made in our understanding of the genetic architecture of 
sporadic SVD following recent GWA studies. Rather than SVD pathology being homogeneous 
across all individuals, it is possible that there are distinct pathological pathways leading to 
SVD in different groups. In a population of stroke patients,176 genetic factors underlying WMH 
were distinct in hypertensive individuals compared to non-hypertensives, with only a very low 
correlation between the genetic components (r2=0.15).176 A recent study using GWAS data 
from a young onset population with MRI-confirmed lacunar stroke showed that genetic 
factors are an important contributor to risk in this population,29 with higher heritability seen 
in this group than in previous populations where most phenotyping was done using CT.177 
Much of the heritability arose from regions of the genome influencing expression of genes, 
or in DNase I Hypersensitivity sites, suggesting that the genetic risk of sporadic SVD is 
conferred through subtle changes to gene expression and regulation. In addition, when 
categorising lacunar stroke cases into those with extensive WMH and those without, analysis 
suggested that disease in the two groups was attributable to different rare genetic variants 
not thought to be in linkage disequilibrium, again highlighting that multiple distinct pathways 
lead to different manifestations SVD in different groups of patients.29 
GWAS studies in MRI-confirmed WMH have identified 13 loci strongly associated with the 
trait, as summarised in Table 1-9.158,178,179 Four of the loci arise from an extended region 
containing NEURL1, PDCD11, and SH3PXD2A. NEURL, a highly conserved E3 ubiquitin ligase. 
is particularly notable as it inhibits the Notch pathway through decreasing expression of the 
Notch ligand, JAG1.180,181 Of interest, five of these loci are found in genes which have been 
implicated in malignant brain tumours of the white matter involving glial cells, suggesting the 




community and stroke patient populations,178 12 of the identified WMH loci also confer risk 
of lacunar stroke,182 and one of the loci, in 1q22, is also associated with ICH.27 
 
Taken together, GWAS to date emphasise that there are likely multiple distinct pathways 
leading to SVD. Some of these pathways are shared across different manifestations of the 
disease, but some are likely to be specific to disease groups; and in some cases are likely to 
act through interactions with environmental or non-genetic risk factors such as hypertension. 
 
Table 1-9: SNPs associated with WMH in community and stroke populations 
SNP Chromosome Nearest 
Gene 
Phenotype Association References 
rs7214628 17 TRIM65 WMH in community and stroke populations 
 
158,178 
rs72848980 10 NEURL WMH in community populations 
 
158,178 
rs7894407 10 PDCD11 WMH in community populations 
 
158,178 
rs12357919 10 SH3PXD2A WMH in community populations 
 
158,178 
rs7909791 10 SH3PXD2A WMH in community populations 
 
158,178 
rs78857879 2 EFEMP1 WMH in community and stroke populations 
 
158,178 




rs11679640 2 HAAO WMH in community populations 
 
158,178 
rs72934505 2 NBEAL1 WMH in community and stroke populations 
 
158,178 
rs941898 14 EVL WMH in community and stroke populations 
 
158,178 
rs962888 17 C1QL1 WMH in community and stroke populations 
 
158,178 












1.7. Concluding remarks 
1.7.1. Reaching a genetic diagnosis in familial SVD 
Cerebral small vessel disease is a complex disease that most commonly occurs due to 
interactions between genetic and environmental factors in the elderly, hypertensive 
population. SVD is the subtype of stroke most likely to present as a familial disorder, the most 
common of which is CADASIL. In recent years, mutations in several other genes such as HTRA1, 
COL4A1, COL4A2, FOXC1 and TREX1 have been identified in other families with CADASIL-like 
or other familial SVD syndromes.  
Some of these diseases have distinctive features which may point towards a specific genetic 
diagnosis. For example, a patient with a clinical phenotype compatible with CADASIL may 
have characteristic anterior temporal pole involvement on MRI. However, many of the other 
monogenic forms of SVD such as CARASIL do not have characteristic MRI features. The 
decision of which candidate genes to test for mutations in is also seldom straightforward, due 
to the overlapping phenotypes between each disorder and the heterogeneity of phenotypes 
between families. Mutation screening tests previously looked at one gene at a time, with the 
testing of multiple genes one after another being prohibitively expensive. Testing for some 
genes may not be available under conventional Sanger sequencing, and there remain many 
families with early-onset SVD with non-specific clinical or radiological features, or where no 
mutations in known genes have been identified. The increasing use of next generation 
sequencing (NGS) technology in clinical diagnosis may serve to identify novel genetic causes, 
as described in Chapters 4 and 5.  
1.7.2. Pathogenesis of SVD: what we understand from genetic studies 
Studies in both monogenic forms of SVD and ‘sporadic’ SVD are now beginning to fill in the 
blank edges in the map of the disease processes in SVD. (Figure 1-4) Shared pathways 
affecting the integrity and function of the ECM appear to play an integral role in the 
development of this disease. It is likely that there are multiple shared pathways, each being 
involved to varying degrees in different manifestations or subtypes of SVD. These genetic 
mechanisms, as well as their interactions with environmental factors, may provide 
explanations as to why different patients in the sporadic disease population exhibit each 




In addition, there is now accumulating evidence of a protein aggregation cascade seen in 
CADASIL, suggesting that the convergence of pathways may extend beyond SVD, and that 
there may be a convergence of pathogenic pathways as seen in neurodegenerative diseases 
in general.  
Elucidating the disease pathways in SVD may allow us to identify therapeutic targets. An 
example is seen in a monogenic large vessel vasculopathy, Marfan syndrome, which can be 
caused by mutations in the fibrillin-1 gene. Fibrillin-1 is a key ECM component and binds to 
the latent TGFβ complex. Antagonists of TGFβ signalling such as losartan have now been 
shown to reduce the development of aortic aneurysms in a mouse model of Marfan 
syndrome.183 The involvement of the TGFβ pathway in SVD may lead us towards the use of 
TGFβ antagonists to halt disease progression, while the protein aggregation cascade suggests 
the potential utility of therapeutic agents currently being developed in the treatment of other 
neurodegenerative diseases with similar mechanisms. 
Further genetic studies in SVD will likely provide more conclusive evidence of the overlap of 
molecular pathways involved in both monogenic and sporadic disease. Although an improved 
understanding of the processes in monogenic or ‘sporadic’ disease may aid the development 
of treatment options for each specific disease, it is likely that the distinction between the two 








Figure 1-4 :The convergence of disease pathways, particularly in the extracellular matrix (ECM), in the mechanisms underlying monogenic SVD. These 
pathways may also be biological correlates for clinical and other disease features identified in post-mortem and transgenic animal studies, as seen in the 
example of CADASIL. Pathological and clinical features are also shared between monogenic and sporadic disease, lending support to the possibility of these 
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2.1 Background and introduction to genetic analysis in disease 
High throughput sequencing (HTS) platforms have become widely used since 2005, with the 
rapidly falling cost of DNA sequencing relative to Sanger sequencing.184 Prior to the availability 
of such technology, progress was made through the use of linkage analysis followed by Sanger 
sequencing of specific haplotypes. The introduction of genome-wide arrays revolutionised the 
approach to genetic studies, shifting the strategy from being primarily pedigree-based to 
population based. With the arrival of HTS, several of these techniques have now been 
combined, as detailed in this chapter.  
2.1.1 Linkage analysis  
Genetic linkage refers to the phenomenon whereby two alleles at different loci are inherited 
together from parents to offspring more often than expected by chance. Linkage analysis is a 
tool that allows the detection of the loci of disease genes, by identifying regions of the 
chromosomes that co-segregate with the disease, and has its basis in the recombination 
between the two loci.185 After an initial disease-causing mutation occurs, recombination 
events or ‘crossing over’ occurs through multiple generations, with marker loci occurring 
within shorter and shorter distances of the causative variant. 
Linkage analysis was formerly the mainstay of genetic studies, and was used to identify loci 
of interest in large pedigrees. These analyses would typically identify a number of genetic 
regions that could be explored in greater depth using Sanger sequencing. Some of the 
successes of linkage analysis include the identification of the Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR) gene in Cystic Fibrosis186, and the huntingtin gene in 
Huntington’s disease.187 Linkage analyses were thus useful in the testing hypotheses in 
patients thought to have a ‘one gene, one disease’ inheritance pattern, but less helpful in the 
study of complex, ‘common disease, common variant’ hypotheses.  
2.1.2 Genome-wide association studies (GWAS) 
With the availability of genome-wide association (GWA) arrays, genetic linkage took a back 




non-Mendelian diseases continues to be explored using association studies between large 
numbers of unrelated individuals. GWAS associations were more powerful in identifying 
genotype-phenotype associations, and circumvented the limitation of small families with 
limited numbers of generations available for study. The aim of GWAS is primarily to identify 
the genetic basis of traits or disease susceptibility using common variants (SNPs) in the 
population.  
GWAS utilises common variations across the human genome, known as single nucleotide 
polymorphisms or SNPs, to identify genetic risk factors for disease. SNPs are single base-pair 
variations in the sequence that occur at high frequency in the population, and serve as 
markers throughout the genome. The underlying assumption is that each SNP has minimal 
impact on function and disease, either through its role in alteration of protein availability or 
function via amino acid changes, mRNA transcript stability or transcription. Hence, a single 
SNP is unlikely to be associated with disease on its own, but disease risk is likely to be shared 
across multiple genetic risk factors interacting with the environment.188  
2.1.3 High throughput sequencing in the context of monogenic SVD 
High throughput sequencing (HTS), or next generation sequencing, refers to highly parallel 
DNA sequencing technologies that can produce hundreds of thousands to millions of reads 
(of length 25 – 500bp) for a low cost, and with a rapid turnover. These technologies can deliver 
complete genome sequences (whole genome sequencing, WGS, as utilised in Chapter 5), or 
the coding sequences only (whole exome sequencing, WES), which covers about 1% or 30 
million base pairs of the genome. Other forms of HTS include sub-exome panels of specific 
genes (as described in Chapter 4), RNA sequencing and methylation sequencing. A 








Table 2-1: Comparison of high-throughput sequencing techniques  





Sequencing of whole genome 
using fragmentation, followed by 
paired-end sequencing and 
mapping to a reference genome 
(or de novo alignment if 
reference unavailable)  
 
• Can identify non-coding variants, 
translocations, copy number variants 
• Can provide phased information 
• Moderate depth of sequencing 
• No information about active transcription 
• Significant cost with storage and interpretation 





Targeted sequencing of exome 
(protein-coding regions of 
genome) using probe-based 
capture technology 
 
• Moderate-high depth of sequencing  
• Cheaper than WGS 
• Easier to analyse and store 
• Single universal panel used for capture 
• Does not cover other important non-coding 
sequences beyond exome 




Targeted sequencing of selected 
regions using probe-based 
capture technology 
• High depth of sequencing 
• Less to interpret and analyse 
• Can be as expensive as WES 
• Need to design specific panels for each region 
covered instead of using single universal panel 
• No information on CNVs outside what is captured 




Sequencing of all transcribed 
sequences (transcriptome) or only 
polyadenylated transcript 
• Can complement WGS or WES to provide 
transcriptional level data 
• Can estimate transcript abundance  
• Can detect rare transcripts, isoforms and 
mutations in abundant transcripts 
• Not limited to transcripts with 
corresponding genomic sequence e.g. 
viral transcripts 
• Challenging to produce cDNA libraries 
• More sequencing needed for low-abundance 
transcripts 







Techniques Description Advantages Disadvantages 
Methylation 
sequencing192 
Quantifying of DNA methylation 
patterns and differences in 
methylation  
• Can provide epigenetic level information 
• Complementary with RNAseq, WGS, WES 
• Role of methylation poorly understood 




These high throughput techniques were first used to provide variant-level information on 
susceptibility loci identified by GWAS, by providing a means of targeted resequencing of the 
region. As common variants could only explain part of the genetic architecture of common 
diseases, it was thought that rare variants may account for much of this ‘missing heritability’. 
These rare variants could be identified using HTS techniques. 
HTS has also been used at the exome- or genome-wide level to identify disease-causing 
variants in patients suspected of having a rare inherited disorder. These studies rely on 
comparisons between unaffected and affected related individuals, or between affected 
unrelated individuals, to discover novel alleles.184 Genetic linkage analysis performed with a 
view to identifying individuals in a pedigree suitable for whole genome sequencing, or 
performed using whole genome sequencing data, can provide statistical evidence for the role 
of a rare variant in a rare disease. It can also serve as a form of verifying purported 
relationships in the pedigree. However, the union of these two techniques still does not 
overcome the possibility that a variant in linkage disequilibrium is falsely associated with the 
disease.193   
HTS is thus likely to improve our understanding of cerebral small vessel disease (SVD) as a 
growing number of novel genes are discovered in the context of disease. The impact of HTS 
in the diagnosis of rare neurological disease has already been seen, with a growing number 
of monogenic causes being described with the use of this technology.194  
With the rapidly declining cost of sequencing, HTS is now no longer predominantly a research 
tool, but is also being used routinely in diagnostic gene panels in the clinic in place of 
conventional Sanger sequencing,195 and already has a growing impact on the diagnosis of rare 
disease.194 Patients may now be routinely tested on targeted gene panels instead of being 




2.1.4 Whole genome sequencing 
In Chapter 5 we describe our study on suspected familial SVD where no known genetic 
diagnosis has been identified. We performed whole genome sequencing in patients and their 
relatives.  
In this process genomic DNA is fragmented into lengths of 150bp, and adaptors are ligated to 
the ends of each fragment. These single stranded fragments are then added to a flow cell, 
where they bind randomly on the surface containing bound primers. The free ends of the 
fragments (containing adaptors) bind to these primers, causing the fragment to arch over to 
form a bridge, as shown in Figure 2-1. Nucleotides are incorporated extending from the 
primer, using the fragment as a template. This forms a double-stranded bridge. These are 
then denatured, leaving twice the number of single-stranded templates anchored to the 
substrate. The process is repeated until millions of dense clusters are formed. Up to a 
thousand identical copes of a single template molecule are created in a cluster.  
Sequencing is performed by adding a single labelled deoxynucleoside triphosphate (dNTP), so 
that it is incorporated using DNA polymerase. This dNTP terminates polymerization, so that it 
can be imaged using a laser, where emitted fluorescence from each cluster is captured to 
identify each base in turn. The label is then enzymatically cleaved to allow incorporation of 
the next dNTP. This cycle is repeated until the sequence of bases in a fragment are all 
determined. The data is subject to quality control at multiple stages, aligned and compared 
to a reference genome (human genome build GRCh37), and differences (‘variants’) are called 
based on this reference genome.196 In our study using WGS by Illumina, a coverage depth of 





Figure 2-1: Bridge amplification in the process of high throughput sequencing by Illumina. Unlabelled 
nucleotides and enzymes are added to initiate amplification. Image from Illumina, Inc.196 
2.1.5 Targeted gene sequencing 
Targeted sequencing of genes of interest, as used in our study of presumed-sporadic early-
onset SVD cases in Chapter 4, involves the sequencing of selected regions of the genome using 
capture probes. This often allows a much higher depth of sequencing of more than 10x that 
achieved in whole genome sequencing.  
Genomic libraries are first prepared and amplified by polymerase chain reaction (PCR). These 
are then hybridised to specifically-designed capture probes which are complementary to 
target sequences in the gene of interest. These probes are then enzymatically extended, and 
the post-capture library is amplified using PCR, and sequenced using methods described in 
the previous section. 
In our study of presumed sporadic early-onset SVD stroke, we used a multi-gene sequencing 
platform known as ThromboGenomics,197 which is described in detail by Simeoni and 
colleagues, and briefly summarised in this chapter.  
2.1.6 High throughput sequencing: quality control and analysis pipeline 
Whole genome sequencing and sub-exome panel sequencing data are run typically run 
through a bioinformatics pipeline for quality control, alignment to a reference genome, 





Nucleotide sequences generated by sequencers such as the HiSeq X used for whole genome 
data, and HiSeq 2000 used for multi-gene sequencing in this work, are stored in text-
based .fastq  files together with quality scores. These scores measure the probability of an 
incorrect base call. The raw data is subjected to quality control steps during which the read 
lengths and number of reads are assessed, and adaptors or contaminants are trimmed from 
the reads.  
The millions of reads generated are then aligned to a reference genome (or transcriptome in 
the case of RNA-seq data). The quality of mapping is assessed, and duplicates are removed. 
The resulting nucleotide sequence alignment  files are in the .sam (sequence alignment/map) 
format, and the equivalent compressed binary format of this file is .bam.  
Variants are called on .bam files by comparing the aligned files to the reference genome. This 
produces variant call format (.vcf) files, which detail information about positions in the 
genome, and quality and mapping scores. Variants are annotated using information from 
predictive tools such as Genomic Evolutionary Rate Profiling (GERP), MutationTaster, Sorting 
Intolerant from Tolerant (SIFT) and Polyphen to provide data on the expected impact and 
deleteriousness of each variant. Further downstream analysis can then be performed, and 
subsets of these resultant files can be created during the analysis process to produce .vcf files 
with different combinations of annotations.  
  




















2.1.7 Current challenges in using HTS in the clinic  
2.1.7.1 Interpretation of variants 
The interpretation of sequencing results remains the greatest challenge in the use of HTS for 
diagnosis in the clinic. This is largely due to the vast amount of data produced in the context 
of an as-yet poorly understood genome. A single assay can produce hundreds of thousands 
of variants in a single individual suspected of having a single variant causative of disease – and 
the challenge lies in identifying which variant is pathogenic.  
While intensive filtering against the predicted impact of variants and their frequencies in the 
general population may help to narrow down candidates, there are likely to also be 
pleiotropic variants where the same mutation in the same gene may have different 
phenotypic effects. For example, hexanucleotide intronic expansions in C9ORF72 have been 
found to lead to the presence of TDP43 positive inclusions in the CNS in both frontotemporal 
dementia (FTD) and amyotrophic lateral sclerosis (ALS). Despite this similar genotype and 
pathology, the clinical presentations of ALS and FTD are vastly different and would not 
conventionally be classed together in the same phenotype for exploratory analysis.198 The 
lack of a one-gene, one-disease correlation can pose a significant challenge to identifying a 
single causative variant.  
In addition, reference genomes and databases are by no means a representation of what is 
normal, but only a reflection of what has already been sequenced. Filtering is often based on 
the assumption that the potentially disease-causing variants are not carried by any of the 
unaffected individuals, however it is more likely that there are a small number of pathogenic 
alleles that do segregate into the general population at low frequencies. The inheritance 
pattern of the disease further complicates this – in recessive disorders where the carrier 
status does not result in disease, carriers may be erroneously included in the control set and 
identification of causative variants becomes complex.199 
Further challenges of using HTS in the context of the work in this thesis are explored in 




2.1.8 Control databases 
Established control databases are useful in genetic studies as they aid in the clinical 
interpretation of the pathogenicity of variants, and provide an additional dataset to that used 
in each study. These databases are, however, limited by the ethnicities and populations 
covered, with European populations taking predominance. Two of the largest sequencing 
databases are used in this thesis.  
The Exome Aggregation Consortium (ExAC) database is a catalogue of exome sequencing data 
of 60,706 unrelated individuals across different populations, allowing the estimation of allele 
frequency for protein-coding genetic variants (http://exac.broadinstitute.org/downloads). 
The database is curated by the Broad Institute, and is derived from disease-specific and 
population-based studies.200  
From the ExAC database grew the genome aggregation database or gnomAD 
(http://gnomad.broadinstitute.org/), which comprises the exome sequences of 123,136 
unrelated individuals and whole genome sequences of 15,496 unrelated individuals. This 
expanded the available dataset significantly to include non-coding regions, and is now able to 
provide a more robust estimate of allele frequencies in the population. Although derived from 
both disease and population-based cohorts, in the latest release (February 2017) severe 
paediatric onset disease-afflicted individuals and their first-degree relatives have been 
removed.201 
2.1.9 Predicting pathogenicity at a gene or protein level 
In-silico bioinformatic tools can be used to predict the impact of a variant, such as if it results 
in a loss or gain of protein function. These can be useful in narrowing down potentially 
deleterious variants, but are not clinically useful when used in isolation. Three illustrative 
examples are discussed here.  
2.1.9.1 SIFT 
SIFT, or sorting intolerant from tolerant (http://sift.jcvi.org/), is an algorithm which predicts 
the deleteriousness of an amino acid substitution. Curated by the Craig Venter Institute, the 




protein would be highly conserved across species or generations of a species, whereas less 
conserved positions are less likely to be critical to protein structure or function and thus 
tolerate substitution. SIFT predicts if a variant is ‘tolerated’ or ‘damaging’ using the degree of 
alteration from closely related sequences.202  
2.1.9.2 Polyphen-2 
Polyphen-2 (Polymorphism Phenotyping v2, http://genetics.bwh.harvard.edu/pph2/), is a 
tool which predicts the impact of an amino acid substitution on the structure and function of 
the resulting protein. It uses physical and comparative factors to compute this, based on 
sequence (i.e. the specific region or domain of the protein), phylogenetic (conservation of the 
protein sequence based on its alignment with homologues), and structural information (the 
impact on protein folding and the three-dimensional conformation). Each variant is classified 
as ‘benign’, ‘possibly damaging’ or ‘probably damaging’.203 Polyphen and Polyphen-2 were 
developed by the Brigham and Women’s Hospital.   
SIFT and Polyphen are both protein-sequence based, and are thus not useful for the 
interpretation of non-coding variation. As SIFT uses only data on conservation, it does not 
take into account any functional information. The Polyphen algorithm is also trained on 
known pathogenic variants, which may not necessarily be predictive of other novel 
pathogenic variants. It is also worth noting that both SIFT and Polyphen have been suggested 
to have high sensitivity but low specificity, thus limiting their utility in the interpretation of 
variants of uncertain significance.204  
2.1.9.3 CADD          
In both our sequencing studies in Chapters 4 and 5 we have used Combined Annotation 
Dependent Depletion (CADD) scores (http://cadd.gs.washington.edu) as a filter for variants 
identified. This tool, developed by the University of Washington and Hudson-Alpha Institute 
for Biotechnology, integrates 63 distinct annotations including SIFT and Polyphen, functional 
genomic data and transcription factor binding information to provide an estimate of 
deleteriousness (i.e. the degree to which fitness is reduced) and pathogenicity. This tool 
scores both SNVs and short insertions or deletions, and prioritizes known pathogenic 




Polyphen it remains an aid to narrowing down variants, and not a clinical tool. The cut-offs 
for potential pathogenicity are also arbitrarily set – in our studies we have used a score of 15 
as a threshold for data produced from both whole genome sequencing and sub-exome panel 
sequencing. This value represents the median score for all theoretical splice site changes and 
variants which result in an alteration of an amino acid.205                                                                                                                                                                                                                                                                                                                                                                            
2.2 Patient cohorts studied 
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL), caused by mutations in the NOTCH3 gene, is the most 
common inherited form of stroke, with an estimated prevalence of 2 to 4 per 100 000 in the 
UK population.40,41 Multiple families have now been identified with CADASIL-like syndromes, 
but with no mutations in the NOTCH3 gene.206,207 While the genetic basis of a few of these 
have subsequently been resolved with the aid of linkage analysis in the context of whole 
exome sequencing,208,209 many other families remain without a genetic diagnosis.  
This thesis explores familial cerebral SVD from by moving from a narrow to broad focus, 
looking first at the phenotype of CADASIL (Chapter 3) as a prototype of familial SVD, and then 
examining multiple monogenic disease genes in a cohort of ‘sporadic’ SVD stroke patients 
(Chapter 4), followed by exploring a larger number of candidate genes in a cohort of NOTCH3-
negative familial SVD patients (Chapter 5). Finally, it considers the prevalence of known 
monogenic SVD-causing mutations in the general population (Chapter 6).  
2.2.1 CADASIL 
Data from 300 symptomatic CADASIL patients (170 females, 130 males) seen in the UK 
CADASIL National Referral Service was collected prospectively over a nineteen-year period, 
from 1996 to 2015. All patients had a confirmed diagnosis of CADASIL, either by direct 
sequencing of the NOTCH3 gene to identify a pathogenic cysteine-changing mutation (n=296), 
by electron microscopy of a skin biopsy demonstrating granular osmiophilic material (n=2), or 
by characteristic imaging features of CADASIL in the context of a family history of genetically-
confirmed CADASIL (n=2). Pre-symptomatic patients diagnosed with CADASIL on predictive 
genetic testing were not included in this study. All patients were evaluated and examined by 
consultant neurologists. Written and informed consent was obtained, and data was collected 




2.2.2 Suspected familial SVD  
Patients with a suspected familial SVD, but who did not have a disease-causing NOTCH3 
mutation, were recruited to the National Institute for Health Research (NIHR) BioResource 
Rare Disease (BRIDGE) study. This was a multicentre pilot study of the UK’s 100 000 Genomes 
Project, and collectively involved the recruitment and whole genome sequencing of 
approximately 10 000 individuals across 14 rare diseases. A summary of these diseases is 





Table 2-2: Rare diseases in the BRIDGE Whole Genome Sequencing study 
Rare disease category Number of patients 
sequenced 
Cerebral small vessel disease 265 (data from 246 available 
at time of writing)  
Bleeding and Platelet Disorders 1110 
Pulmonary Arterial Hypertension 1136 
Primary Immune Disorders 1320 
Specialist Pathology: Evaluating Exomes in Diagnostics 1388 
Steroid Resistant Nephrotic Syndrome 250 
Primary Membranoproliferative Glomerulonephritis 1360 
Ehlers-Danlos and Ehlers-Danlos-like syndromes 94 (WES only) 
Multiple Primary Malignant Tumours 559 
Intrahepatic Cholestasis of Pregnancy 262 
Hypertrophic Cardiomyopathy 241 
Neuropathic Pain Disorders 170 
Stem Cell and Myeloid Disorders 221 
Leber Hereditary Optic Neuropathy 72 
[Genomics England Pilot] 2000 
 
Participants were recruited across 12 sites in the UK, as listed in Table 2-3. Patients presenting 
to acute stroke units and those referred outpatient TIA and stroke clinics were screened for 
eligibility for the BRIDGE study. Potential participants were screened both retrospectively and 
prospectively. Patients who tested negative for NOTCH3 mutations at the South West Thames 




(n=1135), while all clinicians receiving negative NOTCH3 mutation testing reports issued by 
the Royal Devon and Exeter Clinical Genetics Service were informed of the study. A statement 
was included on all negative reports for NOTCH3 mutation screening generated by the clinical 
genetics laboratory to alert clinicians of the possibility of whole genome sequencing under 
the BRIDGE project should their patients be eligible.  
Clinical records for potential participants were reviewed by a consultant neurologist or 
consultant stroke physician for all cases except those reviewed at the Leicester University 
Teaching Hospitals and Royal Devon and Exeter, where records were reviewed by both a 
consultant neurologist and a consultant clinical geneticist. Patients were selected if they were 
suspected to have familial SVD, based on criteria including their clinical presentation, with the 
onset of MRI-confirmed SVD, and clinical features such as lacunar stroke or cognitive 
impairment, at an early age (typically before the age of 60, although this arbitrary cut-off 
served as a guideline rather than an absolute criterion). Other neurological features typical of 
CADASIL such as complicated migraines, seizures and psychiatric disturbance counted 
towards the suspicion of familial disease. These clinical factors were interpreted in the 
context of the patients’ risk factors for sporadic SVD, such as diabetes, hypertension, obesity 
and smoking. Further guidelines for the selection of patients for whole genome sequencing 
are summarised in Table 2-4. As described above, clinical information and MR images for all 
recruited patients underwent assessment by a consultant neurologist, with phenotypic data 
collected using a standardised questionnaire at recruitment and at follow-up encounters.  
In addition to patients testing negative for NOTCH3 mutations on screening by clinical 
genetics departments, patients in the Oxford Vascular study (OXVASC) were also reviewed. 
The OXVASC (https://www.ndcn.ox.ac.uk/research/oxvasc) is a longitudinal study of patients 
with stroke, TIAs and heart attacks in Oxfordshire. Patients presenting with stroke are all 
phenotyped according to the TOAST classification, and are followed up at varying intervals for 
up to 10 years. Medical records for patients with strokes of the SVD subtype at or before the 
age of 65, with a family history of stroke were reviewed. Forty-two records were reviewed, 
three patients were found to be eligible and two were successfully recruited.  
A total of 280 individuals were recruited to the project, and of these 265 samples were sent 
for whole genome sequencing. Nine samples had failed initial stages of quality control (QC) 




sample was not sequenced as it belonged to a pedigree where the proband’s sample had 
failed QC. Of the 265 samples sent for sequencing, seven were further excluded due to other 
diagnoses being made after recruitment (such as CADASIL on clinical genetic testing, or 
neurosarcoidosis), and due to probands in the same pedigree not having been successfully 
sequenced. At the time of writing data was available from 246 individuals (118 index, 121 
relatives, 143 affected). The final set of data will comprise 129 index cases, and a total of 157 





Table 2-3: Sites and total recruitment over a 24-month period for the BRIDGE-SVD Whole Genome 
Sequencing study 












• CADASIL national referral service 
• Neurology and stroke 
outpatients, inpatients 
• Direct referrals 
  
77 44 121 
St George’s 
Hospital, London 
• (Former) CADASIL national 
referral service 
• Neurology and stroke 
outpatients, inpatients 
• All patients testing negative for 
NOTCH3 mutations 
 




• Neurology and stroke 
outpatients, inpatients 
• Patients testing negative for 
NOTCH3 mutations 
 












12 6 18 
Oxford University 
Hospitals 
• OXVASC database210 
• Patients testing negative for 
NOTCH3 mutations 
 




Patients testing negative for 
NOTCH3 mutations 













1 0 1 
Royal Devon and 
Exeter Hospital 
Neurology and stroke outpatients, 
inpatients 
 
1 1 2 




Table 2-4: Selection criteria for patients with suspected monogenic SVD 
Diagnosis of 
SVD 
• MRI-confirmed features of SVD  
• Exclusion of other aetiology for stroke, such as cardioembolic or 




• Early-onset stroke or other features of SVD such as cognitive 
impairment (typically before age 60).  
• Syndromic disease: history of other clinical features which fit 
with recognised monogenic stroke syndromes 
o Other neurology such as complicated migraines, seizures, 
psychiatric disturbance 
o Non-neurological features such as skeletal, facial or 
ocular abnormalities 
 
Risk factors  • Degree of severity of SVD in context of patient’s risk factors, such 
as diabetes, hypertension and smoking 
Family history • Family history of early-onset stroke or dementia, especially if 
occurring in a Mendelian pattern of inheritance 
• Family history of neurological disease which may, in retrospect, 
have been SVD, such as familial hemiplegic migraine, multiple 






• Presence of atypical features on imaging, such as 
o Evidence of SVD beyond what is expected for age and risk 
factors 
o Atypical distribution of white matter hyperintensities on 
T2/FLAIR MRI, such as anterior temporal pole and 
external capsule involvement (suggestive of CADASIL), or 
predominant posterior subcortical white matter 
involvement (suggestive of cerebral amyloid angiopathy) 
• Extensive microbleeds in the cortical (suggestive of CAA) or 
subcortical (suggestive of COL4A1/A2) regions 
• Presence of pseudotumours (seen in RVCL-S) 
• Presence of vascular malformations such as aneurysms 
(suggestive of COL4A1/A2), or dolichoectasia (suggestive of Fabry 
disease) 
 
Exclusion • Exclusion of other causes of white matter disease such as 
metabolic disorders, such as through urine organic acid and very 
long chain fatty acid (VLCFA) analyses. 
• Known Cysteine-changing variant within exon 2 to 24 of NOTCH3 
gene 




2.2.2.1 Phenotypes of patients recruited for Whole Genome Sequencing 
The 265 individuals sequenced under the BRIDGE-SVD study were phenotyped using Human 
Phenotype Ontology (HPO) terms based on the information collected at all initial and follow-
up encounters. All patients with evidence of amyloid or non-amyloid SVD on MRI were 
classified as ‘affected’, and relatives who had not had an MRI were classified as having an 
‘unknown’ disease status. Information and ages at onset were also collected on the features 





Table 2-5: Phenotypic data collected on participants recruited to BRIDGE-SVD  
 Feature and HPO terms HPO terms 
Imaging • Presence or absence of features of cerebral small 
vessel disease on MRI 






• Migraine  
o with aura 
o without aura 







• Encephalopathy*, defined as acute reversible 
encephalopathy with evidence of reduced 
consciousness in the absence of any other organic 
cause, where symptoms lasted for longer than 24 


















• Psychiatric disturbance 
 
HP:0000708 
• Non-dementia cognitive impairment as diagnosed 
on the Brief Memory and Executive Test (BMET) 






















 Feature and HPO terms HPO terms 
Other 
neurology 
• Hearing impairment 
 
HP:0000365 
• Visual impairment 
 
HP:0012373 
• Pseudobulbar signs 
 
HP:0002200 













• Smoking  
• Alcohol excess 








• Type 2 Diabetes Mellitus 
 
HP:0005978 
• Essential hypertension 
 
HP:0000822 
• Ischaemic heart disease  
 
HP:0001677 
• Peripheral vascular disease   
 
HP:0004950 
Family history • Stroke 
• Cognitive impairment or dementia 
• Migraine (with or without aura) 
• Psychiatric problems 
• Epilepsy 
• Any other neurological problems  






• White cell count 
• Platelet count 
• Glucose 
• HbA1C 










2.2.2.2 Recruitment, sample collection and processing 
Patients identified as suitable for whole genome sequencing were contacted via telephone or 
post. These patients and their relatives were either recruited during a home visit, in an 
outpatient research clinic, or through the post. 10-15ml of whole venous blood in 
ethylenediaminetetraacetic acid (EDTA) was collected from participants, either in the 
research clinic, or at their local primary care practice or hospital. Samples not collected locally 
were sent through regular post in sealed specimen bags and padded envelopes, together with 
the consent form. Legacy frozen blood samples from deceased or anonymised patients were 
retrieved and sent directly to the lab. In other deceased patients not local to Cambridge, 
stored DNA samples at room temperature were requested from clinical genetics laboratories. 
Where patients were unable to provide a blood sample, a saliva sample was collected in the 
Oragene DNA (OG-500) kit by DNA Genotek.  
All samples were processed by the Cambridge Translational Genomics (CATGO) laboratory at 
the Cambridge Biomedical Research Centre. These were barcoded, and DNA was extracted 
from whole blood and checked for genomic/self-reported sex and ethnicity matches. Where 
extracted DNA was provided, DNA was checked for integrity and quantity. Samples passing 
initial quality control measures were then forwarded on to Illumina for whole genome 
sequencing. All saliva samples were processed, but not used for sequencing.  
No quality control issues were encountered with fresh blood samples sent through the post, 
or thawed frozen samples. Six out of ten stored DNA samples had insufficient quantity for 
sequencing.  
2.2.3 Patients with early-onset, presumed sporadic SVD (UK Young Lacunar 
Stroke DNA Study) 
In Chapter 4 we investigate the role of monogenic disease genes in the context of presumed 
sporadic SVD, using a targeted multi-gene HTS panel. One-thousand and twenty-nine 
Caucasian patients with MRI-confirmed lacunar stroke occurring at or before the age of 70 
were recruited to the UK Young Lacunar Stroke DNA Study from 2002 to 2012, as previously 
described.29 Patients underwent full investigation for the aetiology of their stroke, and were 
categorised according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 




White matter hyperintensities were graded on MRI using the semi-quantitative Fazekas 
scale.211   
DNA extracted from whole venous blood from 993 participants of the UK Lacunar Stroke 
Study were processed at the Cambridge Biomedical Research Centre.  Stored DNA samples 
were quantified using a Qubit Fluorometer and the GloMax system. 
 The quality of the DNA was then assessed by agarose gel electrophoresis. Samples were 
sequenced on a high-throughput sequencing multi-gene platform known as 
ThromboGenomics.197 In this process, DNA was then fragmented into 200bp fragments and 
the designed probes were used to capture each DNA library.  We designed probes to capture 
the consensus coding sequence (CCDS), 5’ and 3’ UTRs, as specified by Ensembl and RefSeq, 
as well as 1000 bases upstream of the start of the transcript, and variants reported on the 
Human Genome Mutation Database (HGMD) of candidate genes.  
The resulting libraries were amplified, then sequenced using Illumina sequencing as described 
above. Reads were subject to quality control, and aligned to a reference genome (build 
GRCh37), before variants were called.   
The platform called single nucleotide variants, short insertions and deletions, and large copy 
number variants in 16 candidate SVD-associated genes. An automated filtering procedure 
prioritized the variants based on their presence in the Human Gene Mutation Database 
(HGMD), allele frequency and predicted impact on translation, transcription, splicing and 
protein structure.  
2.3 Conclusions 
In this thesis we consider the genetic basis of cerebral small vessel disease from the 
perspective of the ‘one-gene, one-disease’ hypothesis. There are two key approaches taken 
in sequence in this thesis: the recruitment and phenotyping of patients, and the sequencing 
and interpretation of genetic variants. 
We have recruited patients with familial SVD, including both ‘solved’ cases where the genetic 
cause is known (in particular, CADASIL cases only), as well as ‘unsolved’ cases where there is 
no known genetic mutation identified. The selection of cases is a clinical decision made by a 




before the age of 60, family history of stroke in first-degree relatives and syndromic features 
such as complicated migraine with aura. Cases were first tested for NOTCH3 mutations, and 
if these were negative they fed into our whole genome sequencing study. 
We have also used samples from presumed-sporadic young-onset SVD stroke patients. As the 
age at onset of familial SVD is relatively late in life compared to other genetic diseases, it is 
challenging to delineate whether an unsolved case is ‘sporadic’ or ‘familial’. We thus attempt 
to explore the possibility that there are disease-causing mutations in Mendelian disease genes 
in this cohort of individuals 
Using a variety of filter thresholds similar to those previously described,212,213 we narrow 
down the number of variants identified, and interpret these in the context of published 
clinical and functional data. In the age of falling costs of high throughput sequencing 
technologies, we attempt to explore the utility of HTS technologies to provide a genetic 
diagnosis for unsolved familial SVD cases, as well as to provide an estimate of the prevalence 
of these genetic diseases in a cohort of patients with young-onset presumed-sporadic SVD 
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3. Migraine, Encephalopathy and Stroke in CADASIL 
3.1 Introduction 
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is the most common monogenic form of stroke, and is 
caused by mutations in the NOTCH3 gene.51 CADASIL serves as an excellent model of SVD, as 
patients develop similar SVD features on imaging and histopathology at an earlier age before 
the development of other age-related pathology such as tau or Aβ deposits. This disease is 
thus a ‘pure’ prototype of SVD that is relatively uncontaminated by other confounding disease 
processes. This chapter explores CADASIL as an example of monogenic SVD, by examining the 
possible relationships between some of the key clinical features of the disease. 
As described in Chapter 1, the clinical features of CADASIL tend to be exclusively neurological, 
causing subcortical lacunar infarcts and cognitive impairment progressing to vascular 
dementia.43 However, the pathological changes in the form of granular osmiophilic material 
(GOM) are seen in both systemic and cerebral vessels,  
Migraines are often the earliest feature of disease and have been reported in up to 75% of 
cases.43–45 The pattern of migraines differs from that seen in the general population with a 
predominance of migraine with aura, and frequent reports of complicated and prolonged 
aura.43 
Despite its prevalence there have been few detailed studies of migraine in CADASIL.214–217 
Furthermore, little is known about how it responds to therapy and whether the management 
of migraine in CADASIL should differ from that of migraine in the general population.218–221 
Epidemiological studies have demonstrated that migraine, in particular migraine with aura, is 
an independent risk factor for stroke in the general population.222–225 However, whether the 
presence of migraine with aura in CADASIL is predictive of an earlier onset of stroke and a 
more severe phenotype is unknown. Another related clinical phenotype of CADASIL is 
encephalopathy or “CADASIL coma”. This can be preceded by an acute migraine 
headache,43,226 but the associations between migraine and encephalopathy are poorly 




In a cohort of 300 symptomatic patients with CADASIL we performed a cross-sectional study 
examining the prevalence and characteristics of migraine.  We recorded responses to 
migraine medication, and analysed the relationship between migraine, and both stroke and 
encephalopathy. 
3.2 Methods 
Data from 300 symptomatic CADASIL patients (170 females, 130 males) seen in a UK CADASIL 
National Referral Service was collected prospectively over a nineteen-year period, from 1996 
to 2015. All patients had a confirmed diagnosis of CADASIL, either by direct sequencing of the 
NOTCH3 gene to identify a pathogenic cysteine-changing mutation (n=296), by electron 
microscopy of a skin biopsy demonstrating GOM (n=2) or by characteristic imaging features 
of CADASIL, with a family history of genetically-confirmed CADASIL (n=2). Patients diagnosed 
with CADASIL on pre-symptomatic genetic testing were excluded from this study. Patients 
were evaluated and examined by consultant neurologists, written and informed consent was 
obtained, and data was collected using a standardised questionnaire at first review and at 
follow-up encounters. 
Patients were diagnosed with migraine at the point of care according to the International 
Classification of Headache Disorders (ICHD). The first edition (ICHD-1) was used from 1996 to 
2004, followed by ICHD-2 from 2004 to 2013, and ICHD-3 (beta version)227 from 2013 to 2015. 
Details of migraine episodes such as the duration, frequency and auras were collected.  
A cross-sectional analysis was carried out in 2015. The data was reviewed and all episodes of 
migraine were classified according to the ICHD-3 beta, where migraine with aura was defined 
as episodes where the ‘aura is accompanied, or followed within 60 minutes, by headache’. 
Aura types were classified according to typical aura (visual, sensory and/or speech or 
language symptoms with no motor weakness or monocular field defect), hemiplegic (visual, 
sensory and/or speech or language symptoms together with motor weakness) and brainstem 
aura (at least two of dysarthria, vertigo, tinnitus, hyperacusis, diplopia, ataxia and a decreased 




Data was also collected on confusional migraine aura, defined as disorientation and 
anterograde amnesia, with or without a decreased level of consciousness,228 preceding the 
headache and not requiring hospital admission. 
CADASIL encephalopathy or ‘coma’ was diagnosed clinically as an acute reversible 
encephalopathy with evidence of reduced consciousness in the absence of any other organic 
cause, where symptoms lasted for longer than 24 hours,226 and were sufficient to warrant 
hospital admission.  
Stroke was defined as a clinical stroke syndrome with MRI confirmation of a subcortical 
lacunar infarct at a site corresponding anatomically with the symptoms. Haemorrhagic 
strokes or cortical infarcts were excluded from analyses.  
Patients were asked about their responses to migraine treatment, and these were divided 
into two categories: (a) response: a consistent or partial reduction in severity or frequency of 
migraine attacks; or (b) no response: no response or worsening of migraine attacks. 
Prophylactic therapy was defined as medication taken specifically for the prevention of 
migraines, and not in response to an acute attack.  
All patients have given written informed consent and the study was approved by the South 
Thames Research Ethics Committee. 
3.2.1 Statistical methodology 
Quantile–quantile plots and the Shapiro-Wilk test were used to estimate distributions of ages 
at onset of migraine, encephalopathy and stroke. Where distributions of ages at onset were 
non-normal, the Mann-Whitney U test was used to calculate differences between groups. 
Odds ratios were calculated using the 2x2 Fisher’s exact test, or a logistic regression analysis 
where there were multiple categorical variables. Statistical analyses were performed using 
the R statistical software (version 3.2.2). Probability values of p<0.05 were considered 
statistically significant. 
To assess the association between migraine and lacunar stroke risk a competing risks 
regression analysis was used to estimate the difference in cumulative incidence of lacunar 
stroke between migraineurs and non-migraineurs and between the sexes. In competing risks 




the other, such as stroke (in this case, the outcome of interest) and death (a competing risk). 
A competing risks regression analysis can be used to demonstrate the cause-specific hazard 
of an event, as well as the cumulative incidence of the event while taking into account the 
influence of competing risks. It is thus superior to conventional survival analyses, which 
assume that competing events do not occur. 
3.3 Results 
3.3.1 The pattern of migraine in CADASIL 
Two hundred and twenty-six of 300 cases (75.3%) had a history of migraine. Migraine was the 
first feature of CADASIL in 203 (67.7%) (Figure 3-1).  Migraine was more common among 
females (139 of 170 women, 81.8%) than males (87 of 130 men, 66.9%). 
The age at onset of migraine was highly variable, with a median of 28 years (interquartile 
range 20, range 5 – 61, mean ± SD 29.0 ± 13.1). The age at onset was earlier in females 
(median 25 years, interquartile range 20.5, mean ± SD 26.9 ± 12.7) than in males (median 31 
years, interquartile range 18, mean ± SD 32.3 ± 13.2) (p=0.004, w=7422) and followed a left-












Table 3-1: Features of migraine and stroke in 300 symptomatic CADASIL patients. 




 130 170 300  
Migraine 
 
  87 (66.9%) 139 (81.8%) 226 (75.3%)  
Migraine as first 
feature 
 
 75 (57.7%) 128 (75.3%) 203 (67.7%)  
Migraine age at 













32.3 (13.2) 26.9 (12.7)  29.0 (13.1)  
Range 
 


















Migraine with and 
without aura 
 
 3 (2.3%) 2 (1.2%) 5 (1.7%)  
Migraine with aura 
(Percentage of 
those with aura) 
Typical aura 
 



























17 (21.0%) 23 (18.9%) 40 (19.7%) 
Number of auras* 
experienced (% of 
those with aura) 
1 
 
51 (63.0%) 83 (68.0%) 134 (66.0%)  
2 
 









 Male Female Total p-values 












34 (50.0%) 30 (37.0%) 64 (43.0%) 
Lacunar stroke age 




















44.9 (9.6) 48.8 (9.2) 47.0 (9.5) 
Range 
 
28 – 81 26 – 67 26 – 81 
Lacunar stroke – 
past medical history 
of migraine (% of 
those with lacunar 
stroke) 
 
 26 (38.2%) 57 (70.4%) 83 (55.7%)  
Table 3-1 footnotes: Asymptomatic CADASIL patients diagnosed on pre-symptomatic genetic 
testing were not included in this study.  Migraine was classified according to the ICHD-3 beta, 
with aura classified according to typical aura (visual, sensory and/or speech or language 
symptoms and no motor weakness or monocular field defect) and hemiplegic migraine (visual, 
sensory and/or speech or language symptoms, as well as motor weakness). Data was also 
collected for patients who experienced confusional aura.  *Aura types include typical, 
hemiplegic or confusional aura.  †All strokes were subcortical lacunar infarcts, apart from one 
case of fatal brainstem haemorrhage in a patient on warfarin, and one patient with a 






Figure 3-2: Ages at onset of migraine, encephalopathy and stroke for (A) all symptomatic patients, 
(B) females and (C) males. Migraine was often the first feature of CADASIL, and preceded 75.8% of 




Two hundred and three (67.7%) patients with migraine experienced aura, with the majority 
of patients reporting more than one type of aura (Table 1).  Of these 203 patients, 199 (98.0%) 
experienced typical aura, 33 (16.3%) fulfilled criteria for hemiplegic migraine, and 42 (20.7%) 
reported confusional aura (Table 3-1). None of these patients reporting confusional aura 
fulfilled criteria for brainstem aura. 
3.3.2 Response to therapies 
A variety of acute and preventive drugs had been used in treatment of the migraine. Of 226 
patients with migraine, information on the treatment of migraine was available in 213 (94.2%). 
One hundred and three (48.4%) were taking at least one medication for their migraine. 
Seventy-four (34.7%) had taken medication for acute relief of migraine, and 48 (22.5%) had 
taken medication as migraine prophylaxis at some point in time. The treatments used and 





Table 3-2: Treatment and responses to acute and prophylactic management of migraine in CADASIL 







No drugs used in migraine 
treatment 
 
110 (51.6%) - - - 
Drugs used in 
migraine 
treatment 
 103 (48.4%) 
 
   
For prophylaxis 
 
48 (22.5%) 31 10 7 
For acute relief 
 
74 (34.7%) 43 14 17 






31 20 4 7 
Paracetamol† 
 
11 9 1 1 
Ibuprofen 
 
8 5 2 1 
Aspirin† 
 
8 7 0 1 
(Unspecified) 
 





30 20 5 5 
Co-codamol 
 
3 1 1 1 
Co-dydramol 
 
2 1 0 1 
Migraleve† 
 
25 18 4 3 
Co-proxamol (paracetamol + 
dextropropoxyphene) 
 
1 1 0 0 
Other NSAIDs Indomethacin 
 





3 2 0 1 
Tramadol 
 

















24 10 12 2 
Sumatriptan§ 
 
18 9 9 1 
Naratriptan 
 
2 0 1 1 
Zolmitriptan 
 




2 0 2 0 
(Unspecified) 
 
2 1 1 0 
Primidone  
 
1 0 1 0 
Domperidone  
 
1 1 0 0 
Diazepam  
 
1 0 1 0 
Drugs used as regular migraine prophylaxis 
 
β blockers*  
 
25 10 8 10 
Propranolol†‡ 
 
22 8 8 6 
Atenolol 
 
1 0 1 0 
Metoprolol 
 
1 0 0 1 
(Unspecified) 
 





4 3 1 0 
Flunarizine 
 
1 1 0 0 
Verapamil 
 
2 1 1 0 
Nimodipine 
 
1 1 0 0 
Pizotifen‡  
 


















15 6  5 5 
Anticonvulsants  
 
6 4 2 0 
Topiramate 
 




3 2 1 0 
Ergolines  
 
2 0 1 1 
Methysergide 
 
1 0 0 1 
(Unspecified) 
 
1 0 1 0 
Acetazolamide  
 
1 0 0 1 
Fluoxetine  
 
1 0 1 0 
Combinations Pizotifen + 
Amitriptyline 
 









1 1 0 0 
Table 3-2 footnotes: 
 *Some patients have tried more than one type of drug in this class. 
†Drugs used both as regular migraine prophylaxis and pro re nata in acute treatment. 
‡Drugs which failed in isolation or in some combinations but showed good responses in other 
combinations. 




For acute management, simple analgesics such as paracetamol, ibuprofen and aspirin were 
most commonly used (in 31 of 74 patients, 41.8%), and were reported to have a good or 
partial response in 20 patients (64.5 %).  A combination of paracetamol and codeine (the most 
common formulation used was Migraleve) had been used in 30 patients (40.5%), with a good 
or partial response in 20 patients (66.7%). 
Twenty-four patients had taken triptans with data on responses available in 22; of these they 
were associated with a response in 10 (45.5%) and lack of response in 12 (54.5%). One patient 
reported that the effectiveness of sumatriptan wore off after repeated use. Patients did not 
report any worsening of neurological status on triptans (Table 3-2). 
The most common drugs used for migraine prophylaxis were beta-blockers. With these 10 
out of 25 (32%) patients reported a response (40%) and 8 (32%) reported no benefit. 
Responses to other prophylactic agents are shown in Table 3-2. 
3.3.3 The relationship between migraine and encephalopathy 
Thirty-three (11.0%) patients had a history of CADASIL coma or encephalopathy and this was 
the presenting feature leading to a diagnosis of CADASIL in 26 (8.7%), and the first feature of 
CADASIL in 2 (0.67%) (Fig 2). Often initially diagnosed as a viral encephalitis with nonspecific 
results on analysis of cerebrospinal fluid, these episodes recurred in 10 (30.3%) patients. The 
age at onset of encephalopathy followed a bimodal distribution in females and a right-skewed 
distribution in males (Fig 1(B)). The median age at onset of encephalopathy was 40 years 
(interquartile range 19, mean ± SD 41.8 ± 12.1, and range 19-63). The age at onset of 
encephalopathy did not differ between the sexes (p=1.0) (Table 3-3). Four patients developed 




Table 3-3: Features of CADASIL coma or encephalopathy in 33 patients with CADASIL 











Encephalopathy as a 
presenting feature 
 




2 (1.5%) 0 2 (0.67%)  

















































p = 1.0, w 
= 136.5 
 
Mean (SD) 8.2 (3.8) 7.9 (3.3) 8.1 (3.4) 
 
 






 4 8 12 (36%)  












2 2 4 (12.1%)  




Meningism 0 1 1 (0.03%) 
 
 
Vomiting 6 3 9 (27.3%) 
 
 








Encephalopathic episodes were characterised by a reduced conscious level, or confusion, 
lasting up to 3 to 17 days, with a median of 8 days (interquartile range 5). In 25 patients (75.8%) 
the coma evolved from an acute migraine headache. Common accompanying features were 
seizures (n=10), fever (n=4), hallucinations (n=13), nausea and/or vomiting (n=9) and 
meningism (n=2) (Table 3). Patients also reported associated focal neurological symptoms 
typical of migraine aura, such as speech and language disturbances or sensorimotor deficit. 
Although the majority of encephalopathic episodes resolved completely, five patients 
reported the persistence of associated symptoms lasting at least 6 weeks after the acute 
episode.   
Data on brain imaging (with diffusion-weighted MRI) during the episodes was available in 8 
patients, and there were no acute DWI positive lesions. Cerebrospinal fluid (CSF) analysis 
results were available in 7 patients, of which 6 showed raised protein levels and two showed 
leucocytosis. All seven had normal glucose levels. Electroencephalograms (EEGs) were 
performed in five patients and showed generalized slowing.  
Patients with a past history of migraine with aura had a higher odds ratio of developing 
encephalopathy (30 of 33 vs. 173 of 267; OR=5.4, 95% CI 1.6 – 28.4, p=0.002). Migraine 
sufferers with a history of confusional aura also had an increased risk of developing 
encephalopathy (OR=2.5, 95% CI 1.0– 5.8, p=0.04), but there was no increase in risk with other 
aura types, or with sex or age at onset of migraine.  
3.3.4 The relationship between migraine and lacunar stroke 
One hundred and fifty-one patients (82 females, 48.2% and 69 males, 53.1%) had experienced 
stroke, all of which were subcortical lacunar infarcts, apart from one case of fatal brainstem 
haemorrhage in a patient on warfarin, and one patient with a cerebellar vermis haemorrhage, 
both of which were excluded from subsequent analyses. None of the lacunar infarcts were 
fatal. Sixty-four patients suffered more than one stroke.  
The distribution of ages at onset of lacunar stroke followed a symmetrical and unimodal 
distribution in both sexes, with a median age at onset of first stroke of 48 years (interquartile 




50 years, interquartile range 11, mean ± SD 48.8 ± 9.2) than in males (median 43 years, 
interquartile range 11, mean ± SD 44.9 ± 9.6), (p=0.003, w=1976.5) (Figure 3-1, Table 3-1).  
Eighty-three (55.7%) patients (57 females, 70.4% and 26 males, 38.2%) had a past medical 
history of migraine before their first stroke. A history of migraine prior to stroke onset was 
associated with a lower cumulative incidence of stroke, compared to individuals without 
migraine or who developed migraine only after their first stroke.  On competing risks analysis 
of the time to first stroke, the hazard ratio for the presence of a history of migraine prior to 
stroke was 0.5 (95% CI 0.3 – 0.6, p = 2.1x 10-6) (Figure 3-3). Despite the difference in the ages 
at onset of stroke between the sexes, the hazard ratio for sex was not significant (HR for 





Figure 3-3: Cumulative incidence of stroke in (A) males and females, and (B) migraineurs and non-
migraineurs. As demonstrated on competing risks analysis, migraineurs had a lower hazard ratio 
than non-migraineurs (HR = 0.5, 95% CI 0.3-0.6, p = 2.1 x10-6), while the hazard ratio for female sex 





In this study in 300 symptomatic CADASIL patients, migraine was the presenting symptom in 
two thirds, and present in three quarters. The nature of migraine differed from that in the 
general population, with 90% of CADASIL patients experiencing migraine with aura, and 
prolonged and complex auras being common. This is in contrast to the predominance of 
migraine without aura in the general population.229–231  The age at onset of migraine in 
CADASIL was also later than in the general population.232 However, consistent with migraine 
in the general population,233 as well as previous studies of European CADASIL patients,234 
migraine in CADASIL was more common in females, with a mean age at onset of around 4 
years earlier. 
There is little published data on treatment responses to migraine in CADASIL.218–221 In this 
cohort, a significant proportion of patients with migraine did not take medication due to the 
migraine episodes being infrequent. However in those that did, treatment responses seemed 
to be similar to that seen in the general population.235,236 Of interest, 24 patients had taken 
triptans and none had reported serious side effects. Drug information sheets tend to indicate 
that triptans are contraindicated in patients with stroke or TIA, or at high risk of cardiovascular 
disease, because of the theoretical risk that they might exacerbate cerebral ischaemia.237 In 
this retrospective study we found no evidence that this occurred. This is consistent with data 
from the general population which found no association of triptans with stroke risk,238 
however it is important to note that since some of these purported risks are similar to the 
natural progression of the disease it would be challenging to tease out if subsequent TIAs, 
strokes or worsening cognitive impairment could be attributed to the triptans.  A fifth of 
CADASIL migraineurs required regular prophylactic treatment for migraines, with a variable 
response to these preventive medications.  
Encephalopathy in CADASIL was first described as being completely reversible episodes of 
confusion, coma, fever and seizures.226,239 In this study we found that 11% of patients 
developed such episodes warranting hospitalization. Encephalopathy was also the presenting 
feature leading to a diagnosis of CADASIL in majority of these 33 patients, hence CADASIL 
should be considered in the differential of a patient presenting with encephalopathy with 




encephalopathic episodes around the puerperium as previously reported.46,240 The 
predilection for the puerperium suggests a possible hormonal contribution, which might also 
contribute to the increased prevalence of migraine in females.  
Encephalopathy episodes have been previously reported to often develop from a migraine 
attack, and we hypothesised that they might share an underlying aetiology. Consistent with 
this, 76% evolved from a migraine attack, and we found that encephalopathy was more 
common in CADASIL cases who had previously experienced migraine with aura. Furthermore, 
individuals with migraine with aura who had experienced confusional migraine aura were 
more likely to develop encephalopathy, compared with those with other aura types. Our data 
is consistent with a continuum of symptoms in CADASIL, ranging from acute confusional 
migraine episodes lasting up to three days,217,228 status migranosus with persisting aura 
lasting up to 8 days,217 and encephalopathic episodes lasting up to 14 days.43,226 
Migraine with aura is an independent risk factor for stroke, and is associated with white 
matter changes and silent infarct-like lesions on MRI.223 Migraine and stroke also co-occur in 
other monogenic forms of small vessel disease. We hypothesised that migraine might also 
contribute to a more severe phenotype in CADASIL; however, we found no evidence of this 
and indeed non-migraineurs with CADASIL had a higher cumulative incidence of stroke. The 
explanation for this association is uncertain and the finding needs replicating in other cohorts, 
but it is reassuring that migraine with aura is not associated with a worse phenotype. The 
electrophysiological basis of migraine in CADASIL is believed to be Cortical Spreading 
Depression (CSD) in which waves of synchronised depolarisation spread across the brain 
cortex,241 being associated first with an increase in cortical blood flow, followed by a period 
of hypoperfusion.242 It is possible that such episodes could be associated with protection 
against subsequent ischaemia, perhaps by mechanisms related to ischaemic 
preconditioning.243 
While this is one of the largest studies of migraine, encephalopathy and stroke in CADASIL, it 
is not without limitations. As this was a cross-sectional analysis of prospectively collected data, 
it is probable that more severe cases of CADASIL are detected earlier, while there may be 
many NOTCH3 mutation-carrying individuals with few or no symptoms that remain 
undiagnosed. There is currently no clinically accepted definition of encephalopathy in 




encephalopathic episode may be difficult – in this study we have set an arbitrary measure of 
severity (the need for hospitalisation) and a temporal definition (encephalopathic symptoms 
lasting at least 24 hours).  
Our evaluation of treatment responses is also limited by the design of this study. As this was 
a cross-sectional study, patients were not randomised to different types of migraine therapy. 
It is thus challenging to estimate the complication rate from therapy in such a cohort, 
although none of the ischaemic events in this cohort were attributed to triptan use.  
In conclusion our results provide data from a large population of prospectively recruited 
CADASIL patients on the frequency, characteristics and treatment responses of migraine. Our 
data shows that while many patients do not need treatment for their migraine, about half do, 
and in this group similar treatment responses are seen to that in the general population with 
migraine. Our series further characterises the CADASIL coma or acute reversible 
encephalopathy which may lie on the spectrum of migraine auras, sharing similar features 






3.5.1 Correction for ascertainment bias 
There was a disproportionate female-to-male ratio (170 females, 130 males) in this cohort, 
where females had a higher proportion of migraineurs (81.8%) compared to males (66.9%). 
Females also had a later age at onset of stroke (mean 48.4 ± 9.1 years) compared to males 
(45.1 ± 9.7 years). The competing risk regression analysis of all 300 individuals showed a 
reduced cumulative incidence of stroke in migraineurs than non-migraineurs, and no 
difference in the risk of stroke between the sexes.   
In view of the disproportionate sex ratio and differing migraine prevalence within each sex, 
the competing risk regression analysis was re-run using two different approaches to confirm 
the results found in all 300 patients.  
First, equal numbers of each sex were selected – the first 130 females recruited to the study, 
together with all 130 males. This included 183 migraineurs (61.5% of males and 79.2% of 
females), and 77 non-migraineurs. This again showed a reduced cumulative incidence of 
stroke in migraineurs, with a hazard ratio of 0.45 (95% CI 0.32 - 0.62, p = 1.7 x 10-6) (Figure 3-4) 
(A, B). There was no difference in the cumulative incidence of stroke between the sexes. 
Second, patients were selected such that there were equal proportions of migraineurs for 
each sex. All 130 males (66.9% migraineurs) and 94 females were selected. The first 63 
females with migraine recruited to the study were selected, together with the first 31 non-
migraineur females (66.9% migraineurs). This approach produced similar results, with 
migraineurs having a lower cumulative incidence of stroke (hazard ratio 0.46, 95% CI 0.32 - 
0.65, p = 1.4 x 10-5). Again, there was no difference in the cumulative incidence of stroke 










Figure 3-4: Cumulative incidence of stroke in (A) and (C) males and females, and (B) and (D) 
migraineurs and non-migraineurs, in an analysis with an equal number of males and females (A and 
B).  (C) and (D) show the same analysis in 130 males and 94 females both with equal proportions of 
migraineurs. As demonstrated on competing risks analysis in both approaches, migraineurs had a 
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4. A candidate gene study in presumed sporadic, early-
onset small vessel disease 
4.1 Introduction 
Cerebral small vessel disease (SVD) is estimated to cause up to a fifth of all ischaemic strokes 
and is a leading cause of vascular dementia. The main causes of SVD are cerebral amyloid 
angiopathy and arteriosclerosis, with hypertension being the major risk factor. The latter form 
of SVD, which is a disease of the small perforating arteries supplying the white and deep grey 
matter of the brain, and is also responsible for subcortical or deep intracerebral 
haemorrhages,4 is considered in this chapter. 
The majority of SVD cases are thought to be sporadic, arising in the elderly and hypertensive 
population. However, SVD is also the subtype of stroke that is most likely to present as a 
familial disease caused by a mutation in a single gene. The most common monogenic form of 
SVD is Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL), which is caused by cysteine-changing mutations in the 
epidermal growth factor-like repeat (EGFr) regions of the NOTCH3 gene.39 Non-cysteine-
changing variants have been reported as CADASIL-causing, however these associations 
remain unproven and controversial.244 
Familial SVD is a rare group of diseases, with CADASIL estimated to occur in approximately 2 
to 4 per 100 000 population.40,41 A previous study of a population of presumed-sporadic, MRI-
defined SVD stroke patients below the age of 70 (the UK Lacunar Stroke Study) showed that 
only five of 994 patients carried a CADASIL-causing cysteine-changing mutation1, and no 
patients carried Fabry disease-causing mutations.151 This cohort of patients is studied in this 
chapter. 
However, the relative heterogeneity of symptoms and severity of disease features in 
pedigrees with CADASIL and other forms of familial SVD raises suspicion that there may 
remain many undiagnosed cases in the population. Many affected relatives in pedigrees with 
diagnoses of monogenic SVD have milder, non-specific features of familial disease such as 
                                                          




migraine, strokes and white matter abnormalities, and in the context of concomitant risk 
factors these patients may not often lead to a suspicion of familial disease, and would have 
been classed as ‘sporadic’ SVD, or remained undiagnosed. In addition, the five NOTCH3 
mutation-carrying ‘sporadic’ stroke patients mentioned above had few clinical features 
specific to CADASIL, and three did not have any family history of stroke.151 Hence, we 
speculate that many patients with SVD-related lacunar strokes which are presumed to be 
‘sporadic’ may in fact have an underlying monogenic cause. This chapter aims to investigate 
the prevalence of rare variants in known familial SVD genes in a preliminary study of the same 
cohort of patients from the UK Lacunar Stroke Study, using a High-Throughput Sequencing 
(HTS) platform known as ThromboGenomics.197  
4.2 Methods 
4.2.1 Study population 
Over an 8-year period from 2005, 1247 patients with suspected lacunar stroke were recruited 
from 72 specialist stroke centres across the UK. Patients underwent full investigation for the 
aetiology of their stroke, and were categorised according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) classification. One thousand and thirty of these patients with 
European ancestry and an MRI-confirmed lacunar strokes of presumed SVD origin before the 
age of 70 fulfilled inclusion criteria of the UK Young Lacunar Stroke DNA study, as previously 
described.151 White matter hyperintensities (WMH) were graded on MRI using the semi-
quantitative Fazekas scale.211   
As part of the Young Lacunar Stroke DNA study, 994 DNA samples of sufficient quantity and 
quality were previously screened for disease-causing mutations in the NOTCH3 and GLA genes. 
Exons 3, 4, 5, 6, 11, 18, 19 and 22 of the NOTCH3 gene screened using denaturing high-
performance liquid chromatography (DHPLC), and in addition, exons 3 and 4 were screened 
using Sanger sequencing. Up to 90% of mutations in the UK population were previously shown 
to be in these exons.245  This screen showed that 5 individuals carried CADASIL-causing 
mutations. The GLA gene was screened using high resolution melt-curve analysis, covering all 




mutation. No Fabry-causing mutations were identified.151 In this study, DNA of sufficient 
quality and quantity was available from 993 patients.   
4.2.2 Baseline characteristics of patients  
Baseline characteristics and cardiovascular risk factor profiles of these 993 patients are 




Table 4-1: Baseline characteristics of 993 patients included in this study  
Age at first stroke in years, mean (S.D.)  60.1 (8.6) 
 
Number of males 705 (71.0%) 
 
BMI, mean (S.D.) 28.7 (6.2) 
 
Number of patients with: 
 
 
Hypertension 713 (71.8%) 
 
Diabetes 164 (16.5%) 
 
Hypercholesterolaemia 673 (67.8%) 
 
Smoker (current or previous) 697 (70.2%) 
 
Alcohol excess (≥20 units/week) 290 (29.2%) 
 
Migraine  50 (17.9%) 
 
Myocardial infarction/ coronary artery bypass 
graft or angioplasty 
 
35 (3.5%) 
Peripheral vascular disease 28 (2.8%) 
 
Previous or recurrent strokes 37 (3.7%) 
 




Microbleeds present* 63 (18.6%) 
 
S.D.: standard deviation.  
*Gradient echo imaging to allow determination of the presence of microbleeds was 





4.2.3 Gene and transcript selection 
DNA samples were quantified, diluted and sequenced using the ThromboGenomics platform 
at the Cambridge Translational Genomics (CATGO) laboratory, part of the Cambridge 
Biomedical Research Centre. This platform and analysis pipeline have been described in detail 
by Simeoni et al.197 This pipeline identifies variants in 96 genes related to bleeding and platelet 
disorders. In addition, 15 SVD-related genes selected based on peer-reviewed literature, as 
listed in Table 4-2, were added to this platform. These 15 genes were associated with familial 
cerebral small vessel disease (SVD) or its related phenotypes, such as familial hemiplegic 
migraine (FHM), cerebral amyloid angiopathy (CAA) or connective tissue diseases known to 
cause stroke. For each gene, we identified the main transcript on which to report variants 
based on peer-reviewed literature, and submitted these to the Locus Reference Genomic 
database (LRG) (hhttp://www.lrg-sequence.org/).246  
The platform was designed to target (capture) all exonic regions, 5’ and 3’ untranslated 
regions (UTRs, often regulatory regions) and 50bp into each intron. In addition, 1000 base 
pairs (bp) upstream of the gene start sites and all variants listed in the Human Gene Mutation 
Database (HGMD) for those genes were targeted. HGMD is a curated database of genetic 
variants, or ‘mutations’, known to be associated to a disorder. They are classified as disease-
causing mutations (DM), possibly disease-causing mutations (DM?), disease-associated 
polymorphisms (DP), disease-associated polymorphisms with functional evidence (DFP) or as 





Table 4-2: SVD-related candidate genes included on the ThromboGenomics sequencing panel.  





Familial SVD CADASIL 
 







Dominant COL4A1 NM_001845 
COL4A2-related SVD 
 




Dominant FOXC1 NM_001453 





Dominant TREX1 NM_033629 
Fabry Disease Dominant 
X-linked 
GLA NM_000169 
Familial CAA Hereditary Cerebral 
Haemorrhage with 
Amyloidosis (HCHWA-
Dutch, Flemish, Italian, 
Piedmont, Iowa, Arctic) 
 
Dominant APP NM_000484 
Familial British Dementia 
 
Dominant ITM2B NM_021999 
HCHWA-Icelandic 
 
Dominant CST3 NM_000099 
FHM FHM Type 1 
 
Dominant CACNA1A  NM_001127221 
FHM Type 2 
 
Dominant ATP1A2 NM_000702 
FHM Type 3 
 


















Reads were aligned to the human reference genome build GRCh37 using Burrows-Wheeler 
Aligner (BWA) 0.7.10.247 On-target coverage was assessed using BEDtools 2.22.0.248 Single 
nucleotide variants (SNVs) and short insertions or deletions (indels) were called using GATK 
3.3 HaplotypeCaller,249 and large copy number variants (CNVs) were called using a custom 
pipeline based on ExomeDepth 1.1.10.250  To call CNVs in a sample, ExomeDepth finds the 
read depth in regions of interest and compares the sample to an optimized reference set of 
10 other samples measured in the same batch. ExomeDepth’s methods are customized to 
define a reference set and calculate a number of reads per targeted region. To be able to 
detect smaller CNVs, the large targeted regions were divided into chunks of no greater than 
500bp. Deletions were assigned a homozygous status if the observed/expected read ratio was 
less than 0.1, and heterozygous if the ratio was between 0.1 and 1 (exclusive). Duplications 
of one extra copy were called if the ratio was <1.7, and more than one additional copy if the 
ratio was >1.7. A Bayes factor was calculated for each CNV, reflecting the degree of the 
confidence of the call.   
Samples from 993 SVD patients were processed in 3 different batches. In each batch, the CNVs 
were called for the autosomal chromosomes using 10 non-SVD reference samples of any sex, 
and for CNVs in the X chromosome gene (GLA), these were assessed using reference samples 
of the same sex.  
4.2.5 Filtering of variants  
4.2.5.1 Single Nucleotide Variants (SNVs) and Indels  
All variants within 15bp up- and down-stream of exons or any region for which a bait was 
designed were interpreted. Two levels of filtering were applied to SNVs and indels – a relaxed 
and a stringent filter. Using the relaxed filter, all SNVs and indels called were filtered based 
on their predicted impact on the genes (Ensembl 75 dataset), their presence in HGMD Pro 
(2016.3) or locus-specific databases (LSDBs), and their minor allele frequencies (MAFs) in the 
genome Aggregation Database (gnomAD), a database of 123,136 whole exome sequences 
and 15,496 whole genome sequences curated by the Broad Institute 




within the dataset, and which are present in HGMD or other locus-specific databases were 
retained. A summary of criteria is provided in Table 4-3.  
A more stringent filter was also applied on the data. All SNVs and indels called were filtered 
based on their minor allele frequency in the genome Aggregation Database (gnomAD). 
Variants with a minor allele frequency of less than 1 in 10-4 were included in the analysis. 
Combined Annotation Dependent Depletion (CADD) scores, computed using an in silico 
predictive tool which integrates multiple annotations to provide an estimate of 
deleteriousness (http://cadd.gs.washington.edu), were also computed. Variants with a CADD 
score of 15 and above, and which were presumed to cause disease by haploinsufficiency were 





Table 4-3: Filters for single nucleotide variants and indels called on ThromboGenomics.  
RELAXED FILTER 
Fulfilling all of the following criteria:  
• AF <0.1 or AF >0.9 in ThromboGenomics  
• Is at the same position as previously described in HGMD or variant identified in 
another locus-specific database 
• AF <0.025 or >0.975 or not present in gnomAD 
or 
Fulfilling all of the following criteria: 
• Has a predicted moderate or high impact on splice-region on translation in the 
selected gene transcript according to SnpEff 
• AF <0.001 or >0.99 in gnomAD, or not present in gnomAD  
• Has <4 alternate alleles (to guard against errors in repetitive regions) 
STRINGENT FILTER 
Fulfilling all of the following criteria: 
• MAF < 0.0001 in gnomAD 
• CADD score ≥ 15 







Variants were compared with those reported in literature, as well as on ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), an archive of genomic variation and its relationship 
to disease, and the DatabasE of genomiC varIation and Phenotype in Humans using Ensembl 
Resources (DECIPHER)2, a web-based database of genomic variants.252  
Copy Number Variants 
All CNVs within the candidate gene regions with a Bayes factor of 20 and above were included 
in analysis.  
4.3 Results and discussion  
4.3.1 Sequencing quality control  
To identify low quality regions to be excluded from the analysis, the sequencing coverage 
profile of the ThromboGenomics platform was assessed in each batch of samples. Individual 
coverage profiles for each gene showed that targeted regions of transcripts were well-
covered (>100X), beyond a level sufficient for sensitive variant calling (20X), with an exception 
in the ABCC6 gene where the 5th percentile showed low coverage in the 3’ untranslated region 
(UTR). This is likely due to the 3’UTR of ABCC6 not being included in the target region during 
the development of capture probes, possibly because there are a high number of repetitive 
regions in the region. Examples of coverage plots are shown in Figure 4-1.
                                                          
2 This study makes use of data generated by the DECIPHER community. A full list of centres who 
contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via email 






Figure 4-1: Example of a coverage profile of (A) the FOXC1 gene, showing good coverage (>500X) 
across all targeted regions of the transcript, and (B) a section of the ABCC6 gene, showing poor 
coverage (<20X) at the 3’ UTR region which has not been included as a target in the design of capture 
sequences. The coverage is shown for the 5th percentile (red line), 50th percentile (blue line) and 95th 
percentile (green line). The regions targeted by the capture array are represented in blue (‘targets’) 
and the Ensembl transcript model in yellow. The problematic region in ABCC6 is highlighted in red. 




4.3.2 Copy Number Variants (CNVs) 
A total of 50 CNVs (34 deletions and 13 duplications) were called in 102 individuals. Excluding 
CNVs with a Bayes’ factor of less than 20, 17 CNVs (11 deletions and 6 duplications) in 44 
individuals (4.4%) remained. All CNVs were in a heterozygous state, however 6 individuals 
were found to have more than one CNV as shown in Table 4-4. Two patients were compound 
heterozygous for deletions in SCN1A, affecting both exons 1 to 8 or 1 to 9 including the 
promoter, and exons 17 to 25 of the gene. Individuals with both CNVs and SNVs are discussed 
in the section under SNVs.   
A duplication spanning  45 genes including COL4A1 and COL4A2 in the 13q33-q34 locus has 
previously been described in a female singleton with early-onset SVD.87 This individual 
presented at the age of 44 with diffuse white matter hyperintensities, multiple microbleeds 
and multiple subcortical lacunar infarcts, as well as vertebrobasilar dolichoectasia, and there 
was no clear family history of SVD.  In this cohort we identified a duplication of exons 2 to 52 
of COL4A1 and exons 3 to 48 of COL4A2 in a male presenting at the age of 29 with a lacunar 
stroke, having had only a history of cigarette smoking in terms of his cardiovascular risk 








Table 4-4: Individuals with more than one CNV in the 15 candidate genes screened.  















Fazekas score 0 





Deletion ABCC6 6 of 31  
chr16:16313384-
16313589 
Deletion ABCC6 4 of 31  
UK03-
005 
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One individual was found to have a duplication of the entire length of the ABCC6 gene 
(chr16:16243414-16276815) including its promoter. Homozygous or compound heterozygous 
mutations in ABCC6 are associated with pseudoxanthoma elasticum, an autosomal recessive 
connective tissue disease. Duplication of this gene has not previously been associated with 
disease, while a deletion of the whole gene has been found in a compound heterozygous 
patient with pseudoxanthoma elasticum.253 Duplications are challenging to interpret: 
depending on the insertion of the duplication, this variant may or may not disrupt the 
expression of the gene, and expression of the duplication may not have clinical impact. 
Functional studies such as RNA sequencing are necessary to determine the impact of the 
duplication on gene function.  
Four individuals were found to have a deletion of exon 23 to 29 of the ABCC6 gene. This 
deletion has previously been found to be present in a high frequency of Caucasian patients 
with pseudoxanthoma elasticum, where these individuals also carried another missense or 
nonsense mutation on the other ABCC6 allele. In these four patients two were also found to 
have missense variants in the ABCC6 gene, as discussed in the section on SNVs (Table 4-14). 
The deletion is thought to be mediated by Alu repeats (AluSX) occurring at a high frequency 
in this region of the gene.254 Overall, the ABCC6 gene is highly susceptible to CNVs, and this is 
thought to be due to its high proportion of long and short interspersed nuclear elements 
which provide sites for recombination, such as the Alu repeats.253 This repetitiveness also 
complicates the calling of CNVs. For example, the two CNVs called in individual UK02-026 
affecting exons 4 and 6 may in fact be the same CNV that has been poorly called (Table 4-4).  
Two other regions of CNVs were also found in multiple patients. The first is a region spanning 
exon 22 and 23 in SCN1A, deletions of which were identified in three individuals albeit of 
varying lengths. The second is a region spanning exon 1 to 8 in SCN1A which was found in two 
individuals. Autosomal dominant mutations in SCN1A are associated with Familial Hemiplegic 
Migraine Type 3. 




Table 4-5: CNVs appearing in more than one individual.  



































































Table 4-4 footnotes: This table includes CNVs which appear in only one individual, but 





4.3.3 Single Nucleotide Variants (SNVs) and Indels 
SNVs and indels were subject to two levels of filtering. The relaxed filter resulted in 17358 
SNVs filtered in 909 individuals across the 15 candidate genes. A summary of the number of 
each type of variant identified on the relaxed filter is provided in Table 4-6 . The stringent 
filter resulted in 87 SNVs called in 93 individuals.  
Sixteen variants were identified with a high MAF on application of the relaxed filter (>0.9 in 
ThromboGenomics and >0.975 or absent in gnomAD, or >0.99 or absent in gnomAD). These 
imply that a minority of individuals did not carry the identified minor variant that has been 
called as the major variant in the reference genome. These variants, the majority of which are 







Table 4-6: Variants called in each gene in 993 SVD cases where a relaxed filter has been applied.  
Gene Stop-
gained 
Missense Intron Splice donor/ 
acceptor 







1 31 18 0 0 0 8 2 0 0 4 60 
APP 
 
0 9 2 0 3 0 1 0 0 0 1 15 
ATP1A2 
 
0 8 4 0 0 0 0 0 0 0 2 12 
CACNA1A 
 
0 34 14 0 0 0 6 0 4 3 5 62 
COL3A1 
 
0 16 2 0 0 0 3 0 0 0 3 21 
COL4A1 
 
0 19 4 0 1 0 0 0 0 0 5 23 
COL4A2 
 
0 21 3 0 1 0 0 1 0 0 3 24 
CST3 1 0 0 0 0 0 0 1 0 0 0 2 
FOXC1 
 
0 3 0 0 1 1 1 1 4 3 0 13 
GLA 
 
0 3 0 0 1 0 2 0 0 0 0 6 
HTRA1 
 
1 10 1 0 0 0 1 0 0 0 2 13 
ITM2B 
 
0 3 0 0 0 0 0 0 0 0 0 3 
NOTCH3 
 
0 50 6 1 0 0 2 0 0 1 9 59 
SCN1A 
 
0 15 5 0 2 0 5 0 0 0 2 27 
TREX1 
 





Table 4-7: Single nucleotide variants with a high MAF identified on the relaxed filter. 









rs11866320 Intron ABCC6 c.2787+62T>C   43 (4.3) 
 
rs1516446 Missense COL3A1 c.4059T>G p.His1353Gln  43 (4.3) 
 




HTRA1 c.1274+8G>a  41 (4.1) 
 
rs2820581 Intron ATP1A2 c.381+16C>T  42 (4.2) 
 
rs2854246 Intron ATP1A2 c.13-22T>C  42 (4.2) 
 
rs536174 Missense COL4A1 c.1663A>C p.Thr555Pro 42 (4.2) 
 




Missense ABCC6 c.2542A>G p.Met848Val 42 (4.2) 
rs7193932 Intron ABCC6 c.1432-48G>A  42 (4.2) 
 
rs7194043 Intron ABCC6 c.2995+142C>T  42 (4.2) 
 
rs7199864 Intron ABCC6 c.1432-215A>G  43 (4.3) 
 
rs7201980 Intron ABCC6 c.2788-127A>G 
 
 43 (4.3) 
rs7500834 Synonymous ABCC6 c.2400A>G p.Gly800Gly 
 
43 (4.3) 
rs8043704 Intron ABCC6 c.2788-388A>C  
 
240 (24.2) 








Individuals with both CNVs and SNVs 
Compound heterozygous individuals with both CNVs and SNVs in the ABCC6 gene have 
previously been identified in patients with pseudoxanthoma elasticum. Five patients were 
found to have both CNVs and SNVs passing the relaxed filter in ABCC6, and these are 
discussed in a later section of this chapter under ‘ABCC6’.    
No individuals were found to have both a CNV and an SNV passing the stringent filter in the 
same gene. However, with the stringent filter, four individuals were found to carry SNVs in a 
separate gene, in addition to the CNVs described earlier, as summarised in Table 4-8.  
One individual was found to have duplications of the entire lengths of the SCN1A and COL3A1 
genes, as well as a frameshift variant at the 381st amino acid residue of FOXC1. Heterozygous 
frameshift variants at positions 34 and 274 have previously been associated with SVD.91 All 
44 individuals with CNVs passing the Bayes factor filter were also found to carry at least one 
SNV passing the relaxed SNV filter. 
One other individual with a deletion in exon 1 of the ABCC6 gene was also found to carry a 
novel COL4A2 missense variant (p.Trp1512Arg) in the NC1 domain of the protein. This region 
of the gene is thought to be responsible for tropocollagen stabilisation.255 The nearest 
heterozygous variant previously associated with SVD in this region is p.Ala1690Thr,159 also in 








Table 4-8: Individuals with both CNVs and SNVs (passing the stringent filter) in candidate genes 




















































































































































Table 4-8 footnotes: Ages specified are the age at onset of the presenting stroke, and risk factors specified are at the time of the presenting stroke. Family 





Cysteine-altering variants within the EGFr region (exons 2 to 24) of the NOTCH3 gene are 
known to be associated with CADASIL. Five individuals were previously found to have five 
different CADASIL-causing mutations on screening of exons 3, 4, 5, 6, 11, 18, 19 and 22,42 and 
these individuals and variants were again identified in this study. However, there were six 
additional individuals also identified to carry cysteine-altering variants – of which two 
(p.Arg169Cys and p.Cys76Tyr) were in exons that had initially been screened on both DHPLC 
and Sanger sequencing.  
One of the variants, a cysteine-altering variant in exon 22 (p.Cys1222Gly) which was also 
detected in the previous study, did not pass the stringent filter as it was present at a minor 
allele frequency of 1.1 x 10-4 in gnomAD, but was identified on relaxed filtering. This variant 
has previously been reported as a pathogenic mutation in CADASIL,256 however it was also 
identified in a significant proportion of non-SVD controls on whole genome sequencing 
(Chapter 5). 
In total, 11 individuals were found to be heterozygous for CADASIL-causing mutations in the 
NOTCH3 gene, giving an overall diagnostic yield of 1.1%. Six of these individuals had a first-
degree relative with a history of stroke, and seven had white matter hyperintensities on MRI 
(Fazekas score of 2 and above). The majority of these patients had multiple cardiovascular 
risk factors at the time of their presenting stroke. There were no other insertions or deletions 
resulting in a gain or loss of a cysteine variant found in this cohort. The two individuals who 
did not have confluent white matter hyperintensities carried variants in the latter part of the 
EGFr region (p.Cys1119Tyr and p.Cys1222Gly in exons 20 and 22), lending further support to 
the hypothesis that mutations in this part of the protein may result in a milder clinical 
phenotype.59 There were no other variants (non-cysteine-altering) which passed the stringent 
filter. The clinical features of, and mutations identified in these 11 individuals are summarised 








Table 4-9: NOTCH3 cysteine-altering variants identified on both relaxed and stringent filters 
ID Sex Age  Risk factors Imaging features Family 
history 
Variant Exon dbSNP 
ID 



















No gradient echo 
performed 
None c.227G>A  
p.Cys76Tyr 





























Fazekas score 3 



























Fazekas score 3 
Minor left anterior 
temporal pole 
involvement 





















ID Sex Age  Risk factors Imaging features Family 
history 
Variant Exon dbSNP 
ID 














Fazekas score 3 























Fazekas score 2 
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ID Sex Age  Risk factors Imaging features Family 
history 
Variant Exon dbSNP 
ID 






M 53 BMI 35 Isolated lacunar 
infarct 
Fazekas score 1 



























Fazekas score 1 




























BMI 29  
WMH 

















Fazekas score 2 
No microbleeds on 
gradient echo 
None Identified 
on DHPLC  





On relaxed filtering, and excluding cysteine-altering variants in exons 2 to 24, 144 individuals 
(14.5%) carried 51 unique variants passing filters in the NOTCH3 gene respectively. All 
individuals were heterozygous for these variants. Two patients each carried two NOTCH3 
variants (p.Pro496Leu/p.His1235Leu), however one of the variants (p.Pro496Leu) has a minor 
allele frequency of 1.1 x 10-2 in gnomAD. Two individuals shared a disruptive inframe insertion 
(p.Arg12_Arg13insArgArgArg), however this does not introduce or remove a cysteine residue.  
While only cysteine-changing mutations are thought to be disease-causing, it has been 
suggested that other non-cysteine altering variants may be associated with disease.263  
However, these associations are often not replicated, are in patients who have not had the 
entire EGFr region of the gene sequenced, and have not had the diagnosis of CADASIL 
confirmed on post-mortem analysis or skin biopsy. In this study, one of these variants, 
c.509A>G (p.His170Arg) was identified in 9 patients. This variant has been also been described 
as a polymorphism57 and is present in a significant number of individuals in control databases 
(Chapter 5), with a frequency of 1.7 x 10-3 in gnomAD, indicating that this variant is not 
pathogenic for CADASIL.  
HTRA1 
Missense and nonsense HTRA1 mutations have been reported in Cerebral Autosomal 
Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL).61 More 
recently, heterozygous missense and nonsense mutations in HTRA1 have also been identified 
in patients with an autosomal dominant form of SVD.67,174 The HTRA1 gene encodes for the 
high temperature requirement serine protease A1, and is thought to cause a vasculopathy via 
the loss of inactivation of the TGFβ pathway.136 
Eight missense and 1 nonsense variants in the HTRA1 gene were identified in 12 heterozygous 
individuals (1.2%) on stringent filtering. There were no compound heterozygotes or 
homozygotes. Two variants had previously been associated with disease: p.Arg302Ter has 
been reported in both autosomal recessive and autosomal dominant disease,61,264 while 
p.Asp450His was reported in autosomal dominant disease.67 p.Arg302Ter has been 
demonstrated to result in a mutant protein with 21 to 50% of normal protease activity.61 




Five novel variants were found in the trypsin domain of the protein, with one variant 
(p.Arg227Trp) appearing in four individuals. This variant is within the trypsin domain of HTRA1, 
close to the trypsin active site in position 220. A summary of the clinical features and 
heterozygous HTRA1 variants identified is provided in Table 4-10, and a plot of the position 
of each variant on a linearized HTRA1 protein molecule is provided in Figure 4-2.  
 
 









Table 4-10: Heterozygous HTRA1 variants identified on stringent filtering 































4.1 x 10-6 Novel variant  
UK05
-083 


















- - Novel variant  
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-018 
















7.9 x 10-5 Novel variant  
UK10
-007 






















































































Trypsin - - Novel variant  
UK01
-029 
























































Migraine with aura 
Isolated 
lacunar infarct 
Fazekas score 1 
Microbleeds on 







8.1 x 10-6 Novel variant  
UK36
-002 
M 41 None Isolated 
lacunar infarct 










1.2 x 10-5 Novel variant  
UK30
-001 





















- - Novel variant  
UK05
-059 











None  c.1348G>C 
p.Asp450Hi
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On relaxed filtering only three additional variants were identified. These were p.Pro4Ser in 
the signal peptide domain, and p.Gln151Lys and p.Asp336Asp in the trypsin domain. 
p.Gln151Lys is a variant that was recently reported as a heterozygous mutation in a male 
singleton from a pedigree with an autosomal dominant pattern of inheritance of disease. This 
individual had progressive ataxic gait, dysarthria, dysphagia and cognitive decline from the 
age of 59, and had two affected relatives (mother and maternal uncle). His brain MRI showed 
white matter changes, microbleeds and atrophy.265 In this study the variant was identified in 
a female with a stroke occurring at the age of 68, no family history of stroke and no white 
matter hyperintensities or microbleeds on MRI. This variant, occurring in the Kazal-like 
domain of the HTRA1 protein (and thus not near the serine protease active site) is predicted 
to have a moderate impact on VEP, and is rare, with a frequency of 0.00016 in gnomAD.  
COL4A1 and COL4A2 
COL4A1 and COL4A2 encode the α1 and α2 chains of the collagen IV protein respectively. 
Missense mutations in COL4A1 and COL4A2, typically but not always affecting the glycine 
residue in the repetitive Gly-X-Y region of the collagen chains, were first found to be 
associated with paediatric porencephaly and hemiplegia. These were subsequently found to 
be associated with cerebral small vessel disease, and ischaemic and haemorrhagic subcortical 
lacunar strokes.87 Patients may also have muscular or renal manifestations of the disease.85 
Mutations affecting the C-terminal or NC1 domain of the gene, thought to be responsible for 
triple helix assembly,266 have also been associated with SVD.165 
Ten individuals (1.0%) carried 9 missense COL4A1 variants passing the stringent filter. All 
variants were present in the heterozygous state, and there were no compound heterozygotes. 
Only one of the variants affected a glycine residue in the triple helix repeat regions of the 
protein (p.Gly332Arg), and this variant has previously been reported to likely be benign on 
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/311067/). One variant 
(p.Pro1337Leu) was shared by two individuals. This variant is found in a low complexity region, 
and has also previously been reviewed on ClinVar as a likely benign variant in the context of 
COL4A1-related SVD (https://www.ncbi.nlm.nih.gov/clinvar/variation/311030/). Only one 




C4 domain associated with the assembly of the tropocollagen molecule.266 The remainder of 
the variants were found in low complexity regions. 
One previously reported pathogenic variant passing the stringent filter, p.Pro352Leu, was 
present in one patient. This variant was previously described in a single case of presumed-
sporadic intracerebral haemorrhage (ICH), and was shown on functional analyses to impair 
the secretion of COL4A1 into the extracellular space.156 Two other previously reported 
variants (p.Arg1238Cys,267 p.Gln1316Glu268), which were found in one individual each, only 
passed the relaxed filter. Both variants are found in a large proportion of unrelated controls 
on whole genome sequencing and other control database, as discussed in detail in Chapter 6. 
All three variants were found in low complexity regions of the protein. All variants passing the 
stringent filter, as well as all previously reported mutations are summarised in Table 4-11. A 
plot of these variants is provided in Figure 4-3. 
 
Figure 4-3: Missense and frameshift COL4A1 and COL4A2 variants passing the stringent filter, and 
COL4A1 variants previously associated with SVD. 
Nine missense COL4A2 variants in 9 individuals (0.9%) passed the stringent filter. There were 
no compound heterozygous or homozygous individuals. One of these variants (p.Gly466Ser) 
alters a glycine residue in the Gly-X-Y triple helix repeat region, and two variants were in the 




None of these variants passing the stringent filter had previously been reported as disease-
causing, however one variant associated with disease, which passed only the relaxed filter, 
was identified in 34 individuals. This variant (p.Glu1123Gly) had previously been reported in 
a paediatric case of porencephaly269, an adult with probable cerebral amyloid angiopathy 
(CAA)-related intracerebral haemorrhage (ICH), and an adult with an ICH in the basal 
ganglia.159 This variant was also demonstrated to impair secretion of COL4A1 and COL4A2, 
and was not identified in 142 age-matched controls.159. This variant affects the X residue in 
the Gly-X-Y triple helix repeat region. In these reports there was no evidence for segregation 
of the variant with disease as the patients were  singletons,159 and this variant also has a high 
frequency in control databases (MAF 9.5 x 10-3 in gnomAD) beyond that expected for a highly 
penetrant monogenic disease as detailed in Chapter 6. It is thus possible that this variant is a 
polymorphism which has erroneously been described as a disease-causing mutation.  Figure 
4-3 illustrates the position of all variants passing the stringent filter, as well as p.Glu1123Gly. 
The clinical features of individuals carrying variants which passed the stringent filter are 
summarised in Table 4-11. 
Additional variants identified in 16 individuals on relaxed filtering were scattered across the 
gene, with six missense variants in triple helix repeat regions, four in low complexity regions 
and two in the NC1 domain. One frameshift variant (p.Gly1423_Pro1424fs) was identified in 
a low complexity region near the NC1 domain. This variant would theoretically disrupt the 
NC1 domain, and thus may have implications on tropocollagen assembly. 
On stringent filtering, none of the patients were found to have variants in both COL4A1 and 
COL4A2. One patient was found to carry a missense variant (p.Pro427Leu) in COL4A2 and a 
splice region variant in COL4A1 (c.652_653insCAC), with both variants passing only the 









Table 4-11: COL4A1 and COL4A2 variants passing the stringent filter, and previously reported COL4A1 mutations identified in this cohort. 







































F 70 Treated 
Hypertension 
Migraine with aura 
Multiple 
lacunar infarcts 






stroke at 70 
Father – 
stroke at 81 
Sibling – 















F 45 BMI 37 Isolated 
lacunar infarct 





















Migraine with aura 
WMH 






























































































































































































M 65 Former smoker WMH 




































M 69 Former smoker 
Alcohol excess 
WMH 








































M 58 Untreated 
hyperlipidaemia 
WMH 
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Mother – 





1.2 x 10-5 Novel 
variant 
 






The FOXC1 gene encodes for the Forkhead box C1 transcription factor. Autosomal dominant 
FOXC1 missense, nonsense and frameshift mutations, as well as deletion or duplication of the 
gene locus (6p25) have been associated with ocular abnormalities described as the Axenfeld-
Rieger Syndrome.91,270 Some of these mutations have also been found to be associated with 
white matter abnormalities.91  
None of the variants reported in literature on FOXC1-associated SVD were identified in this 
cohort, both on relaxed or stringent filtering. We identified two variants in two individuals 
(0.2%) on stringent filtering: one inframe insertion (p.Thr68_Pro69insThrProGln) in a 
heterozygous patient who also carries a deletion in the ABCC6 gene, and one frameshift 
variant (p.Ala381_Gly382fs) in a heterozygous patient also carrying duplication of the COL3A1 
and SCN1A genes. The inframe insertion was sited in a low complexity region near the 
forkhead box domain, and the frameshift variant was also in a low complexity region, some 
distance away from the nearest frameshift variant reported in disease at position 274. The 
FOXC1 gene has only 1 exon, thus this frameshift variant would conventionally be considered 
a disruptive, high impact variant. These cases are summarised in Table 4-8.  
Eleven other variants found in 17 individuals passed the relaxed filter. One individual carried 
two variants – an inframe deletion (p.Arg27_Ala30del), and a missense variant (p.Pro297Ser). 
There were no additional frameshift variants identified. The majority of these variants were 







Originally described as multiple distinct syndromes, Retinal Vasculopathy with Cerebral 
Leukodystrophy and Systemic Manifestations (RVCL-S) was recently found to arise due to 
frameshift mutations near the C-terminus of the TREX1 gene.78 The TREX1 gene encodes the 
3’ repair exonuclease, and missense mutations in this gene are also associated with Aicardi-
Goutiéres Syndrome,271 a neurological disease with paediatric onset, and familial chilblain 
lupus.272  
In this study, 3 missense variants (p.Gly197Ala, p.Arg229Gly, p.Lys230Asn), one inframe 
deletion and one frameshift variant found in 5 individuals (0.5%) passed the stringent filter, 
and there were no additional variants identified on relaxed filtering.  The only frameshift 
variant identified (p.Ala194fs) lies 41 residues upstream of the nearest previously reported 
frameshift variant in RVCL-S (p.Val235fs), away from the C-terminus. It was also identified in 
the same patient on a separate study using Sanger sequencing, and was reported as 
p.Ala139Valfs*21 on a different isoform.273 The variant was found to almost completely 
abolish function in an assay of TREX1 nuclease activity in this study.273 The p.Ala194fs variant 
was also previously reported in a paediatric case of Aicardi-Goutiéres syndrome, with cerebral 
calcification, white matter atrophy, global developmental delay, progressive microcephaly, 
congenital glaucoma as well as skin and cardiac abnormalities on the DECIPHER database 
(Patient 303873).252 This child was also found to have a missense TREX1 variant (p.Arg169His), 
where the frameshift was paternally inherited, and the missense variant was maternally 
inherited.  
All variants were present in a heterozygous state. A summary of these novel variants is 








Table 4-12: TREX1 variants passing both stringent and relaxed filters 
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M 64 Untreated hypertension Isolated lacunar 
infarct  
Fazekas score 1 
No microbleeds 
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Fabry disease is an X-linked dominant metabolic storage disease caused by mutations in the 
GLA gene, which causes abnormal depositions of globotriaosylceramide in the cells of 
multiple organ systems, including the small blood vessels of the brain.274 Six variants 
identified in 21 individuals passed the relaxed filter, however none of these were found on 
application of the stringent filter. Ten of these individuals were hemizygous males and the 
remainder were heterozygous females. One of these variants (p.Asp313Tyr), identified in two 
females and four males, was previously described in Fabry disease, and has been 
demonstrated in in-vitro assays to result in decreased alpha-galactosidase A enzyme 
activity.275  However, this variant was previously also identified in a child whose clinical 
features did not fit with the diagnosis of Fabry disease,276 and multiple submitters to ClinVar 
have listed this variant as ‘likely benign’ or of ‘uncertain significance’ according to various 
guidelines or criteria (https://www.ncbi.nlm.nih.gov/clinvar/variation/10738/). 
Candidate genes associated with related phenotypes 
Variants were also identified on stringent filtering across the candidate genes associated with 
familial hemiplegic migraine (FHM) (CACNA1A, SCN1A, ATP1A2), cerebral amyloid angiopathy 
(APP, ITM2B, CST3) and Ehlers Danlos Syndrome Type IV (COL3A1). All individuals were 
heterozygous for these variants, and there were no compound heterozygous individuals. The 
majority of variants were found outside of domains of the proteins previously associated with 








Table 4-13: Variants passing stringent filters in candidate genes associated with related phenotypes 
Related 
phenotype 










- 1 - In signal peptide  
c.1856C>T  
p.Pro619Leu 
rs373838193 1 4.3 x 10-5 In low complexity region 
VUS on ClinVar for Aortic 
aneurysm/ dissection and 

















rs200394946 1 9.7 x 10-5 In collagen triple helix repeat 
domain. 
VUS on ClinVar for Aortic 
Aneurysm/dissection and 











- 1 - In amyloid A4 N-terminal 




rs755841034 2 4.1 x 10-6 In low complexity region, near 
p.Val225Ala, a VUS associated 






























rs759926843 1 1.6 x 10-5 In low complexity region  
c.1909+5G>A 
Intron and splice 
region 
 
rs200271509 1 1.5 x 10-5 In coiled coil domain  
c.2148C>T 
p.Ile716Ile 
rs145564988 1 6.9 x 10-5 In C-terminus domain. 
Ile716Thr reported on ClinVar 
(no clinical interpretation 
available). Ile716Val associated 











































rs139499540 1 5.5 x 10-5 Between E1-E2 and Cation 
ATPase domains 








- 1 - Near metal ion binding sites at 
residues 714 and 718.  
p.Asp718Asn reported as 






rs201398669 1 2.5 x 10-5 Low complexity region  
c.633T>C 
p.Ser211Ser 
rs202216404 1 6.2 x 10-5 Ion transport domain 
p.Ser211Asn reported as VUS 








- 1 - Intron variant  
c.2524G>C 
p.Glu842Gln 
- 1 - Between ion transport 
domains. p.Ala841Ser reported 
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- 1 - Low complexity region  
c.2960G>A 
p.Arg987Gln 
- 1 - Low complexity region. 
p.Arg987Pro reported as VUS 
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rs201311000 1 3.3 x 10-5 Between ion transport 
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Remarks  Ref 
c.6400C>T 
p.Arg2134Cys 
rs121908235 1 6.2 x 10-5 Outside of Ca channel IQ 
domain 
VUS for unspecified phenotype 
and associated with episodic 























- 1 - Patient also has a deletion in 
ABCC6 



















rs769582667 1 3.2 x 10-5 Low complexity region  
c.1457C>G 
p.Ala486Gly 



















- 1 - Cytoplasmic domain of voltage-
gated Na ion channel.  
p.Arg580Gln reported as VUS 
for early infantile epileptic 
encephalopathy. p.Arg580Ter 
reported as pathogenic for 
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On stringent filtering, none of the 993 individuals carried more than one ABCC6 variant, and 
none were homozygous for any ABCC6 variants. As a result, all ABCC6 variants were filtered 
out on the basis that haploinsufficiency would not be a mechanism for disease.   
On relaxed filtering, 33 individuals were found to be compound heterozygotes for missense 
ABCC6 variants. None of these individuals carried more than one variant present at a minor 
allele frequency in gnomAD of less than 1 x 10-4. Of the 60 variants detected, there were 27 
missense variants present at a frequency of less than 1 x 10-4, 8 missense, 1 frameshift and 1 
intron and splice region variants were previously reported as being associated with autosomal 
recessive disease.  
Some patients with pseudoxanthoma elasticum were previously found to carry a CNV and an 
SNV in the ABCC6 gene. In this cohort, 5 individuals had both CNVs and missense variants in 
the ABCC6 gene. Two of these individuals had CNVs and SNVs that were both previously 
reported as being associated with disease. These two individuals would thus have a genetic 
profile compatible with previously documented cases of pseudoxanthoma elasticum, 
although neither of these individuals were known to have clinical features of 









Table 4-14: Compound heterozygous individuals carrying both CNVs and SNVs (passing relaxed filter only) in the ABCC6 gene  
ID CNV identified Exons affected 
by CNV 














Missense variant previously reported as 
pathogenic on ClinVar.  




















Missense variant previously reported as 
pathogenic.  














Individuals with SNVs in multiple genes 
Two individuals were found to each have two variants passing the stringent filter in different 
candidate genes. One individual had a cysteine-altering variant in exon 7 of the NOTCH3 gene, 
which would be expected to account for all of the patient’s clinical features. These variants 
are summarised in Table 4-15. 
Table 4-15: Patients found to have SNVs on more than one SVD candidate gene. 
ID Gene Variant 1 MAF in 
gnomAD 







- CACNA1A c.3436G>A 
p.Val1146Ile 










4.4 Conclusions  
In this study of 993 patients with presumed-sporadic, early-onset SVD stroke, we have 
demonstrated the use of a multi-gene HTS platform to screen for rare variants associated with 
monogenic SVD and related phenotypes. Using this platform, we have achieved robust 
coverage of all coding regions of the 15 candidate genes.  
This cohort of patients was previously screened for NOTCH3 mutations on a limited number 
of exons. In this study we have found that two mutations were initially missed on both DHPLC 
and Sanger sequencing, and that a total of 11 (1.1%) patients carried CADASIL-causing 
mutations. This provides further evidence that HTS methods, with their high coverage of 
bases, are more sensitive than conventional sequencing techniques.  
We demonstrate that previously reported (or theoretical, in the case of CADASIL) disease-
causing mutations across 15 genes associated with SVD and related phenotypes were 
identified in this cohort at two different levels of filtering. This includes CADASIL-causing 
mutations, autosomal dominant SVD-associated mutations in HTRA1 and a frameshift 
mutation in TREX1 previously associated with cerebral white matter disease. This suggests 




low clinical index of suspicion for monogenic disease. The caveats here are that few known 
mutations have been reported for each gene, and that the ThromboGenomics platform only 
calls variants in the coding, upstream and downstream variants. There may thus be many 
more monogenic disease-causing variants in the non-coding regions or other genes that are 
not known, but are also causative of strokes in this population.  
The identification of known variants on only the relaxed filter also calls into question the 
pathogenicity of these variants, particularly variants which have also been found in high 
frequencies in control databases. We found that one cysteine-altering mutation in NOTCH3, 
a missense HTRA1 variant and a COL4A2 variant previously associated with autosomal 
dominant disease are present at higher frequencies than other known mutations and were 
thus excluded on more stringent filtering strategies. In contrast, a large number of variants 
were found to pass the stringent filter in CACNA1A. This suggests that in larger genes 
conventional filtering strategies may be limited in their utility to narrow down the list of 
possible causative variants, without reducing the risk of excluding truly pathogenic ones.  In 
this example, additional pedigrees sharing the same phenotype and genotype, as well as 
large-scale functional screening may lend further evidence for pathogenicity in these variants. 
These issues call into question both the arbitrary filter thresholds that we have set, as well as 
whether these variants are truly highly penetrant disease-causing mutations. 
There are a few possible explanations for the relatively high frequency of known variants in 
this cohort of patients. It is possible that these variants cause a milder form of disease only 
associated with stroke and not the other syndromic features (which would likely have led to 
exclusion from the study due to suspicion of familial disease). For example, although NOTCH3 
mutation carriers did tend to have more severe white matter hyperintensities, this was not 
the case for mutation carriers in other genes, where many individuals had only isolated 
lacunar infarcts, a lack of a convincing clinical history (e.g. that of migraine), or a lack of a 
family history which would have suggested a likely familial disease. We have also identified 
patients carrying both CNVs and SNVs in the ABCC6 gene, all of which have previously been 
associated with pseudoxanthoma elasticum. None of these patients were clinically diagnosed 
with pseudoxanthoma elasticum or documented to carry clinical features of this disease.  
While it may be that some of these variants are indeed disease-causing but result in milder 




in genes such as COL4A2 these may have been erroneously associated with the disease in the 
first place. This may have been due to the limited availability of controls prior to the 
development of large-scale control databases. One example here is the variants identified in 
COL4A2, which have been demonstrated on functional assays to result in impaired secretion 
of both COL4A1 and COL4A2 chains as well as the accumulation of protein in the endoplasmic 
reticulum leading to stress in the endoplasmic reticulum.159 Two of these variants were found 
in large numbers of controls. Functional in-vitro assays are limited in their ability to 
recapitulate disease features and thus may not adequately serve as a surrogate for the true 
impact of variants in vivo. The heterogeneity of disease features between and within families 
with suspected familial SVD raises the question of whether ‘pathogenic’ variants are indeed 
present in high background frequencies in the general population, and whether these may be 
responsible for ‘sporadic’ cases of stroke. This is also discussed in Chapter 6.  
There is also the possibility that carrying multiple variants (rare or otherwise) together may 
increase the risk for early-onset SVD. Beyond examining known pathogenic variants, future 
work should also investigate the hypothesis that multiple variants in different genes may 
contribute to disease risk in this cohort of patients, by comparing the burden of rare variants 
in cases and controls. However, this study is limited by the lack of a suitable control dataset 
apart from databases such as gnomAD. An ideal set of controls would be age- and ethnicity-
matched, MRI-phenotyped to confirm the absence of stroke or cerebral disease, and 
sequenced on the same platform.  
We have shown that the ThromboGenomics HTS platform can be useful for the simultaneous 
screening of multiple genes, suggesting its potential use as a diagnostic tool for patients with 
suspected familial forms of SVD. With milder phenotypes of monogenic disease now coming 
to the fore, we speculate that this platform may also be useful for those with presumed 
sporadic disease and a lower index of clinical suspicion for familial disease.  
In this study we have found that a limited screen of the coding regions of a small number of 
candidate genes already raises more questions than answers, by calling multiple variants of 
uncertain significance. The clinical interpretation of these variants remains a significant 
challenge, and understanding the background carrier rate of these purported ‘disease-causing 
mutations’ will significantly boost the clinical utility of rapid sequencing tools. This question 
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5. Rare variants in suspected familial SVD: a candidate gene 
approach using whole genome sequencing 
5.1 Introduction 
Cerebral small vessel disease (SVD) is the most common subtype of stroke to present as a 
familial disease. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) is the most common form of monogenic SVD, however in 
recent years a number of new genes have been found to also be associated with familial SVD, 
either through traditional linkage analysis in pedigrees, or in combination with whole exome 
sequencing. Some examples are COL4A1 and COL4A2-related SVD, or Retinal Vasculopathy 
with Cerebral Leukodystrophy and Systemic manifestations (RVCL-S). The clinical features and 
pathogenesis of these diseases have been discussed in Chapter 1.  
Although each of these monogenic diseases are typified by distinctive neurological or non-
neurological features which may guide the diagnostic process, patients often do not develop 
these features of the syndrome. They may instead present with non-specific features of SVD 
at an earlier age than expected, in the context of cardiovascular risk factors, alongside a vague 
family history of strokes or dementia. Hence, despite recent advances, there remain many 
families with suspected monogenic SVD where no known genetic cause has been identified. 
These patients have been described as having a NOTCH3-negative CADASIL-like 
syndrome.207,283 However, testing for mutations in multiple genes one after another using 
traditional Sanger sequencing for mutations in known disease-associated genes can be time-
consuming and costly, and often do not lead to a genetic diagnosis. In clinical practice, most 
clinicians only test for mutations in the NOTCH3 gene. 
With the rapid decline in cost of high-throughput sequencing (HTS) over the past two decades, 
HTS can play a significant role in the diagnosis of rare genetic diseases, and it is likely that this 
technology will eventually become routinely used in the clinic. A comparison of different HTS 
techniques such as WGS and whole exome sequencing has briefly been discussed in Chapter 
2. Whole genome sequencing (WGS) allows the simultaneous analysis of multiple candidate 
genes in patients with a suspected genetic disease, circumventing the diagnostic ‘odyssey’ of 




variants such as splice-site variants are also captured with WGS. These regions form the bulk 
of the genome, and may also lead to disease, as seen in other collagen-related disorders.284 
Non-coding regions are not typically captured on other forms of HTS such as whole exome 
sequencing or targeted capture sequencing, as summarised in Chapter 4.  This chapter 
explores the use of whole genome sequencing (WGS) in the investigation of patients with 
suspected familial SVD with unconfirmed genetic aetiology.  
In this chapter we aim to investigate two hypotheses about this population of patients. The 
first is that rare, previously described monogenic causes of SVD are present in this population, 
and rare variants in genes identified in associated phenotypes such as familial hemiplegic 
migraine, cerebral amyloid angiopathy and leukodystrophy are also important in this 
population.  
The second hypothesis is that rare variants in genes identified in genome-wide association 
studies (GWAS) in SVD may also play a role in this population of familial SVD. A recent meta-
analysis of GWAS in sporadic stroke by the MEGASTROKE collaboration by the International 
Stroke Genetics Consortium has identified multiple loci associated with stroke reaching 
genome-wide sequence, with one locus found to be associated with the SVD subtype. GWAS 
analyses of SVD-associated phenotypes (white matter hyperintensities, small vessel ischaemic 
strokes, small vessel intracerebral haemorrhage and migraine) have also identified 12 loci at 
levels of significance strongly suggestive for association (unpublished data). We aim to 
investigate if these loci may also harbour rare monogenic disease-associated variants.  
This chapter examines the prevalence of both known and novel rare variants in monogenic 
SVD genes in families with suspected familial SVD where no genetic diagnosis has been made. 
It will also investigate the presence of rare variants in other candidate genes such as those 
from associated phenotypes (cerebral amyloid angiopathy, familial hemiplegic migraine, 
connective tissue disease associated with stroke and leukoencephalopathy), and those from 





5.2.1 NIHR BioResource Rare Diseases Pilot Study (BRIDGE) 
Over a 24-month period from October 2014 to October 2016, patients with suspected familial 
SVD were identified and recruited across 12 sites in the UK, as part of the National Institute 
of Health Research (NIHR) BioResource Rare Disease study (BRIDGE), a multicentre whole-
genome sequencing (WGS) study of approximately 10,000 patients. Affected and unaffected 
relatives of these patients were also recruited to the study. The term ‘singleton’ is used here 
to refer to index cases where no relatives have been recruited. 
Patients with MRI-confirmed early-onset SVD were selected based on clinical suspicion of 
familial disease. Further details about the recruitment process and selection criteria are 
discussed in Chapter 4. SVD was one of fourteen rare disease categories in the study, and the 
list of sites, studies and overall recruitment figures are summarised in Chapter 2.  
Funding for the project was provided by the National Institute for Health Research (NIHR, 
grant number RG65966). The study was approved by Research Ethics Committees in the UK 
and appropriate national ethics authorities in non-UK enrolment centres. 
5.2.2 Selection of candidate genes 
Seventy-three genes across the genome were selected for investigation. These were selected 
based on peer-reviewed literature, and include those previously described in monogenic SVD 
and cerebral amyloid angiopathy and related phenotypes such as familial hemiplegic migraine 
(FHM), leukodystrophy, connective tissue diseases known to cause stroke and other 
amyloidosis-causing genes.   
Gene loci identified with strongly suggestive evidence (p < 5 x 10-6) of being associated with 
sporadic subcortical ischaemic or haemorrhagic strokes of presumed small vessel origin, 
white matter hyperintensities on MRI, or migraine in GWAS studies were selected as 
candidate regions. Genes which the identified SNPs were expression quantitative trait loci 
(eQTLs) of, and the two nearest genes to the lead SNP were included in the gene list. Nearby 
genes (within 1Mb) that were part of the Forkhead family of transcription factors were also 




Table 5-1: List of candidate genes investigated 




































































































5.2.3 Whole genome sequencing (WGS) 
Whole genome sequencing (WGS) was performed by Illumina on HiSeq X Ten generating 
150bp paired-end reads per lane with minimum coverage of 15X for at least 95% of the 
genome. Reads were aligned to the hg19 (GRCh37) build of the human genome using the 
Isaac Aligner, and variants were called using the Isaac VariantCaller.285  
5.2.4 Variant filtering 
5.2.4.1 Single nucleotide variants (SNVs) 
Variants were classified according to their annotation using the Ensembl 81 Variant Effect 
Predictor (VEP), the Exome Variant Server ESP6500SI-V2 (evs.gs.washington.edu/EVS/) and 
the Human Gene Mutation Database (HGMD) 2016.2. These were then filtered according to 
the Combined Annotation Dependent Depletion (CADD) score, computed using an in silico 
predictive tool which integrates multiple annotations to provide an estimate of 
deleteriousness (http://cadd.gs.washington.edu).  All variants with a CADD score below 15 
were excluded from analysis. The remaining variants were then filtered according to their 
minor allele frequency (MAF) in control databases, with variants present at a frequency of 
greater than 3 in 10 000 being excluded. These include the Exome Aggregation Consortium 
(ExAC) v0.3 (exac.broadinstitute.org/downloads), Phase 1 of the UK10K, and the UK10K 
TWINS release databases. Variants with a MAF greater than 3 in 10 000 in unrelated SVD 
patients in BRIDGE were also excluded. Allele frequencies in the genome Aggregation 
Database (gnomAD) (http://gnomad.broadinstitute.org/) were retrospectively reviewed for 
all variants passing filters.  
Variants that were present in relatives but not in sequenced index cases, as well as variants 
that did not segregate with the pattern of inheritance of disease in the pedigree were 
excluded from further analysis. For example, if an affected individual carried a rare variant 
but this was not found in another affected relative, this variant was not considered as a 
possible causative variant. Where a known pathogenic mutation is identified in one gene (e.g. 
known cysteine-altering variant in NOTCH3), rare variants identified in other genes are not 




possible to demonstrate, the variants carried by the affected proband are retained for 
consideration.  
The diagnostic yield was calculated as a percentage of all index SVD cases sequenced, while 
the allele frequency was calculated as a percentage of all affected individuals, including those 
from the same pedigree.  
5.2.4.2 Copy Number Variants (CNVs) 
Copy number variants (CNVs) refer to structural variants, insertions, deletions, duplications, 
inversions and translocations generally greater than 1kb in size. In this study, CNVs were 
called using the Manta Structural Variant Caller (http://github.com/Illumina/manta), which 
calls structural variants and insertions or deletions (indels) from mapped paired-end 
sequencing reads,286 and the Canvas Copy Number Variant Caller 
(http://github.com/Illumina.canvas), which identifies regions of the genome that are not 
present, present once, or more than twice in a sample assumed to be mostly formed of paired 
chromosomes.287 Only CNVs within protein-coding regions with an allele frequency of less 
than 0.001 were considered.  
5.2.5 Modelling of NOTCH3 variants 
Epidermal Growth Factor-like repeat (EGFr) sequences of the NOTCH3 protein were obtained 
from Uniprot (protein ID: Q9UM47), and aligned using the multiple sequence alignment tool 
of Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). 3D modelling of the EGFr1 
domain was performed using the Swiss-Model tool. EGFr domains were visualised using the 
Chimera software.288 Mapping of NOTCH3 variants was performed by Gido Gravesteijn, at the 





5.3 Results and discussion 
5.3.1 Baseline characteristics 
One hundred and forty-three index cases with suspected familial SVD, and 137 of their 
relatives were recruited according to the criteria described in Chapter 2. Whole genome 
sequencing data was available from 246 participants (121 index cases, 125 relatives). Of these, 
three index cases were no longer eligible after recruitment, having received diagnoses of 
CADASIL confirmed on clinical genetic testing (n=2) or neurosarcoidosis (n=1). Four other 
participants were also excluded from further analyses as the probands from these pedigrees 
had not successfully been sequenced at the time of writing. Of the remaining 239 individuals 
included in this analysis, 118 were index cases and 121 were relatives. There was a total of 
143 individuals with MRI-confirmed diagnoses of SVD.  
The clinical features of all 118 index cases at baseline are described in Table 5-2. Samples from 
these participants were sequenced alongside 9110 controls (patients and relatives from other 
rare disease studies in BRIDGE), and 7348 of these were unrelated individuals. These were 
included in the analysis as a control population. (Figure 5-1). 
 




Table 5-2: Clinical features of 118 index cases with suspected familial cerebral SVD 
 Male Female  Total 
All patients 60 58  118 
 
Age at presentation (mean ± SD) 52.5 ± 8.7 52.5 ± 11.0 52.5 ± 9.9 
 



































Migraine (n, %) 21 (35.0) 40 (69.0) 61 (51.7) 
 
Age at onset (mean ± SD) 30.9 ± 14.4 30.9 ± 13.5 30.9 ± 13.7 
 
Migraine with aura 12 (20.0) 33 (56.9) 45 (38.1) 
 
Stroke (n, %) 49 (81.7) 18 (31.0) 67 (56.8) 
 
Ischaemic stroke  44 (73.3) 17 (29.3) 61 (51.7) 
 
Haemorrhagic stroke 8 (13.3) 2 (3.4) 10 (8.5) 
 
Age at onset of stroke (mean ± 
SD) 
53.1 ± 6.2 53.0 ± 10.7 53.0 ± 7.7 
 
Encephalopathy (n, %) 3 (5.0) 8 (13.8) 11 (9.3) 
 
Age at onset (mean ± SD) 59.0 ± 2.9 50.3 ± 17.5 52.9 ± 15.3 
 
Cognitive impairment 16 (26.7) 24 (41.4) 40 (33.9) 
 
Age at onset 51.4 ± 8.6 52.5 ± 10.5 52.1 ± 9.8 
 
Dementia 0 5 (8.6) 5 (4.2) 
 
Age at onset - 52.3 ± 7.6 52.3 ± 7.6 
 
Seizures 4 (6.7) 6 (10.3) 10 (8.5) 
 






5.3.2 Copy Number Variants (CNVs) 
Across the genome, 354 CNVs were called in 184 individuals from 96 different pedigrees. All 
CNVs that were not present in the index case of a pedigree, or did not segregate with the 
pattern of inheritance of disease within pedigrees were excluded, leaving 155 remaining CNVs 
in 98 individuals from 79 pedigrees. 
5.3.2.1 CNVs in candidate genes 
Two SVD singletons were found to have large, non-overlapping deletions spanning 12 to 13 
genes on chromosome 13q13 and 13q31. A large chromosome 13q33-q34 duplication 
spanning 45 genes including COL4A1 and COL4A2 was previously described in a singleton with 
early-onset SVD. This individual did not have a clear family history of SVD,87 and no other CNVs 
on chromosome 13 have previously been associated with SVD. In this study, the CNVs did not 
overlap with the COL4A1 or COL4A2 gene region. 
Chromosome 6p25 duplications affecting the FOXC1 gene have also been identified in 
previous reports of FOXC1-associated SVD. In this study, one singleton was found to have a 
deletion in 6p24.3 affecting the GCNT2 gene, and two affected individuals in one family were 
found to have a deletion in the same chromosome (6p24.1), affecting the TBC1D7 gene, as 
described in Pedigree F102. No CNVs were found to affect the FOXC1 gene. 
The PITX2 gene, which acts in the FOXC1 pathway leading to both familial SVD and the 
Axenfeld-Rieger Syndrome, is found on chromosome 4. No CNVs were identified in the PITX2 
gene region in our study, with the nearest deletion found in a singleton residing more than 
5.8 million bases downstream in the RP11-55L3.1 gene.  






A white male of Italian ancestry (Figure 5-2, III-1) presented with a haemorrhagic stroke in 
the pons at the age of 52, and was found on MR imaging to have white matter hyperintensities, 
lacunar infarcts and microbleeds in both the cortical and subcortical regions. (Figure 5-3A-C) 
He had no previous history of migraine or psychiatric problems.  
His mother (II-4) had a history of multiple subcortical ischaemic and haemorrhagic strokes 
from the age of 74. Her past medical history was only significant for treated anxiety, and her 
MRI showed multiple lacunes, white matter hyperintensities and multiple microbleeds in the 
cortex. (Figure 5-3D-F) Her father had died of a cerebral haemorrhage at the age of 48, and 
her sister had a diagnosis of dementia, although the type of dementia had not been specified.  
Both the proband and his mother were found to have a heterozygous deletion of 
chromosome 6: 13310619-13337175, affecting the TBC1D7 gene. TBC1D7 (TBC1 Domain 
Family Member 7) is a component of the tuberous sclerosis complex (TSC), which has roles in 
limiting cell growth. Deletions resulting in frameshift and premature termination mutations 
have been associated with autosomal recessive macrocephaly/ megalencephaly syndrome. 
This disease is characterised by the abnormal enlargement of the cranium and brain at birth 
or in childhood, and intellectual disability.  Brain MRI in these patients have shown enlarged 
corpus callosum and cerebral calcifications, or were normal. 289,290 Autosomal dominant 
mutations in TBC1D7 have not been described in disease, and it is not known 
histopathologically if this disease is on the SVD spectrum.  
Sequencing and MR imaging to confirm the presence of the maternal aunt (II-5) diagnosed 
with dementia, as well as other unaffected relatives may serve to provide further evidence 





Figure 5-2: Pedigree F102. Both affected individuals in pedigree F102 (III-1 and II-4) have a 6p24.1 deletion 






Figure 5-3: MR images of III-1 of Pedigree F102 (A) T2-weighted FLAIR image showing white matter 
hyperintensities and lacunes, (B) T1 image showing acute pontine haemorrhage, and (C) Gradient echo 
imaging showing cortical and subcortical microbleeds and an old left-sided haemorrhage. His mother, 
II-4 had similar features on (D) T2-weighted FLAIR imaging, showing white matter hyperintensities and 





5.3.2.2 Other CNVs 
There were no other identical CNVs that were present in more than one singleton or pedigree. 
Two singletons were found to have overlapping CNVs in chromosome 16: one with a 300 
000bp deletion, and the other a 6000bp deletion within this region. The overlapping gene, 
C16orf45, has previously been associated with Lisch’s endothelial corneal dystrophy. While 
corneal opacities and other ocular abnormalities have been described in familial SVD, these 
two index cases were not known to have any ocular abnormalities.  
A summary of all CNVs identified is provided in the appendix.  
5.3.3 Single Nucleotide Variants (SNVs) 
In 118 SVD index cases and 121 affected or unaffected relatives, a total of 337 rare variants 
in the 73 candidate genes passed filters. An average of 4.6 variants per gene passed filters, 
with majority of these being non-coding variants. The proportions of each type of variant 




Figure 5-4: Proportion of each type of variants called in candidate genes across all SVD participants 
which passed filters. This includes variants excluded from analysis e.g. where the variant was not 
present in the index case, or where variants did not segregate with the pattern of inheritance of disease. 
Genes have been organised according to the category from which they were selected. Those with no 
variants passing filters have not been included in this figure. Legend notes: 3’UTR: 3-prime 





 CADASIL-causing and other rare NOTCH3 variants are identified in a presumed CADASIL-
negative cohort of familial SVD patients 
CADASIL is caused by cysteine-altering variants in the epidermal growth factor repeat-like 
(EGFr) region of the NOTCH3 gene. These mutations do not lead to a loss- or gain-of-function, 
but result in the abnormal deposition of the NOTCH3 ectodomain in the walls of the small 
blood vessels.119  
In this study, 3 cysteine-altering variants were identified in 3 index cases: one previously 
reported variant p.Arg169Cys (exon 4),124,259 a novel variant p.Cys76Tyr (exon 3), and a variant 
p.Cys212Arg (exon 4) which has not been reported in literature but has been identified in 
another patient with a clinical diagnosis of CADASIL, seen at the UK CADASIL National Referral 
Clinic.  
As with all probands included in this analysis, all three patients previously had a genetic 
diagnosis of CADASIL excluded prior to WGS. Two were screened on Sanger sequencing (exons 
3 and 4) and denaturing high performance liquid chromatography (DHPLC) (exons 3, 4, 5, 6, 
11, 18, 19 and 22), while the remaining patient was screened for mutations in exons 2 to 24 
on Sanger sequencing alone. None of the patients were found to have any mutations. In this 
cohort of 118 index cases, this gave a diagnostic yield of 2.5%, and a combined allele 
frequency of 2.1% (of all affected cases). The patient with a p.Cys76Tyr mutation was 
subsequently re-tested in a clinically-accredited laboratory using Sanger sequencing, which 
validated the presence of this mutation.  
Two pedigrees were found to carry non-Cysteine changing missense variants. Two of these 
variants were identified in a singleton, as discussed below (Pedigree F37). The remaining 
variant, p.Thr328Ile, was found in all three members of a pedigree (one affected, two of 
unknown disease status).  All variants identified were in a heterozygous state.  A summary of 
coding NOTCH3 variants identified in index cases is provided in Table 5-3. Non-coding variants 








Table 5-3: Coding NOTCH3 variants passing filters, identified in SVD index cases. Variants that were not found in the index case of the pedigree, or did not 
segregate with the disease in the pedigree, are excluded from this list.  
Variant Consequence CADD Diagnostic 
yield 
AF  Unrelated 
controls 






25.1 0.0042 0.0035 - - - - • Not reported in literature 
• Present in 1 patient seen at UK 
National CADASIL Referral Clinic.  
• p.Cys212Cys present at an AF of 






27.5 0.0042 0.0035 - - - - • Novel 




















Missense 29.5 0.0042 0.0035 - 1.7 x 10-5 1.2 x 10-5 - 
c.983C>T 
p.Thr328Ile 
Missense 27.4 0.0042 0.0035 - - 1.1 x 10-5 0.00028 Identified in 1 pedigree – 1 affected, 2 
unknown disease status 
 
AF: allele frequency in all affected SVD cases. 





Pedigree F37: Two non-cysteine altering missense mutations in cis on NOTCH3 gene 
A 57-year-old white British female (Figure 5-5, III-1) presented with cognitive impairment and 
recurrent subcortical SVD-related lacunar infarcts at the age of 57. She had a history of 
migraine with aura. On MR imaging of the brain at age 57, she was found to have bilateral 
white matter hyperintensities affecting the external capsules, but not the anterior temporal 
poles. (Figure 5-6). She did not have any granular osmiophilic material (GOM) on electron 
microscopy of her skin biopsy, although her small blood vessels had an abnormally thick 
basement membrane.  
Her father (II-3) had had 6 strokes from the age of 62. Her brother (III-2) had a similar history 
of migraines, having his first stroke at age 53. DNA collected from her identical twin sisters 
(III-3 and III-4) who were asymptomatic and had normal MR imaging of the brain, and 
daughter (IV-1), who had a history of migraine, depression and anxiety, and a normal MRI at 
the age of 40, was sequenced.  
 




The proband was found to carry two rare non-cysteine-altering NOTCH3 variants in cis (on the 
same haplotype), p.Asp45His and p.Gly52Arg. None of her relatives who were sequenced (III-
3, IV-1) were found to carry either of these variants, thus these variants segregate with the 
presumed pattern of inheritance of the disease based on MRI phenotyping.  
The two variants lie six residues apart, and both lie within the first EGFr domain of the 
NOTCH3 gene. These residues were both close to the two cysteine residues which are 
predicted to form one disulphide bond.  
On three-dimensional mapping of the variants on the NOTCH3 wild-type model, the backbone 
was predicted to deviate slightly from the wild-type model, resulting in a change in the 
orientation of the second cysteine residue of the EGFr domain. (Figure 5-7A and Figure 5-7B) 
However, this model does not demonstrate consequences for disulphide bridge formation, 
and it is thus not possible to conclude that this patient has CADASIL resulting from altered 
cysteine pairing.  
 
Figure 5-6: T2-weighted MR imaging of the proband of pedigree F37, showing confluent white 





Figure 5-7: 3D modelled EGFr domain 1 of the NOTCH3 protein with an overlay of the variants identified 
in the proband of Pedigree F37. (A) The p.Gly52Arg variant is circled, with the wildtype glycine residue 
marked in dark blue, and the variant arginine is marked in green. This variant is not predicted to cause 
a major change in the EGFr domain backbone. (B) The Asp45His variant is circled, with the wildtype 
domain in light blue and variant domain marked in purple. The second cysteine residue of this domain 
is predicted to have a slightly altered position compared to the wildtype, although it is not known 




5.3.3.1 HTRA1 mutations are the next most common cause of undiagnosed familial SVD 
after CADASIL 
Mutations in the HTRA1 gene are associated with an autosomal recessive form of familial SVD 
known as CARASIL,61 and in recent years heterozygous carriers of HTRA1 variants have also 
been found to have a milder form of symptomatic familial SVD without the extra-neurological 
features of CARASIL.67,264  
Nine HTRA1 variants were identified in 10 index cases, as summarised in Table 5-4. Of these, 
five variants in six index cases were coding (missense or nonsense variants), and three of 
these (p.Pro285Leu, p.Val175Met, p.Arg370Ter) have previously been reported in either or 
both CARASIL and autosomal dominant HTRA1-associated familial SVD. (Figure 5-8) Two novel 
missense variants were identified, and one of these cases is discussed below (Pedigree F05). 
The overall diagnostic yield was 5.1% of index cases, with a combined allele frequency of 6.3% 
in all affected cases. The clinical features of all five index cases with missense and nonsense 
variants are summarised in Table 5-5 . 
Three intronic variants were identified in three probands (two singletons), and one relative 
whose disease status is unknown. These variants are summarised in the appendix at the end 
of the chapter. Intronic mutations have not previously been reported in CARASIL or autosomal 
dominant familial SVD.  
 
 
Figure 5-8: Heterozygous missense and nonsense variants identified in HTRA1. p.Pro285Leu and 
p.Pro331Leu are found within the trypsin domain of HTRA1. Variants at or near these positions have 
been found to result in inactive protein on in-vitro functional analyses, while p.Arg370Ter has been 




Pedigree F05: a novel HTRA1 variant found in three affected individuals in a pedigree 
A white British female (Figure 5-9, III-1) presented with an encephalopathic episode at the 
age of 46, and was diagnosed with cognitive impairment within the same year. She had a 
history of migraine with aura during her pregnancy at 38 years old.  
A year later, her 51-year-old sister (III-2) was also admitted during an acute confusional 
episode subsequently diagnosed as encephalopathy. This sister had a history of recurrent TIAs, 
migraine with and without aura and anorexia nervosa. She subsequently suffered a fatal 
stroke at age 52, although it is unclear if this was a haemorrhagic stroke or an ischaemic stroke 
with haemorrhagic transformation.  
Their mother (II-2) was relatively fit and well until the age of 70, when she developed 
recurrent TIAs manifesting as transient dysphasic episodes. These episodes did not result in 
any positive findings on diffusion-weighted MRI, and she had no positive changes on 
electroencephalogram (EEG) testing. Their paternal grandfather had also suffered a stroke at 
the age of 65. 
On MR imaging, all three of the pedigree had confluent white matter changes with subcortical 
lacunar infarcts. (Figure 5-10) The proband also had white matter abnormalities involving the 
anterior temporal pole. Screening of the NOTCH3 gene in both the proband and her sister, 
and the GLA gene in the sister, revealed no mutations. On examination of their skin biopsies, 
no granular osmiophilic material (GOM) were detected, although the sibling was noted to 
have re-duplication of the basement membrane.  
DNA from whole blood was collected from the proband and her sister, Whole genome 
sequencing revealed a heterozygous p.Pro331Leu variant in both sisters. Sanger sequencing 
performed on DNA from saliva from their mother confirmed that she also carried this novel 
variant.  
p.Pro331Leu is a variant in the trypsin-like serine protease inhibitor domain of the HtrA1 
enzyme. This domain performs the key enzymatic function of the protein (Figure 5-8). 
Previous functional analyses have demonstrated that a mutation near this position 






Figure 5-9: Pedigree F05 
 
 
Figure 5-10: MR images of pedigree F05. MRI T2-FLAIR images of (A) The proband (III-1), (B) her 




Pedigrees F122 and F34: a CARASIL -causing HTRA1 variant found in two pedigrees 
In this cohort we identified three affected individuals from two pedigrees each carrying a 
single copy of the p.Arg370Ter variant in HTRA1. This variant is absent from 7348 unrelated 
controls, and is present in less than 3 in 10 000 individuals in control data sets (1.6 x 10-5 in 
gnomAD) (Table 5-4).  
The first variant carrier is the proband of Pedigree F122 (Figure 5-11A), a 68-year-old white 
British male (II-3) who presented complaining of memory problems. He struggled with DIY 
tasks that he previously carried out with ease, and had lost confidence in driving. On cognitive 
testing he showed deficits in attention, verbal fluency and recall, in keeping with vascular 
cognitive impairment.  
In the preceding year he had multiple seizure episodes, during which he would become 
unrousable for about half an hour, and would then be confused. He would often be 
incontinent of urine during these episodes, but would not be observed to have any stiffening 
or twitching.  
On MR imaging of the brain, he was found to have extensive white matter changes and an old 
thalamic infarct (Figure 5-12). His sister (II-2), who was also found to carry the variant, was 
diagnosed with vascular dementia at the age of 71. She was also found to have white matter 
changes on her MRI suggestive of vascular disease.  Their mother (I-2) had had a history of 
migraine with aura from the age of 25, and had a stroke at 70 years. Their brother (II-1) had 
an episode of collapse in his 20s, although little else was known about this episode.  
The third carrier, from Pedigree F34 (Figure 5-11B), was a 48-year-old white British male (III-
1) who presented with a subcortical ischaemic lacunar stroke. He had a previous history of 
complicated migraines with aura, and aura without headache from the age of 25, during 
which he would develop unilateral facial numbness. His MRI showed patchy white matter 
hyperintensities, bilateral lacunar infarcts and numerous microbleeds in both the cortical and 
subcortical regions (Figure 5-12). His mother (II-2) suffered her first stroke at age 32, dying of 
a subsequent stroke at the age of 57.  
The p.Arg370Ter variant in HTRA1 was previously described in two consanguineous families 




were asymptomatic at the time of sequencing, although no brain imaging had been 
performed. In vivo analyses of the Japanese CARASIL patient’s fibroblasts showed that this 
mutation results in a loss of function of the resulting HTRA1 protein, by causing nonsense-
mediated mRNA decay.61 Leukocytes from a heterozygous carrier of p.Arg370Ter in a 
consanguineous Japanese family showed only the presence of wild-type HTRA1 mRNA,61 thus 
providing further evidence of nonsense-mediated decay of the variant mRNA strand resulting 
from this variant.  
The HtrA1 enzyme is a homotrimeric protein. Disease-causing mutations are thought to result 
in either the loss of high temperature requirement serine protease A1 (HtrA1) enzyme 
function, or the failure to form a functional HtrA1 trimer, impairing the function of HTRA1 on 
the TGFβ pathway.292 It was previously suggested that heterozygous missense mutations 
could exert a dominant negative effect by affecting the function of the wild-type protein, and 
that nonsense mutations resulting in haploinsufficiency would not cause SVD.67 However, a 
heterozygous loss-of-function mutation p.Arg302Ter which was previously described in 
CARASIL was subsequently identified in a Japanese patient with SVD and no extra-
neurological features of CARASIL.264 This variant also results in nonsense-mediated mRNA 
decay.  
The presence of p.Arg370Ter in three affected individuals in two unrelated pedigrees, and its 
low frequency in control data sets thus also lend support for the pathogenicity of this variant 
in the heterozygous state. Despite the absence of a mutant HTRA1 protein in another 
heterozygous carrier of this variant, the variant may still lead to haploinsufficiency and thus a 





















Figure 5-12: MR imaging of the proband in pedigree F122 showing (A) and (B) confluent white matter 
hyperintensities, and (C) a left thalamic infarct on T2 imaging. This patient did not have any clinical 
strokes. The proband in pedigree F34 had patchy white matter hyperintensities on T2-FLAIR imaging 









Table 5-4: Missense and nonsense HTRA1 variants passing filters, identified in SVD index cases. Variants that were not found in the index case of the 
pedigree, or did not segregate with the disease in the pedigree, are excluded from this list.  











35 0.0042 0.0035 - - 4.1 x 10-6 - Novel  Mutation near this 
position (p.Ser328Ala) 








44 0.0085 0.0070 - 8.2 x 10-6 1.6 x 10-5 - Reported in 
CARASIL61,291 
 
Loss of function 
involving nonsense-















Mutation near this 
position (p.Ala173Pro) 
reported in both 
CARASIL and 
autosomal dominant 
disease, results in 
catalytically inactive 












































Variant is within 
activation loop domain 
needed to induce its 
active conformation68 
AF: allele frequency in all affected patients.  Unrelated controls: unrelated, non-SVD patients in BRIDGE.  








Table 5-5:  Clinical features of probands with heterozygous missense or nonsense HTRA1 variants 
Pedigree Variant Clinical features  Sex Age at 
onset* 
MRI brain findings Significant family history  
F39 p.Pro285Leu • Migraine aura without headache 
• Depression 
• Executive dysfunction 
Female 45 Confluent WMH • Father – recurrent strokes, 
cognitive impairment from age 
58.  
• Paternal aunt, uncle died of 
strokes in early 60s. 
 
F05 p.Pro331Leu • Migraine with aura 
• Encephalopathy 
• Cognitive impairment 
Female 46 Confluent WMH 
involving anterior 
temporal poles 
MRI confirmed SVD in sister (migraine, 
TIAs, encephalopathy, psychiatry, 
stroke) and mother (TIAs). All three 




p.Val175Met • Complicated migraines 
• Encephalopathy 
• Muscle aches and stiffness 
(diagnosed ‘polymyalgia 
rheumatica’) 




Sister – one episode of dysphasia, 
recurrent vertigo from age 59, 
diagnosed with benign paroxysmal 
positional vertigo, incidental finding of 
WMH on MRI. Also carries variant. 
 
F28 p.Val175Leu • TIA 
• Small vessel ischaemic stroke 
• Depression, emotional lability 
• Parkinsonism: limb rigidity, 




















Pedigree Variant Clinical features  Sex Age at 
onset* 
MRI brain findings Significant family history  
F34 p.Arg370Ter • Small vessel ischemic stroke  
• Migraine with and without aura 




cortical but also in 
subcortical regions. 
 
Mother – stroke at 32 years, died of 
stroke at 57. 
F122 • Cognitive impairment 
• Recurrent encephalopathy 
• Mild hearing impairment 
• Migraine 
Male 68 Confluent WMH and 
brain atrophy 
Sister – MRI confirmed SVD, diagnosed 
vascular dementia at age 61. Both 
proband and sister carry variant 




5.3.3.2 Novel coding and non-coding mutations in COL4A1 and COL4A2 may be associated 
with haemorrhagic SVD 
Mutations in, and duplications of the COL4A1 and COL4A2 variants are associated with a form 
of familial SVD characterised by white matter abnormalities and both ischaemic and 
haemorrhagic subcortical strokes.87 Mutations were first identified in infants with 
hemiparesis and cognitive delay, who were found to have porencephaly.86 Other rare clinical 
features include schizencephaly and retinal vascular tortuosity.269 
Type IV collagen α-chains each have a similar structure: they have a non-collagenous domain 
(NC1) at their C-terminus, multiple tripeptide Gly-X-Y repeats forming a long central triple-
helical domain, and a short N-terminal triple-helical 7S domain.115 Typical SVD-causing 
mutations affect the glycine residue of the Gly-X-Y repeats, although variants have also been 
described in other domains.165 Disease is thought to result from either haploinsufficiency, or 
a dominant-negative effect of heterozygous variants.294 
Six and 10 index cases were found to carry novel heterozygous variants passing filters in the 
COL4A1 and COL4A2 genes respectively. Although no known disease-causing mutations were 
identified in this cohort, one patient with a history of subcortical haemorrhagic strokes was 
found to have a glycine-altering variant within the Gly-X-Y tripeptide repeat region in COL4A1 
which also results in a frameshift and premature termination codon (p.Gly1369ArgfsTer33). 
This variant not only affects the triple-helical domain but also alters the sequence of the 
remaining peptide, and is thus likely to be deleterious. (Figure 5-13)  
One proband carried variants in both COL4A1 and COL4A2. This patient had both a missense 
variant in COL4A1, and an intronic variant in COL4A2, although the COL4A2 variant was also 
shared with an asymptomatic sibling. These variants are summarised in Table 5-6, and the 
clinical features summarised in Table 5-7. 
One pedigree, comprising two affected and three unaffected individuals, was studied in a 
separate study which identified a 3’ untranslated region variant (c.*32G>A). This study further 
demonstrated the segregation of this variant in the extended pedigree of 10 affected and 10 
unaffected individuals.295 Although this variant was also identified in the two affected 
individuals recruited to this study, the variant did not pass filters as it had a CADD score of 8.3. 




have a 3’ UTR variant (c.*658T>A), however this variant had a CADD score of 12.9 and thus 
did not pass the filter.   
Although mutations in the 3’ untranslated region, and splice sites of the COL4A1 gene have 
been described,165,209 intronic variants have yet to be reported in both COL4A1 and COL4A2. 
In this cohort we found intronic variants passing filters in the COL4A1 and COL4A2 genes in 
two pedigrees with haemorrhagic strokes. These pedigrees are described in Table 5-7 and 
Pedigree F104.  




Figure 5-13: Heterozygous missense and frameshift variants identified in COL4A1. 
p.Gly1369ArgfsTer33 is found within the Gly-X-Y tripeptide repeat of the α1 procollagen chain. 
p.Trp1578Cys of COL4A1 is found within the NC1 domain, a region which uses methionine-lysine 






A 50-year-old white British gentleman presented following his second subcortical 
haemorrhage, having suffered his first episode three years before. At the time of his first 
bleed he was found to be hypertensive, however his blood pressure had been well-controlled 
at the time of the second.   
Following his first stroke he had developed significant depression and anxiety, and was also 
diagnosed with cognitive impairment, showing problems with executive functioning. This was 
in keeping with the features seen on MRI, including white matter hyperintensities and 
subcortical microbleeds (Figure 5-14) 
His paternal grandfather died of a stroke at the age of 76, and there were no first-degree 
relatives who were known to have had strokes, dementia or other neurological symptoms, 
although his mother had died prematurely at the age of 64 from a malignancy. On whole 
genome sequencing, he was found to carry an intronic deletion in the COL4A2 gene (c.100-
1916_100-1877delAGGGCTGTACTAGCTCACCTGTGTGG 
GGGGAGGGCAGTACinsGCGGGCGGGA). This variant was not carried by his asymptomatic 
father or asymptomatic 58-year-old brother. As both relatives are above the age at which 
MRI-changes are expected to be seen, imaging in both these individuals would help to rule 
this variant in or out as a likely cause for his disease.  
 
Figure 5-14: MR imaging of the proband from Pedigree F104, showing (A) bilateral subcortical 
haemorrhages and (B) white matter hyperintensities on T2-weighted imaging, and (C) a microbleed in 








Table 5-6: Coding COL4A1 and COL4A2 variants passing filters, identified in SVD index cases. Variants that were not found in the index case of the pedigree, 
or did not segregate with the disease in the pedigree, are excluded from this list. All variants were absent in unrelated BRIDGE controls.  
Gene Variant Consequence CADD Diagnostic 
yield 
AF ExAC gnomAD UK10K Functional impact 
COL4A1 p.Gly1369ArgfsTer3
3 
Frameshift - 0.0042 0.0070 - - - • Affects Gly-X-Y repeat 
• Likely results in loss of function 
 
p.Trp1578Cys Missense 27.7 0.0042 0.0070 - - - • p.Gly1580Arg/Ala previously 
reported.269,296  
• Within NC1 domain at C-
terminus where cys residues 
highly conserved266 
• Additional cys may affect 
disulphide bond formation 
 
COL4A2 p.Pro41Ser Missense 24.9 0.0042 0.0070 2.5 x 10-5 3.2x10-5 - • In 7S domain, important in 
covalent assembly of 
heterotrimers into procollagen 
molecule through disulphide 
bonds and lysine-hydroxylysine 
crosslinks.297 
• Large proline side chain is next 
to a cysteine -may affect 
disulphide bond interactions 
 
NC1: Non-collagenous domain 1 

























M 44 Bilateral subcortical 
haemorrhages, minimal WMH 





(Also has RNASEH2B 
frameshift variant) 







M 49 Multiple areas of WMH, 
multiple lacunar infarcts 
• Father – stroke from age 65 
• Mother – cognitive impairment and 
depression in early 60s 





Migraine with aura 
TIAs 
F 70 Confluent WMH affecting 
external capsules and anterior 
temporal poles, multiple 
lacunar infarcts  
 
• Mother – stroke age 52 
• Maternal grandmother – stroke in 50s 













M 60 Confluent WMH, subcortical 
microbleeds, multiple lacunar 
infarcts 
• Asymptomatic sibling shares this variant 


















M 43 Multiple lacunar infarcts • Mother – stroke age 59, severe depression 
• Maternal half-sister – stroke age 49, 












M 50 Confluent WMH, cortical and 
subcortical microbleeds, 
superficial siderosis, multiple 
lobar haemorrhages. At age 
56, this patient fulfils modified 
Boston criteria for probable 
CAA.17 
 
• Maternal uncle – stroke and dementia (age 
at onset unknown) 
• Maternal niece: cerebral palsy, epilepsy, 
‘microcephaly’ 
• Maternal nephew: ‘arachnoid cyst’, 
intellectual delay, epilepsy 
F110 COL4A2 
p.Pro41Ser 





M 49 Confluent WMH, multiple 
lacunar infarcts and 
haemorrhage, microbleeds 





(Also has CSF1R intron 
variant) 
 
Migraine with aura 
Lacunar stroke 
Minor hand tremor 
and motor apraxia 
F 61 Confluent WMH • Consanguineous parents 
• Mother – TIAs, recurrent ICH from age 47. 
• Maternal grandmother – stroke from age 
40. 
• Shares intronic variants in COL4A2 and 













M 49 Confluent WMH, bilateral 
basal ganglia haemorrhages, 
microbleeds 
• Variant not carried by father or two 
brothers (all asymptomatic) 

















Lacunar stroke M 49 Patchy WMH, multiple lacunar 
infarcts 
• Mother – stroke age 55 









F 45 Confluent WMH • Variant not carried by unaffected sibling 
(alopecia, degenerative disc disease, 
cervical dystonia, normal brain MRI) 
• Father – recurrent strokes from age 67 
• Paternal uncle – stroke at age 65 
















F 40 Confluent WMH • Mother – stroke, vascular dementia 
diagnosed at age 84 















M 51 Confluent WMH, lacunar 
infarcts, microbleeds 
• Paternal grandmother – dementia (age at 
onset not known, father died of non-
neurological causes at age 54) 

























F 65 Confluent WMH, lacunar 
infarct 
• Brother – stroke from 57, cognitive 
impairment, depression, ‘Meniere’s 
disease’ 
• Sister – migraine with aura 
• Daughter – Scheurmann’s disease 




5.3.3.3 CARASAL: a third pedigree with the single known mutation 
The CTSA gene encodes the Cathepsin-A enzyme, a subunit of a lysosomal multienzyme 
complex which has roles in the lysosomal transport, activation and stabilisation of β-
galactosidase and neuraminidase-1. This enzyme also inactivates selected neuropeptides and 
regulates a lysosomal pathway of protein degradation.34 Recessive (both homozygous and 
compound heterozygous) mutations in this gene are associated with galactosialidosis, a 
lysosomal storage disorder with both paediatric and adult onset. Infantile patients present 
with hydrops fetalis, visceromegaly, psychomotor delay, facial and skeletal dysmorphisms. 
Juvenile (2-7 years) and adult presentations (age 25-48 years) include myoclonus, ataxia, 
angiokeratoma and other neurological impairments.34 One infant with galactosialidosis has 
been reported to also have cortical-subcortical infarctions.298  
Heterozygous mutations in the CTSA gene were not identified until recently, in a form of 
familial SVD described as Cathepsin A-related Arteriopathy with Strokes and 
Leukoencephalopathy (CARASAL). CARASAL was described in two unrelated Caucasian Dutch 
families, with affected members in both families carrying the same rare missense variant in 
the CTSA gene (p.Arg325Cys) inherited in an autosomal dominant pattern.299 Affected 
individuals were reported as having headaches, migraines, TIAs, mild cognitive impairment 
and both ischaemic and haemorrhagic strokes, and were diagnosed with 
leukoencephalopathy after the age of 40. Post-mortem studies in three affected individuals 
of a pedigree showed white matter atrophy, small infarcts in the white matter, deep grey 
matter and cerebellum, extensive leukoencephalopathy and fibrous thickening of the small 
vessels, as well as a higher number of oligodendrocyte progenitor cells (OPCs) than sporadic 
SVD controls. No GOM were found on electron microscopy.299 The molecular pathogenesis of 
CARASAL has not been established, although the authors speculated that the inhibition of 
OPC maturation, in addition to vascular impairment, may contribute to the disease of the 
white matter.299    
In this study we identified one singleton carrying a single copy of the same variant 
(p.Arg325Cys) in the CTSA gene, as described in Pedigree F32. Another upstream variant was 
found to be carried by a proband and their asymptomatic offspring, although the disease 





A white British female presented at the age of 68 with an episode of sudden-onset confusion, 
during which she was described as being unable to remember or recognise her family. She 
remained confused for five days after which she improved, but never returned to normal, 
complaining of memory problems. On cognitive testing she was found to have deficits in 
attention and orientation, memory, fluency and language, scoring 63/100 on the 
Addenbrookes Cognitive Examination III.  She had another two episodes of confusion over the 
following year, and these were diagnosed as recurrent encephalopathic episodes. She also 
complained of fatigue.  
She had a history of depression diagnosed at the age of 25 and was treated with citalopram 
and cognitive behavioural therapy in the community. She suffered a relapse at the age of 67 
following a bereavement. On imaging her MRI showed extensive white matter 
hyperintensities extending into the anterior temporal poles and involving the external 
capsules. (Figure 5-15)  
She had lost contact with her parents, who died in their 60s and 70s of unknown causes, and 
her brother. She had a sister who has asymptomatic at the age of 75.   
She was tested for mutations in exons 2 to 24 of the NOTCH3 gene, common mutations in the 
POLG gene (for mitochondrial disorders) and the mitochondrial mutation m.3243A>G 
(causative of Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes or 
MELAS), all of which did not yield positive results. A skin biopsy yielded no significant results 
on electron microscopy. On whole genome sequencing she was found to carry the 
p.Arg325Cys variant in the CTSA gene.  Although little is known about the effects of this 
variant, the introduction of a cysteine residue may interfere with the formation of disulphide 
bonds and thus alter the three-dimensional conformation of the protein, or the formation of 





Figure 5-15: T2-weighted FLAIR MR imaging of the proband from Pedigree F32, showing (A) and (B) 
confluent white matter hyperintensities (C) involving the anterior temporal poles  
5.3.3.4 Rare variants in familial hemiplegic migraine genes may be associated with SVD  
The clinical features of familial hemiplegic migraine (FHM) are similar to some manifestations 
of cerebral SVD. Patients typically present with complicated migraine episodes and 
encephalopathy, and have shown reversible changes in cerebral blood flow on MR imaging, 
but do not have other MRI abnormalities beyond punctate white matter lesions expected in 
the general migraine population.300,301 
In this study we have screened all participants for rare variants in six candidate genes 
associated with familial hemiplegic migraine. Only one coding variant passed our filters, as 
discussed here in Pedigree F08.  A summary of all non-coding variants identified in these 






A 66-year-old white British female was referred to the service from the Ear, Nose and Throat 
(ENT) surgeons. (Figure 5-16, III-3) She had been referred to the ENT service with a history of 
dizziness. On MR imaging she was found to have widespread white matter hyperintensities, 
most of which were peripheral and which were also affecting the anterior temporal poles. 
There were also marked perivascular spaces (Figure 5-17). There were also extensive 
perivascular spaces.  
In the same year, she reported concerns with her memory and was found on neuropsychiatric 
assessment to have an impairment of her verbal and recognition memory, processing speed 
and complex executive function in keeping with a mild vascular cognitive impairment. She 
was described by her family as normally being ‘an anxious personality’, and reported a history 
of agoraphobia although this was not formally diagnosed. 
She had a strong family history of strokes on both sides of the family. Her mother had also 
developed ‘dizzy spells’ in her seventies, and died from her first stroke at the age of 75. (II-4) 
Her father (II-3) died prematurely in the war, however his sisters (II-1 and II-2) both died from 
their first strokes in their seventies. Her paternal grandmother (I-2) had also died from a 
stroke at age 67. Her brother (III-3) developed TIAs from the age of 79, and was found on MRI 
to have marked brain volume reduction and features of SVD. Her daughter (IV-1) reported 
experiencing ‘word-finding difficulties’ at the age of 42 and a past medical history of absence 
seizures, but had not had an MRI scan.  
Both the proband and her brother (III-3) were recruited to the study, and both were found to 
have a novel rare missense variant, p.Gly2002Ser in the CACNA1A gene. The proband’s 
daughter was also recruited, and was not found to carry this variant.  
CACNA1A encodes the α1A subunit of CaV2.1, a voltage-sensitive P/Q type calcium channel. 
CaV2.1 is highly expressed in the central nervous system and is essential to the release of 
vesicles containing neurotransmitters from the pre-synaptic terminal.302 Autosomal dominant 
SNVs and CNVs in the CACNA1A resulting in loss of function of this channel are associated 
with Familial Hemiplegic Migraine Type I (FHM), Episodic Ataxia Type 2 and Spinocerebellar 




Segregation of the variant with disease in this pedigree could potentially be demonstrated 
with MR phenotyping of the proband’s daughter (IV-1), as well as sequencing and imaging in 
the proband’s sister (III-1).  
 







Figure 5-17: MR imaging of the proband from Pedigree F08 showing (A) white matter hyperintensities 
in the anterior temporal poles (A), and marked dilated perivascular spaces (B) on T2-weighted imaging. 
The white matter hyperintensities were mostly peripheral on T2 and T2 FLAIR imaging (B and C), and 





5.3.3.5 Rare variants in genes associated with sporadic SVD may be implicated in 
monogenic SVD 
Common variants in monogenic SVD genes have been demonstrated to have a possible 
association with features of SVD such as WMH in both stroke and community-based 
populations.157,166 We hypothesized that rare variants in gene loci recently identified in GWAS 
of sporadic SVD may also be associated with monogenic disease.  
In this study we have screened 30 genes near loci with suggestive levels of significance in 
GWAS of sporadic SVD.  Coding variants (missense, nonsense, frameshift and in-frame 
insertions or deletions) were found in seven genes. Only one variant was identified in each of 
these genes, and none of the variants were found in more than one pedigree. An example of 
one of these pedigrees is discussed below in Pedigree F18, and a summary of these variants 
is provided in Table 5-8.  Non-coding variants identified in these genes are summarised in the 
appendix at the end of the chapter.  
Pedigree F18 
A 64-year-old White British female (Figure 5-18, III-3) was seen by the ENT surgeons having 
complained of a longstanding sore throat and swallowing problems. She was diagnosed with 
gastro-oesophageal reflux disease, however routine MR imaging of the head and neck 
revealed areas of white matter hyperintensities suggestive of SVD (Figure 5-19A), following 
which she was referred to the Neurology service. She had no previous history of migraine, 
stroke and other neurology or psychiatry.   
She had a strong family history of strokes on the maternal side. Her mother (II-2) had a stroke 
at the age of 72 and a diagnosis of ‘Parkinson’s disease dementia’, which on retrospect may 
have been a vascular dementia. Her maternal uncle (II-3) also had a diagnosis of ‘Parkinson’s 
disease’. Her maternal grandfather (I-3) died of a stroke at the age of 50 although this was 
thought to have been secondary to a brain tumour. Her maternal grandmother (I-4) died of a 
stroke at the age of 70.  
Her brother (III-2) had a history of multiple small vessel ischaemic strokes from the age of 57. 
At age 58, he was diagnosed with vascular cognitive impairment, having difficulties with 




tinnitus, dizziness and progressive deafness, and was diagnosed with Meniere’s disease. He 
had a past medical history of depression from the age of 19, and also reported a previous 
history of ‘episodes of confusion’ in his late thirties. On MR imaging he was found to have 
white matter hyperintensities and lacunar infarcts. (Figure 5-19B)  
Her sister (III-1) had a history of migraine aura without headache from the age of 51, but 
otherwise had no other neurological symptoms and had not had an MRI scan. All three siblings 
were recruited for whole genome sequencing. Both the proband and her brother were found 
to carry a rare (absent in gnomAD) p.Val224Leu variant in the FOXC2 gene.  
FOXC2 is found within the 16q24 locus, which contains a SNP associated with SVD which 
reaches genome-wide significance on the largest GWAS in SVD to date.179 The FOXC2 gene 
encodes for a member of the Forkhead ‘winged-helix’ family of transcription factors 
(Foxc2).306 The Foxc2 transcription factor is involved in multiple developmental pathways. 
Both Foxc1 and Foxc2 are critical in cardiovascular development, and are expressed on the 
endothelium and smooth muscle cells of blood vessels.306,307  Autosomal dominant mutations 
in the FOXC2 gene have been described in lymphedema-distichiasis, a congenital form of 
lymphoedema associated with double rows of eyelashes, cardiac defects, cleft palate, 
extradural cysts and photophobia.308  
Like other forkhead transcription factors, it has been suggested that Foxc2 has different roles 
in development and in the adult. Foxc2 has been shown to have a role in glucose metabolism 
in the adult, with increased Foxc2 expression counteracting mechanisms associated with type 
2 diabetes mellitus and obesity.309 Altered Foxc2 function leading to impaired glucose 
metabolism in the brain may thus be a plausible mechanism for the development of SVD in 
this pedigree.  
The variant identified lies 102 residues 3’ of the forkhead motif in the Foxc2 protein, and its 
significance on the Foxc2 protein function and disease is thus unknown. Although the FOXC2 
gene has not previously been associated with any SVD-related phenotype, its roles in both 
vasculature development and glucose metabolism may contribute to the development of SVD.  
In this pedigree, MR imaging to confirm the disease status of the proband’s sister (III-2) would 











Figure 5-19: MR imaging of the proband and her brother in pedigree F18. T2-weighted MR imaging 
of (A and B) the proband, showing white matter hyperintensities, and (B and C) her brother, showing 





5.3.3.6 Patients with rare variants in multiple candidate genes 
Several patients were found to carry variants passing filters in more than one candidate gene, 
as summarised in the appendix. This is particularly pertinent in larger genes with long non-
coding regions (Figure 5-4). For example, there were 34 unique intronic SNVs identified in the 
CACNA1A gene, which has a non-coding region of 409156bp in length, as opposed to NOTCH3, 
with 33277bp of non-coding regions and only 2 intronic variants identified. Excluding variants 
which did not segregate with disease in the pedigrees, there were 18 intronic variants in 
CACNA1A, of which two were in carriers who had competing genetic diagnoses in the form of 
missense or nonsense variants in the HTRA1 or NOTCH3 genes (cases described earlier). 
Although intronic variants may have consequences (such as through the introduction of a new 
splice site), it is difficult to identify which ones are of significance.  An example of a patient 
carrying rare variants in two different candidate genes is described in Pedigree F103.  
Pedigree F103 
A white British male (Figure 5-20, III-1) presented at age of 49 having been diagnosed with 
cognitive impairment, showing problems in attention, concentration and working memory, 
as well as in semantic fluency. He also developed depression in that year, and by the following 
year had new onset dizziness and nausea, was unsteady on his feet, along with tinnitus. He 
had a past medical history of migraine with visual aura beginning in his teenage years.  
On MR imaging of the brain at age 49 he had multiple areas of white matter hyperintensities 
not involving the anterior temporal poles, as well as lacunar infarcts (Figure 5-21). He did not 
have evidence of microbleeds or superficial siderosis on susceptibility weighted imaging. 
He had a positive family history for stroke, although this did not show a specific pattern of 
inheritance. His father (II-1) suffered his first stroke at age 65 and died of a stroke at age 67, 
while his mother (II-2) had a history of cognitive impairment and depression in her early 60s, 
dying of unspecified causes at the age of 68. His son (IV-2) had a history of migraines, but had 
not yet had an MRI scan of his brain.  
On whole genome sequencing, the proband was found to carry a missense variant 
p.Trp1578Cys in the NC1 domain of the COL4A1 gene. Although both tryptophan and cysteine 




position is likely to affect the three-dimensional conformation of the protein. Furthermore, 
the NC1 domain is involved in the assembly of the collagen heterotrimer, and cysteine 
residues in this domain are highly conserved as they serve to cross-link triple-helical 
molecules via disulphide bonds.266 The introduction of an additional cysteine residue may 
impact the correct formation of such bonds and thus lead to dysfunctional collagen molecules.    
The proband was also found to carry a frameshift variant, p.Val41LeufsTer23 in the gene 
RNASEH2B.  RNASEH2B encodes for the Subunit B protein, a component of ribonuclease H2 
which serves to cleave ribonucleotides at sites of DNA replication and repair.310 Homozygous 
and compound heterozygous mutations in RNASEH2A, RNASEH2B and RNASEH2C, which 
make up the ribonuclease H2 complex, as well as both recessive and dominant mutations in 
TREX1, SAMHD1, IFIHD1 and ADAR have been associated with the Aicardi-Goutières 
syndrome (AGS). AGS is a paediatric-onset disease characterised by encephalopathy, basal 
ganglia calcification and white matter abnormalities.311 Although the variant in this case is 
heterozygous, it is not possible to exclude a haploinsufficiency or dominant negative effect 
resulting in a less severe, adult-onset form of Aicardi-Goutières syndrome as seen in TREX1, 
or a combined effect of both the COL4A1 and RNASEH2B variants.  
Determining which, or if both or neither of these variants are causative for disease in such a 
pedigree is particularly challenging. It may help to sequence and perform brain imaging in the 
other relatives in this pedigree, although none of those surviving are known to be 
symptomatic, and many are below the age at which they would be expected to show changes 
on MRI. The presence of the same variant(s) in other affected pedigrees with similar 





Figure 5-20: Pedigree F103 
 
 
Figure 5-21 (A-C): MRI T2-FLAIR images of the proband from Pedigree F103, showing multiple areas 








Table 5-8: Coding (missense, nonsense, frameshift, inframe insertion and inframe deletion) variants passing filters in all other genes, which have not been 
excluded based on segregation analysis. Coding variants in NOTCH3, HTRA1, CTSA, COL4A1 and COL4A2 have been described earlier.  All variants reported 
here were not previously reported in mutation databases (HGMD, ClinVar and LOVD).  
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In this study of 118 pedigrees with suspected monogenic SVD, we have screened for the 
presence of rare variants across 73 candidate genes associated with both familial and sporadic 
SVD, associated phenotypes such as familial hemiplegic migraine, amyloidosis, connective 
tissue disease and leukodystrophy. This cohort of individuals has a broad range of disease 
severity both between and within families, with some index cases having SVD diagnosed only 
as an incidental finding on MR imaging.  
Three cysteine-altering variants in exons 3 and 4 of NOTCH3 were identified in patients 
previously screened for NOTCH3 mutations on older technology such as DHPLC, and Sanger 
sequencing which is currently the gold standard for clinical genetic testing. Although these 
may be false positive calls on whole genome sequencing, the validation of one of these 
variants in subsequent testing in a clinically accredited lab makes this less likely. These 
findings highlight the limitations of existing technology used in the clinic, and demonstrates 
the benefits of using HTS which allows better sensitivity in detecting mutations.  
We have described a patient with two non-cysteine changing variants in cis on the NOTCH3 
gene, and were unable to demonstrate a clear impact of these variants on disulphide bond 
formation using molecular modelling. In line with the current consensus on NOTCH3 variant 
interpretation, our discovery of only two pedigrees with non-cysteine altering variants 
suggest that these variants in NOTCH3 are indeed unlikely to cause familial SVD. However, 
this study was limited by the lack of MRI-confirmed phenotyping of relatives and limited in-
silico modelling of the variants, making it is difficult to be certain whether these variants are 
segregating with disease.  
Heterozygous HTRA1 variants appear to be the next most common cause of familial SVD after 
CADASIL, with missense and nonsense variants occurring in 5.1% of index cases and 6.3% of 
affected cases (including relatives). This is similar to frequencies seen in other cohorts of 
NOTCH3-negative familial SVD patients in Italy (6.3% of all affected cases),265 France (4.97% 
of index cases)67 and Japan (5.3% of index cases).68 Consistent with published literature, these 
families show a milder phenotype than that seen in CARASIL, and also significant 
heterogeneity, with some patients with SVD showing minor or non-specific symptoms such 




missense, and one nonsense (p.Arg302Ter) mutations were thought to cause disease through 
a dominant negative effect, we have shown here three individuals with SVD carrying the 
p.Arg370Ter variant, suggesting that haploinsufficiency due to p.Arg370Ter may also be 
sufficient to cause a milder form of CARASIL.  
Fewer variants in COL4A1/A2 were identified. These patients had phenotypes that largely fit 
with the phenotype of published cases, with the predominant clinical features being a 
combination of ischaemic and haemorrhagic strokes and subcortical microbleeds. A spectrum 
of phenotypes was also seen with variant carriers, with some patients having predominant 
cognitive impairment and no strokes. The majority of variants identified were non-coding, 
and these may potentially be pathogenic variants which create new splice sites which alter 
the Gly-X-Y helical repeat region, as recently demonstrated in COL6A1, associated with COL6-
related dystrophy.284 The impact of the non-coding variants on the resulting mRNA may be 
demonstrated on RNA sequencing.  
Both HTRA1 and CTSA are conventionally associated with early onset autosomal recessive 
disease. HTRA1 was first described in early onset SVD in CARASIL, with patients in their 20s 
developing strokes. CTSA was first described in galactosialidosis, a disease with paediatric 
onset, and was only recently linked with autosomal dominant SVD.  Our findings in HTRA1 
and CTSA support recent reports that heterozygous variants in these genes are associated 
with adult-onset familial SVD. Despite this being a hereditary disease, its relatively late onset 
may have obscured the uncovering of its genetic basis. It appears that a single copy of 
mutations in genes previously known to cause early-onset autosomal recessive diseases may 
be sufficient to allow relatively normal development, but may cause cerebrovascular disease 
in the later stages of life. Beyond looking for novel genes in undiagnosed rare diseases, it is 
thus also worth re-examining the functions and involvement of genes previously implicated 
only in recessive disorders.   
We have shown that multiple pedigrees were found to have variants in more than one 
candidate gene.  In this chapter we have only screened 73 genes – on a genome-wide scale it 
is likely that every individual has hundreds or thousands of possible variants. This highlights a 
key challenge in the clinical interpretation of results from whole genome sequencing. In the 
absence of MR imaging of all adult members of each pedigree it is difficult to determine if one 




coding variants, for which there is limited to no functional data available, and these may not 
be present in existing control databases. Hence even with clear segregation demonstrated it 
would be premature to conclude on the pathogenicity of variants without showing the 
functional impact or true population allele frequency of these variants.  
The utility of in silico predictive tools such as the CADD score, and in vivo and in vitro 
functional studies is also limited. As demonstrated in one of our pedigrees where a 3’UTR 
variant has been shown to segregate with disease in a separate study,209 but did not pass 
filters in our study, arbitrary cut-off values for predicted pathogenicity and minor allele 
frequency may result in the exclusion of disease-causing variants. Furthermore, diseases may 
not necessarily result from loss- or gain-of-function mutations as seen in CADASIL (Chapter 1).  
A clear understanding of the mechanisms of disease at the molecular and histopathological 
level is essential to confirm a genotype-phenotype association.  
The role of monogenic disease genes in sporadic SVD has been suggested in recent years, and 
it is possible that the reverse is also true. In this study we have proposed a possible role for 
rare variants in familial hemiplegic migraine genes (CACNA1A) and genes in loci associated 
with sporadic SVD (CARF, FOXC2, MLC1, RNASEH2A, RNASEH2B, SAMHD1, ZNF474). We have 
demonstrated two pedigrees each with two affected individuals carrying rare novel variants 
in CACNA1A (Pedigree F08) or FOXC2 (Pedigree F18). Although CACNA1A has not previously 
been associated with white matter abnormalities, and FOXC2 has only purported roles in the 
developing vasculature and glucose metabolism, it is possible that these have pleiotropic 
effects. Rather than a dichotomous distinction between monogenic and sporadic SVD or 
familial hemiplegic migraine and familial SVD with complicated migraines, it may be more 
likely that patients lie on a spectrum between the two, with each individual’s specific 
environment (in this context, cardiovascular risk factors) influencing the age at onset of 
disease.  
Further work for this data set would require phenotyping of all sequenced symptomatic and 
asymptomatic adult relatives using MR imaging. This would allow the use of linkage analysis 
to narrow down gene loci segregating with disease, as well as filtering within trios in cases of 
suspected de novo or recessive disease. This would allow a hypothesis-free approach rather 
than limiting the search to known genes associated with neurovascular or white matter 




the brain vasculature, may also have a role in disease, and a targeted screen of these genes 
may also reveal novel genes involved in the disease process. Finally, gaining a better 
understanding of the non-coding space, such as by using RNA-sequencing analysis to 










Table 5-9: Summary of variants identified in all 118 pedigrees. Variants which do not segregate with the pattern of inheritance of disease in the pedigree 
have been excluded from this list.  
Pedigree Candidate 
gene 
SNV SNV type CNV within gene CNV type Remarks 
F01 APP c.1458+5711_1458+5722delTTTTTTTTTTTT Intron  RP11-521D12.2 Deletion  
CACNA1A c.2172+998_2172+1001delTTTC Intron  RP11-83M16.6 Deletion 
CECR1 c.753+2659delT Intron  DNAH8 Deletion 
   PBX4 Deletion  
 
F02 APP c.58-10602_58-10576delATTTTATTAAAAT 
CTTCTAATAAAAAA 
Intron  AC062021.1 Deletion  
   DLAT Deletion 
   RP11-551L14.1 Deletion 
 
F03 COL4A2 c.1596+636_1596+637dupGG Intron RP11-2E17.1 Deletion  
SAMHD1 c.696+584_696+585dupTT Intron RP4-568F9.6 Deletion 
PRDM16 c.439-33525_439-33522dupCCCC Intron  
 
  
F04 ATP1A3 19:42501940_C/CCCCCCACG Upstream  CYP20A1 Deletion  
CACNA1A c.4591-732_4591-730delAAG Intron LAT2 Deletion  
NBEAL1 c.6508+413_6508+417dupGCCAG Intron  RNA5SP347 Deletion 
ZSCAN9, ZKSCAN4 Deletion 
 
 
F05 HTRA1 p.Pro331Leu Missense    
APP c.58-11781_58-11778delAACA Intron  
 
   
F07    EPCAM, MIR559 Deletion  
 
 
F08 CACNA1A p.Gly2002Ser Missense    
FOXC2 16:86600205_A/G Upstream     















SNV SNV type CNV within gene CNV type Remarks 
F09 ATP1A2 1:160084457_AG/A Intron RP11-402J7.2 Deletion  
CACNA1A c.978+1429_978+1431dupATG Intron 
 
   
F10 COL4A1 c.144+1918_144+1919insAG Intron 
 
   




Intron  AC111155.1 Deletion  
NBEAL1 c.51+12044_51+12045delTT Intron  
 
   
F12 COL3A1 2:189879981_A/AT Downstream  CTD-2269F5.1 Deletion  
   EXD1, RN7SL497P Deletion  
 
F13 APP c.1458+5147_1458+5148insCCTTTCCTTTCC 
TTTCCTTTCCTTTCCTTT 
Intron  OR5C1 Deletion  
PRDM16 1:3359482_GTGT/G Downstream  RP11-430B1.2, MYO5C Deletion  
SH3PXD2A c.72+26561G>T Intron     
SH3PXD2A c.473-1239_473-1231delGCCCCCCCC Intron     
EIF2B2 c.434-46_434-
32delTTTTTTTTTTTTTTTinsATATATATATATA 
Intron    
MIR216A / 
MIR217 
2:56212347_C/T Downstream     
MIR216B 2:56229175_C/T Downstream  
 
   
F15 PRDM16 c.38-4765_38-4758dupGGTCTTAC Intron  NMRK2 Deletion   
ZCCHC14 c.*3566T>C 3’UTR SLC39A11, SCARNA24 Deletion 
 
 
F16 COL4A1 c.144+6701_144+6705delCTTTA Intron RALGDS, GBGT1 Deletion  
KIF18B c.-15+4779_-15+4781delTGT Intron     
PRDM16 c.3285-2204_3285-2198delCCTGCCC Intron     
TUBB4A c.278-2010delT Intron  
 
   
F17 EARS2 c.295+1153G>C Intron  
 
AC114765.3 Deletion  
F18 FOXC2 p.Val224Leu Missense DNAH2 Deletion   










SNV SNV type CNV within gene CNV type Remarks 
F19    Y_RNA Deletion 
 
 
F20    MYOM2 Deletion  
 
 
F21    PKD1L2 Deletion  
   MMP9 Deletion  
   PTGIS Deletion 
 
 
F23 COL4A1 c.1897+559_1897+561delCCT Intron HYAL1 Deletion  
FAM126A c.626+3795G>A Intron  WDR49 Deletion  
SH3PXD2A c.473-1228_473-1227insCG Intron TRMT44 Deletion  
   ZNF682 Deletion 
 
 
F24    SLC3A1,PREPL,CAMKMT Deletion   
   AC005176.2, AC005176.3, LGALS16, LGALS17A, 
AC093063.3, 
AC093063.2, AC006133.3, LGALS14, CLC, LEUTX 
Deletion  
   RERGL Deletion  
   RP11-331H13.1, SCAPER, MIR3713 Deletion 
 
 
F25 GSN 9:124098555_GC/G Downstream     
 
F26 KIF18B 17:43029291_CTCTC/ATATATATATATA Upstream AC002485.1, RP11-24C14.1 Deletion  
 
   NCAM2 Deletion 
 
 
F27 EARS2 c.1353-1591delT Intron NDUFAF2, AC008498.1 Deletion  
   VPS37A, MTMR7 Deletion  
   LINC00423, TOMM22P3, KL, AL161898.1, STARD13, 
STARD13-IT1, STARD13-AS, RP11-141M1.1, 
AL138999.1, RP11-141M1.3, RP11-37L2.1, RP11-179A7.2 
 
Deletion  
F28 HTRA1 p.Val175Leu Missense GRB10 Deletion  
CACNA1A c.540-5082_540-5081delTA Intron     
TUBB4A c.*128delC 3’UTR    
ICA1L c.-8+10250_-8+10251insTTT Intron  
 










SNV SNV type CNV within gene CNV type Remarks 
F29 COL4A1 c.145-5665_145-5634delCACATATAT 
ATATATATACATATATATATATAinsTATT 
Intron L3HYPDH, RP11-701B16.2 Deletion  
ZNF474 p.Arg102Ter Nonsense    
GSN 9:124099535_C/G Downstream 
 
   
F31 SNORD118 17:8076200_GA/G Downstream  
 
NLGN1-AS1 Deletion  
F32 CACNA1A c.4866+727_4866+728delCT Intron     
CACNA1A c.1669-1930_1669-1926delTTTTG Intron    
CTSA p.Arg325Cys Missense   CARASAL-causing 
mutation 
ZNF474 c.-213+1131_-213+1134delTCAT Intron  
 
   
F33 EIF2B1 p.Val24Met Missense TBC1D2B, SH2D7 Deletion  
FAM126A c.743+407A>C Intron     
FAM126A c.626+3782G>A Intron     
EFEMP1 c.517+7277C>T Intron  
 
   





Intron LINC00877 Deletion  
SH3PXD2A c.*5178_*5187dupGTGTCTGTGT 3’UTR 
 
   
F35 COL4A2 c.2425+1717_2425+1725delCATACACAC Intron    
FOXF1 16:86541560_T/TG Upstream     
LMNB1 c.359+13169_359+13172dupTAAA Intron  
 
   




  NOTCH3 variants 
in cis. Neither 
carried by 
unaffected relative 




CACNA1A c.6780+227_6780+228insCCCCCC Intron    
 c.293+15236_293+15243delTTTCCTTT Intron    
NBEAL1 c.516-1069_516-1067delACA Intron    
F39 
(=F54) 
HTRA1 p.Pro285Leu Missense    










SNV SNV type CNV within gene CNV type Remarks 






   
 
F40 HTRA1 c.777+6599delG Intron GCNT2 Deletion  
CACNA1A c.1346-1598_1346-1594dupAAGAT Intron  TMEM135 Deletion  
SAMHD1 c.1062+550delCinsTTTTTTTTTTTT Intron  ITCH Deletion  
SAMHD1 c.209-2090_209-2079delTTTTTTTCTTTT Intron     
 
F42 ATP1A3 19:42502584_G/A Upstream    
SH3PXD2A c.1225-
2233delAinsGTAAACTTTTTTTTTTTTTTTTTT 
Intron     
 
 
F43 COL4A2 c.99+16231_99+16232delTG Intron ARL2BPP7 Deletion  
APP c.58-20144delC Intron MYH1 Deletion  
TREX1 3:48512824_TACAAAAAT/C Downstream  EFCAB13 Deletion  
CARF c.1494+251dupA Intron     
WDR12 c.741+866_741+867dupAA Intron  
 
   
F44 NOTCH3 p.Cys212Arg Missense   CADASIL-causing 
mutation 
ATP1A2 1:160118195_TAGAG/T Downstream    
EVL 14:100528561_A/ATG Upstream     
EVL c.180+5977_180+5980dupATCC Intron     
PRDM16 c.38-9424_38-9423delTGinsCGTCCATCTATCCA Intron     
HEPACAM c.86-4128delT Intron     
EFEMP1 c.517+12656_517+12657delTG Intron  
 
   
F45 CACNA1A c.1255+465dupT Intron     
NBEAL1 c.1098+4385dupT Intron    
F47 ABCC6 c.601-361delC Intron RAB11FIP5, RP11-44N22.3 Deletion  
DEGS2 c.826-752_826-751insGGGGC Intron  RFPL4AL1, RFPL4AP1 Deletion  
EVL 14:100613995_G/GGCCCC Downstream     
FAM126A c.-28-8949_-28-8947delTTA Intron  
 










SNV SNV type CNV within gene CNV type Remarks 
F48 CACNA1A c.539+22891_539+22912delACCCTACT 
CCACACTCCCCACTinsCCCCCCCC 
Intron     
 c.539+22882delAinsCCCCCCCCCCCCCCCCCCTC Intron    
LOX c.1036-95A>G Intron  
 
 
   
F50 APP c.1091-1210_1091-1207delATCA Intron  TRAJ46, TRAJ45, TRAJ44, TRAJ43, TRAJ42, TRAJ41, 
TRAJ40, TRAJ39, TRAJ38 
Deletion  
 c.57+24642_57+24645delTAAA Intron DLL3, SELV Deletion  
PRDM16 c.38-4431_38-4419delTCTTACACACGGTinsC Intron  
 
   
F51 GSN p.Gln528Pro Missense WDR63 Deletion  
EIF2B4 2:27584647_TGAG/T Downstream  RP11-448N11.3 Deletion  
   UBBP5, LIN28AP2, RP11-342C20.2, MIR4500HG, 
MIR4500, SLITRK5, LINC00397, RP11-471M2.3, TET1P1, 
RP11-545P6.2, AL354896.1, RPL29P29, 
LINC00433, LINC00560, RP11-29P20.1 
 
Deletion  
F52 ZCCHC14 16:87529390_T/TCCC Upstream  CCT3 Deletion  
SCN1A c.3429+3845_3429+3846insGTATTT Intron  MARVELD1, ZFYVE27, SFRP5 Deletion  
   RNU6-457P Deletion  
   RP11-659F24.1, RP11-526H11.1 Deletion 
 
 
F53 CACNA1A c.5625+280G>A Intron  AC016907.3 Deletion  
CARF c.-211+43G>A Intron    
WDR12 2:203777090_G/A Upstream  
 
   
F54 SAMHD1 c.348+745_348+760delAAACAATGTATAGTAT Intron  RP11-600K15.1 Deletion  
ICA1L c.866+1447_866+1448insTA Intron  
 
   
F55 SH3PXD2A c.399-166C>A Intron  MYO9B, CTD-2528A14.5, CTD-3032J10.2 Deletion  
DARS2 1:173789430_T/A Upstream     
NBEAL1 c.7420-1162dupG Intron  
 
   
F57 APP c.865+10820_865+10821dupGA Intron    
JPH3 16:87631934_GGC/G Downstream  
 










SNV SNV type CNV within gene CNV type Remarks 
F58 PRDM16 c.38-5052_38-5039delCGGTCTTACACACG Intron  ADCY2 Deletion  
EIF2B4 2:27586203_C/CT Intron  
 
SAV1, RN7SL452P Deletion  
F59 PMF1 c.162-5888_162-5883delCCCTGC Intron  C1orf222 Deletion  
   TTC30A Deletion  
   RP11-195M16.1 Deletion  
F60 PRDM16 c.438+25539_438+25568delTAGG 
ACAGTTGGGAGAAGGACAGTCAGGAG 
Intron     
F62 EVL c.359-9474C>T Intron  SLC22A23 Deletion  
SAMHD1 c.1746+1359delT Intron  
 
   
F63 COL4A2 c.100-22218_100-22217dupGC Intron SLC3A1, PREPL Deletion  
PRDM16 c.439-5180_439-5153delACACACT 
CATCCCAACACAGCCCTCCCA 
Intron  RP11-83M16.1 Deletion  
   HEXA Deletion 
 
 
F64 SAMHD1 p.Leu493Pro Missense DNAJB8, DNAJB8-AS1 Deletion  
ATP1A3 19:42501943_C/CCTGGG Upstream FANCD2P2 Deletion  
CACNA1A c.978+10925delT Intron C9orf66, DOCK8 Deletion  
BGLAP 1:156214645_G/GGCTGGT Downstream MIR548AP Deletion  
PMF1 1:156214645_G/GGCTGGT Downstream  CRISPLD2 Deletion 
 
 







   
F67 GFAP 17:42994270_G/A Upstream  LARGE Deletion  
LMNB1 5:126175766_AAGG/A Upstream 
 
   
F68 FOXF2 6:1388250_A/ACCCCCCCC Upstream  ALDH8A1 Deletion  
PRDM16 c.388-5040_388-5038delGTT Intron  
 
EFCAB6 Deletion  
F69 APP c.58-23994_58-23992delTTCinsCTTTTCT 
TTTCTTTTTTTTTTTTTTTTT 
Intron     
KIF18B c.801G>A Synonymous 
  










SNV SNV type CNV within gene CNV type Remarks 







Intron  U3, ZIM3 Deletion  
F72 ATP1A2 1:160085150_GCT/G Upstream  CTC-340A15.2 Deletion  
CACNA1A c.1669-1930_1669-1926delTTTTG Intron  SERHL, RRP7A Deletion  
JPH3 c.1160+1415_1160+1417delAGC Intron     
SH3PXD2A c.428-1296_428-1295dupAA Intron     
DARS2 c.840+208delG Intron     
NBEAL1 c.4761+2621_4761+2622insATTTTTT Intron     
NBEAL1 c.6015+74T>C Intron  
 
   
F73 KIF18B 17:43029250_ACCATGT/A Upstream  
 
CLTA Deletion  
F74 NOTCH3 p.Cys76Tyr Missense WWOX Deletion CADASIL-causing 
mutation 
RNASEH2A p.Gln126His Missense L3MBTL4 Deletion  




Intron     
NBEAL1 c.2420-1059_2420-1058delAT 
 
Intron     
F75    RP11-55L3.1 Deletion  
   DOK3 Deletion  
F76 ATP1A3 19:42502544_C/G 
 
Upstream  PARD3B Deletion  
F77    HMGN2P18 
 
Deletion  
F78 NOTCH3  p.Thr328Ile Missense    
ICA1L c.1243+420_1243+430delTCCTGTGTCCA Intron     
SCN1A 2:166844424_AT/A Downstream    
 










SNV SNV type CNV within gene CNV type Remarks 
CCCGGTGTinsCACC 
CSF1R c.1627-2825G>A Intron     





   
 




Intron MICU1 Deletion  
CSF1R 5:149493575_A/T Upstream  RP11-553E24.2 Deletion  
ITM2B 13:48802664_AGTAT/A Upstream  CTD-3037G24.4, CTD-3037G24.3, SNX29 Deletion  
DEGS2 c.83-680_83-679insAG Intron  ZNF566 Deletion  
SH3PXD2A c.604+10390delA Intron     
ICA1L c.985+3728_985+3733delTTTTTA Intron     
 
F81    RP4-568F9.6 
 
Deletion  
F82 GFAP p. Arg29Cys Missense    
LMNB1 c.1386+396_1386+398delGAG Intron     
MLC1 22:50495579_T/TGGGAGGGGGGGTCGGGGTG Downstream 
  
   
F88 APP c.225+7943delG Intron   COL4A1 3’UTR 
variant segregating 
with disease – not 
passing filters 
 
F90 SAMHD1 c.209-2107_209-2094delTTTCTTCTTTTCTTinsC Intron  SPICE1 Deletion  
   KHDRBS2 Deletion  
   APOBEC3D Deletion 
 
 
F91 ABCC6 p.Gly992Arg Missense AC005150.1 Deletion  
CARF c.1559-890_1559-889insATATATAT Intron 
 
   
F92 APP c.57+4594delG Intron MSR1, MRPL49P2 Deletion  
LMNB1 c.360-9147_360-9136delCATTTGTTTGTT Intron 
 
ZNF816-ZNF321P, ZNF816 Deletion  










SNV SNV type CNV within gene CNV type Remarks 
APP c.1225-177_1225-174delATTA Intron  PKIB, RP11-95G17.2 Deletion  
CACNA1A c.5528+525dupC Intron     
SH3PXD2A c.398+9147delC Intron    
GFAP 17:42996750_A/AT Upstream  
 
   
F94    RP11-568J23.4 Deletion  
 
 
F95 HTRA1 p.Val175Met Missense    
ATP1A2 1:160081647_CGG/C Upstream 
 
   
F96 CACNA1A c.399+970delC Intron  BIRC6 Deletion  




Intron    
F97 CARF p.Thr657Ile Missense CTD-2377D24.8 Deletion  
APP c.57+12441delA Intron    
PRDM16 c.439-62964_439-62963delTG Intron     
SH3PXD2A c.604+3299delC Intron     
DARS2 c.1191+28delT Intron     
NBEAL1 c.52-12093delA Intron 
 
   




Intron     
F99 ATP1A2 1:160083751_G/GT Upstream     
EIF2B3 c.294+8349C>T Intron 
 
   
F100 APP c.57+22922A>G Intron    
JPH3 c.1161-4888dupT Intron  
 
   
F101   Missense POT1-AS1, EEF1GP1 Deletion  
   CTD-2135J3.3 Deletion 
 
 
F102 DARS2 c.128-614_128-613delAA Intron  TBC1D7  Deletion  










SNV SNV type CNV within gene CNV type Remarks 
      
F103 COL4A1 p.Trp1578Cys Missense PRTFDC1 Deletion  
RNASEH2B p.Val41LeufsTer23 Frameshift ADAMTS18 Deletion  
   RNA5SP443 Deletion  




F104 COL4A2 c.100-1916_100-1877delAGGGCTG 
TACTAGCTCACCTGTGTGGGGGGAGGGCAGTA 
CinsGCGGGCGGGA 
Intron  RP11-165H23.1 Deletion  




Intron     
DARS2 c.1129-575delA Intron 
 
   
F105 GLA X:100649780_TTTTTTTT/ATATTTA Downstream AL031176.1 Deletion   
GSN c.504+652C>T Intron    




Intron     
 
F107 JPH3 c.383-9601delC Intron  FECHP1 Deletion  
   ATG10, AC114969.1 Deletion 
 
 
F108 EIF2B3 c.1203-7409delAinsTTTTTTTTTTTT Intron  
 
GATS Deletion  
F109 CECR1 c.973-422_973-421insATTTTTT Intron     
FAM126A c.-29+8308delG Intron     
EIF2B3 c.149-158_149-157insAAAAAAA Intron  
 
   
F110 HTRA1 c.777+4939G>A Intron GORAB Deletion  
COL4A2 p.Pro41Ser Missense RP11-510I6.3 Deletion  
PRDM16 c.38-31675delC Intron  RP11-152P17.2, Y_RNA Deletion  
PRDM16 c.38-4986_38-4985insCCTTACA 
CACGCGGTCTTACACGCGG 
Intron  AP002387.1 Deletion  










SNV SNV type CNV within gene CNV type Remarks 
LMNB1 c.360-5990_360-5989dupCG Intron PLIN4 Deletion  
   CTD-3020H12.3 Deletion 
 
 





F113 LMNB1 p.Glu559Ala Missense    
ATP1A3 c.2133+278_2133+279dupGG Intron    
ATP1A3 c.7-2227_7-2224delAGAG Intron     
PRDM16 c.37+41258_37+41296delTGTGGGGACAC 
AGTGTCTGTGGCTCCCCCATGTCCTGGG 
Intron     
RNASEH2A 19:12912601_G/A Upstream 
  
   
F115 ATP1A3 19:42501935_T/TCCCCCCC Upstream  NTNG1 Deletion   
   RP11-428P16.2 Deletion  
   RP11-174M13.1 Deletion  
   ZNF431 Deletion 
 
 
F116 ZNF474 c.-212-2270delG Intron  AC092155.4 Deletion  






Intron  C16orf45 Deletion  
CSF1R c.890-822_890-821insCA Intron CNTLN Deletion  
EVL c.488-59delA Intron  
 
   
F118 LMNB1 c.-349A>G 5’UTR RP11-91I11.1 Deletion  
ICA1L c.911-2725delA Intron  DCTPP1 Deletion  
 
F120 ITM2B c.117+1548_117+1549delTA Intron GBP7,GBP4 Deletion  
EVL c.181-4540delG Intron     
 
F121 NOTCH3  c.4736+1035_4736+1036insGGGGGGG 
GGGGG 
Intron RP11-193H5.5, MTND6P15, MTND5P18 Deletion  










SNV SNV type CNV within gene CNV type Remarks 









   
F123 COL4A2 c.180+7416_180+7417delCT Intron AGO1 Deletion  
PRDM16 c.388-3993_388-3992delAG Intron  RP11-13E5.2, DCAF12L2 Deletion  
LMNB1 c.359+9667dupA Intron 
 
   
F124 CACNA1A c.978+6492dupA Intron GNG12-AS1, WLS Deletion  
SCN1A c.2416-314_2416-313dupGA Intron  RP11-703H8.9 Deletion  




F125 PRDM16 c.439-68874_439-68873insGGGGGGG Intron  
 
FAM135B Deletion  
F126 COL4A1 p. Gly1369ArgfsTer33 Frameshift RP11-124B13.1 Deletion  
COL4A2 c.181-30810delG Intron    
ADAR      
CSF1R 5:149493458_CAGAT/C Upstream    
CACNA1A c.4950+621_4950+632delACCCTCTCCTTG Intron     
ADAR 1:154583318_GACAAAATTG/AAAAAAAA 
AAAAAAAT 
Upstream     
NBEAL1 c.6508+418_6508+419insTTTT Intron     
 
F128    SMG1 
 
Deletion  
F132 APP c.57+12572A>C Intron    
EARS2 c.486-2202_486-2199dupAATG Intron    
LMNB1 c.360-3828_360-3827insATATATAT Intron  
 
   




Downstream     










SNV SNV type CNV within gene CNV type Remarks 
CTSA 20:44516873_T/A Upstream    





Intron     
F137 CACNA1A c.978+509delC Intron     
 
F139 ATP1A3 19:42501343_AG/A Upstream    
PRDM16 1:3358271_C/GCCGGTTCCT Downstream    
SH3PXD2A c.154-10399_154-10398delCT Intron 
 
   
F141 FAM126A c.744-1447dupG Intron     
PRDM16 c.439-62996_439-
62982delACTGTGTGTGTGTGC 




Intron     












Table 5-10: Non-coding SNVs passing filters identified in 118 probands. Variants present in patients 
with a known pathogenic mutation in another gene, or variants present in relatives but absent in the 
proband in a pedigree, or variants not segregating with disease within the pedigree are excluded.  












CECR1 c.753+2659delT Intron 
c.973-422_973-421insATTTTTT Intron 
CTSA 20:44516873_T/A Upstream 
FOXC1 None  
GLA X:100649780_TTTTTTTT/ATATTTA Downstream 
X:100648388_AAAG/A Downstream 
HTRA1 c.472+12941C>T Intron 
c.777+4939G>A Intron 
c.777+6599delG Intron 
NOTCH3 19:15267550_T/G Downstream 
c.4736+1035_4736+1036insGGGGGGGGGGGG Intron 
c.118+1244_118+1247delCACA Intron 






















 Gene Variant identified Variant type 
SNORD118 17:8076200_GA/G Downstream 




SCN1A 2:166844424_AT/A Upstream 
c.3429+3845_3429+3846insGTATTT Intron 
c.2416-314_2416-313dupGA Intron 




















































APP None  
ITM2B c.117+1548_117+1549delTA Intron 
13:48802664_AGTAT/A Upstream  
GSN 9:124098555_GC/G Downstream 
9:124099535_C/G Downstream 
c.504+652C>T Intron 
















DARS2 c.664-415_664-414delAA Intron 





EARS2 c.1353-1591delT Intron 
c.486-2202_486-2199dupAATG Intron 
c.295+1153G>C Intron 














EIF2B4 2:27584647_TGAG/T Downstream  
2:27586203_C/CT Downstream 





GFAP 17:42994270_G/A Upstream 
17:42996750_A/AT Upstream 
HEPACAM None  









MLC1 c.894+580_894+603delCCTGATGGGGGGATGGAGTCACTG Intron 
22:50495579_T/TGGGAGGGGGGGTCGGGGTG Downstream 
RNASEH2A 19:12912601_G/A Upstream  
RNASEH2B None  










TUBB4A c.*128delC 3’UTR 




COL3A1 2:189879981_A/AT Downstream 














BLAP 1:156214645_G/GGCTGGT Downstream 
DEGS2 c.826-752_826-751insGGGGC Intron 
c.83-680_83-679insAG Intron 
EFEMP1 c.517+7277C>T Intron 




FOXC2 16:86600205_A/G Downstream  
FOXF1 16:86541560_T/TG Upstream 



























2:56216414_G/A Upstream  
MIR216B 2:56229175_C/T Upstream  










OXER1 None  


















































 Gene Variant identified Variant type 
WDR12 c.741+866_741+867dupAA Intron  
2:203777090_G/A Upstream 
ZCCHC14 c.*3566T>C 3’ UTR 
c.284-9451delT Intron 
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6. The frequency of known mutations in the general 
population 
6.1 Introduction 
High throughput sequencing (HTS) techniques, as described in Chapter 2, have significantly 
contributed to our understanding of the genetic basis of rare Mendelian diseases.184 Earlier 
genetic studies relied on the genotyping of extensive pedigrees to identify disease-associated 
loci by linkage analysis. This, coupled with Sanger sequencing led to the identification of novel 
variants and disease-associated genes, although not always with success. More recently, the 
use of HTS techniques sometimes coupled with linkage analyses have led to an exponential 
growth in gene and variant discovery in the diagnosis of rare diseases.184,313 
A pitfall of the use of HTS lies in the fact that while it allows the screening of multiple genes 
simultaneously, providing a high yield of variants in each patient, it may not necessarily lead 
to any clinical benefit in the search for a genetic diagnosis. The discovery of novel variants 
with no prior association with disease or functional analyses is of limited utility as these are 
classed as ‘variants of uncertain clinical significance (VUCS)’. These variants are 
understandably either left out of clinical genetics reports, or are returned to the clinician with 
a note of caution. This means that the endeavour often raises more questions than answers, 
and may not lead to a genetic diagnosis and the provision of appropriate genetic counselling.   
One strategy used to sieve out potentially disease-causing variants is an arbitrary threshold 
for minor allele frequency (MAF) of variants in the general population. Highly penetrant 
heterozygous mutations known to cause rare Mendelian diseases are expected to be rare in 
the population, in line with the relatively low prevalence of these diseases. For example, the 
population prevalence of CADASIL is estimated at 2 to 4 per 100,000 in the UK.40,41 An example 
is shown in Chapters 4 and 5 where we have used minor allele frequency as a filter to identify 
potentially disease-causing variants. The assumption in such studies is that highly penetrant 
mutations associated with rare Mendelian diseases are likely to also be rare in the population, 





However, recent evidence suggests higher-than-expected frequencies of disease causing 
mutations in control populations. For example, a recent study in the Exome Aggregation 
Consortium (ExAC) database showed that CADASIL-causing variants were present in up to 3.4 
per 1000 individuals in the control dataset, and suggested that some of these variants may 
result in a milder, later-onset phenotype.59 A study of known mutations in epilepsy-associated 
genes and their frequency in ExAC has also shown that some of the known disease-causing 
variants may be present in a much higher frequency than would be expected for the disease, 
particularly if there is insufficient segregation data for the variant.314 While control databases 
such as ExAC are by no means repositories of disease-free, well-phenotyped ‘healthy’ 
individuals, these frequencies were nevertheless beyond the estimated population 
prevalence of the disease.  
Understanding the frequency of VUCS in the general population is valuable in aiding our 
interpretation of these variants in the clinical context. Highly penetrant variants which are 
thought to be the causative mutations in our cohort of families with suspected familial SVD, 
are theoretically unlikely to be present in high frequencies in the general population since the 
disease is known to be rare. In this study, we aim to provide an estimate of the allele 
frequency of known disease-causing mutations in known familial SVD-associated genes in the 
BRIDGE whole genome sequencing population, as well as in two control databases, the Exome 
Aggregation Consortium (ExAC) and genome aggregation databases (gnomAD). 
6.2 Methods 
6.2.1 Known disease-causing variants 
A literature search for known genes related to familial SVD was performed on PubMed for 
publications dating from 1993 to April 2017. A comprehensive search strategy was developed 
using the search terms detailed in Table 6-1. Key words were combined, such as ‘cerebral small 
vessel disease’ and ‘genetics’, using ‘AND’. Known SVD-associated genes (NOTCH3, HTRA1, 
COL4A1, COL4A2) were included in the search terms. All abstracts in English were reviewed, 
and the full texts of relevant systematic reviews, case reports, prevalence or observational 
and candidate gene studies were reviewed to create a database of known disease-causing 




Table 6-1: Search terms used for the systematic review of monogenic SVD genes.  
Disease  Features on imaging Monogenic diseases or genes 
• Cerebral small vessel 
disease 
• Binswanger disease 
• Cerebral microangiopathy 
• Lacunar stroke 
• Lacunar infarct 
• Subcortical stroke 
• Vascular dementia 
• Vascular cognitive 
impairment 
• Subcortical dementia 
• Leukoaraiosis 
• Leukoencephalopathy 
• White matter disease 
• CADASIL, NOTCH3 




Published disease-causing variants in each gene were identified from peer-reviewed 
literature and mutation databases. These include the Leiden Open Variation Database (LOVD, 
http://www.lovd.nl/3.0/home), and the Human Gene Mutation Database (HGMD, 
http://www.hgmd.cf.ac.uk). Although these variants have previously been reported in 
disease it is important to note that not all have the same level of evidence for pathogenicity. 
Some variants may have only been identified in single cases, without evidence of segregation 
with disease in the pedigree, or in-vitro evidence to illustrate the impact of the mutation on 
protein function.  
NOTCH3 mutations identified in patients attending the UK National CADASIL Clinic, but had 
not previously been reported in literature, were also included in this analysis. The total 
number of variants included is summarised in Table 6-2, and the full list of variants identified 
is provided in the appendix.  
Cysteine-altering variants affecting the epidermal growth factor-like repeat (EGFR) regions, 
encoded by exons 2 to 24 of the NOTCH3 gene, are known to cause CADASIL. These variants 
are neither gain- or loss-of-function variants, but are instead thought to lead to the abnormal 
cleavage of the NOTCH3 ectodomain, setting off a cascade of aggregation of proteins around 
the smooth muscle cells of the small vessels,119 as described in Chapter 1.  
Cysteine-sparing variants, though previously reported as being associated with 
CADASIL,262,315,316 are no longer thought to be disease-causing in majority of cases due to the 




EGFR regions.317–320 However, a few of these variants have been identified in families with 
complete screening of all 23 variants, segregation of the variant in the pedigree or have 
granular osmiophilic material, and as a result there has been a recent review suggesting the 
possible pathogenicity of at least a few of these variants.321 For completeness, all cysteine-
sparing variants have been summarised in a separate table in the appendix, and have also 
been queried in control databases as part of this study.  
Table 6-2: Number of variants reported as disease-causing in NOTCH3, HTRA1, COL4A1 and COL4A2 
Gene Total no. of 
mutations reported 




No. of mutations 
reported in 
homozygous cases 
Table in appendix 
NOTCH3* 
 
278 273 8 Table 6-8 
HTRA1  
 
33 20 13 Table 6-10 
COL4A1 
 
80 80 0 Table 6-11 
COL4A2 
 
10 10 0 Table 6-12 
*Only cysteine-changing variants are included in this table.  
6.2.2 Presence of known disease-causing variants in controls 
Patients recruited to the BRIDGE study under rare diseases other than SVD served as 
presumed SVD-free controls in this study. These individuals were recruited as either affected 
or disease-free individuals in different rare disease categories, as described in Chapters 2 and 
5. Whole genome sequencing was performed in 7348 unrelated non-SVD individuals. The 
MAF of known disease-causing mutations as listed in the appendix was calculated in this set 
of controls. Data on the age, sex, disease category and disease status for patients carrying 
SVD-associated disease-causing variants was collected.  
The frequencies of known disease-causing variants were also queried in two publicly 
accessible genomic databases: the ExAC v0.3 database, and genome Aggregation Database 
(gnomAD). The ExAC database is a repository of exome sequencing data from 60706 
individuals, curated by the Broad Institute (http://exac.broadinstitute.org/downloads). 
GnomAD is a database of 123,136 whole exome sequences and 15,496 whole genome 




(http://gnomad.broadinstitute.org/). Combined Annotation Dependent Depletion (CADD) 
scores, computed using an in silico predictive tool which integrates multiple annotations to 
provide an estimate of deleteriousness (http://cadd.gs.washington.edu), were also queried.  
The term ‘diagnostic yield’ is used here to describe the proportion of unrelated individuals 
carrying a variant or group of variants, while the term ‘allele frequency’ is used here to 
describe the proportion of alleles sequenced in controls (assuming two alleles sequenced per 
individual).  
6.3 Results and Discussion 
Previously reported disease-causing mutations in HTRA1, COL4A1 and COL4A2, and cysteine-
changing mutations in NOTCH3 were identified in 214 out of 7348 unrelated controls. All 
except one mutation (in COL4A2) were identified in the heterozygous state. None of the 
controls carried more than one mutation.  
All mutations except one (in COL4A1) had CADD scores above 15, a threshold used in Chapter 
5 as a filter for rare variants in individuals with familial cerebral SVD. Cysteine-sparing variants 
in NOTCH3 have not been included in the above summary.  
6.3.1 NOTCH3 
Nine cysteine-altering NOTCH3 variants in exons 2 to 24 of the gene were identified in 19 
unrelated controls (diagnostic yield of 0.26%). The CADD scores for all nine variants ranged 
from 22.8 to 30.0, and six of these variants were novel.  Each variant was found in 1 to 6 
unrelated controls, with these controls being recruited under various rare diseases, with a 
broad age range of 5 to 80.  
Although the age at onset of symptoms in CADASIL can vary greatly,43 MRI changes  tend to 
be present by around the age of 35 in CADASIL mutation carriers, as shown in earlier studies 
in small cohorts of pre-symptomatic and symptomatic individuals.217,322 Excluding individuals 
where the age is not known or below 35, there remain 9 unrelated controls carrying cysteine-
altering NOTCH3 variants which are presumed to be pathogenic. These results are 




Electron microscopy of a kidney biopsy from a ten-year-old p.Cys522Ser variant carrier with 
membranoproliferative glomerulonephritis was performed, and this showed characteristic 
subendothelial dense deposits typical of membranoproliferative glomerulonephritis. Granular 
osmiophilic material (GOM, see Chapter 1) was not specifically looked for, and images were not 
available for re-evaluation. Evidence of GOM has been documented in patients with CADASIL as young 








Table 6-3: Frequency of cysteine-altering variants in exons 2 to 24 of NOTCH3 identified in unrelated controls in BRIDGE. All variants identified were in a 
heterozygous state.  


















p.Phe270Cys 6 of 33 25.6 1 6.8 x 10-5 F 65 Multiple primary 
malignant tumours 
 
- - Novel  
p.Cys522Ser 10 of 
33 
28.6 1 6.8 x 10-5 M 10 Membranoproliferative 
glomerulonephritis  
- - Novel GOM not 
described 




p.Gly667Cys 10 of 
33 
 
26.0 1 6.8 x 10-5 F 68.7 Bleeding disorder - 4.1 x 10-6 LOVD  
p.Arg728Cys 14 of 
33 
 
26.4 1 6.8 x 10-5 F 65.7 Pulmonary arterial 
hypertension 
- 8.4 x 10-6 57,324  
p.Arg785Cys 15 of 
33 
25.9 1 6.8 x 10-5 M Not known Unaffected, recruited 
under Leber Hereditary 
Optic Neuropathy 
 
- 3.2 x 10-5 Novel  
p.Tyr916Cys 15 of 
33 
 










- - Novel  





























M Not known Not known – Genomics 
England Pilot 
 
F 80 Multiple primary 
malignant tumours 
 
M 46 Primary immune 
disorder 
 
F 4 Paediatric neurology 
 
p.Arg1231Cys 22 of 
33 
30 6 4.1 x 10-4 F 36 Pulmonary arterial 
hypertension 
 






M Not known Pulmonary arterial 
hypertension 
 











F 12 Rod-cone dystrophy 
 
 
M 10 Paediatric neurology 
 
p.Cys1324Trp 24 of 
33 
24.7 1 6.8 x 10-5 M 26 Factor VII deficiency - - Novel  




The two most commonly occurring variants were p.Arg1231Cys, with an allele frequency of 
4.1 x 10-4, and p.Cys1222Gly, with a frequency of 3.4 x10-4. Both of these variants have 
previously been associated with patients suspected of having CADASIL.43,57,58,245,256,325,326 
These variants are also relatively common in ExAC and gnomAD, with p.Arg1231Cys occurring 
in nearly 1 in 1000 individuals.  Although a definite genotype-phenotype correlation has not 
been proven in CADASIL,43,58,258 cysteine-altering variants in  epidermal growth factor-repeat 
like regions (EGFr) outside of the first six repeats have recently been suggested to be 
associated with a milder form of disease.59 As p.Arg1231Cys and p.Cys1222Gly are found in 
the 31st EGFr repeat, the presence of these variants in a significant number of controls who 
may still be pre-symptomatic serves to support this hypothesis. p.Cys1222Gly was also a 
variant that did not pass stringent filtering in our study on sequencing in presumed-sporadic, 
early-onset SVD cases (Chapter 4).  
Cysteine-sparing variants previously associated with CADASIL were also queried in the three 
control datasets. These variants are not thought to be pathogenic, and have not been 
included in the total of 214 unrelated controls found to carry disease-causing variants. These 
variants were found in relatively higher frequencies in this study. Of 16 reported variants, 5 
were identified in 49 unrelated controls across the disease phenotypes, giving an overall 
diagnostic yield of 0.67%. The most commonly occurring variant was p.His170Arg, found in 
35 controls, giving an allele frequency of 0.24%. This is comparable to the frequency of the 








Table 6-4: Frequency of cysteine-sparing NOTCH3 variants previously associated with familial SVD in control datasets. These variants are no longer thought 
to be disease causing.  












Disease phenotype ExAC gnomAD Ref Remarks 
p.Arg61Trp 2 of 33 32 3 2.1 x 10-4 2 F 
1M 
Unknown  Not known – Genomics England pilot 
(n=2) 








p.His170Arg 4 of 33 23.8 35 0.0024 20 F 
15 M 
10 unknown 
Range 13.3 - 
85.0 
Mean ± SD 
49.1 ± 20.9  
Bleeding and platelet disorder (n=5) 
Hypertrophic cardiomyopathy (n=3) 
Leber’s hereditary optic neuropathy 
(n=1) 
Multiple primary malignant tumours 
(n=4) 
Neuropathic pain disorder (n=1) 
Pulmonary arterial hypertension 
(n=6) 
Primary immune disorder (n=6) 
Primary membranoproliferative 
glomerulonephritis (n=1) 
Paediatric neurology (n=4) 
Not known – Genomics England pilot 
(n=6) 
 
0.0018 0.0017 263  
p.Thr577Ala 11 of 33 13.9 2 1.4 x 10-4 2 F 40.0 
35.0 





p.Ser978Arg 18 of 33 13 7 4.3 x 10-4 3 F 
4 M 
Unknown  Multiple primary malignant tumours 
(n=3) 
Stem cell and myeloid disorders (n=1) 



























Disease phenotype ExAC gnomAD Ref Remarks 











Two out of 33 reported HTRA1 mutations were identified in nine controls, giving an overall 
diagnostic yield of 0.12%. Both variants have CADD scores above 30. These findings are 
summarised in Table 6-5. 
p.Gln151Lys, which was previously described only in autosomal dominant SVD, was identified 
in 8 unrelated individuals, although the ages of majority of these controls were not known at 
the time of writing. This variant is also relatively common in gnomAD, with a frequency of 1.6 
x 10-4. p.Gln151Lys is located in the Kazal-like domain of the HTRA1 protein, and its impact on 
the function of the HTRA1 enzyme is not known. This variant was previously reported in a 
singleton with ataxic gait, dysarthria, dysphagia and cognitive decline from the age of 59. This 
patient also had two affected relatives, and his brain MRI showed white matter 
hyperintensities, microbleeds and diffuse atrophy.  Genetic analysis in the relatives, and 
functional assays of this mutation were not performed.330  
The nonsense mutation p.Arg302Ter, identified in only 1 control recruited at age 22, has 
previously been described in both CARASIL and autosomal dominant disease. The evidence 
for the pathogenicity of the p.Arg302Ter variant is more conclusive than for p.Gln151Lys. 
p.Arg302Ter was first identified through linkage analysis in a patient from a consanguineous 
family with autosomal recessive disease (CARASIL). The proband had white matter 
hyperintensities on brain MRI, alopecia, spondylosis, stroke and dementia in the fourth 
decade of life.  This variant has been shown in vitro to result in nonsense-mediated mRNA 
decay, and functional analyses demonstrated the resulting haploinsufficiency in the form of 
reduced enzyme activity, and failure of the formation of a covalent complex with α1-
antitrypsin as compared to the wild-type protein. The variant was also shown to result in the 
increased synthesis of extracellular matrix proteins, which theoretically results in vascular 
fibrosis.61 This variant was subsequently reported in the heterozygous state in a 63-year-old 
patient with multiple lacunar infarcts, cognitive impairment and gait disturbance. This patient 
had white matter hyperintensities and multiple microbleeds on his brain MRI, however 
imaging and genetic analyses were not performed in any of his relatives.264  
Evidence for the pathogenicity of different HTRA1 variants thus varies between reports. The 




variant may in fact have incomplete penetrance, or these carriers in the general population 
may instead be pre-symptomatic undiagnosed cases. It is also possible that the variant was 
falsely associated with disease to begin with. Similarly, the presence of p.Arg302Ter in a 22-
year-old could be explained by the fact that autosomal dominant SVD is not expected to 







Table 6-5: Frequency of CARASIL and autosomal dominant SVD-causing mutations in the HTRA1 reported in literature, in unrelated BRIDGE controls 



















p.Gln151Lys 1 of 9 31.0 8 5.4 x 10-4 F Not known Bleeding and 
platelet disorder 
5.3 x 10-5 1.6 x 10-4 330  
M Not known Bleeding and 
platelet disorder 
M Not known Bleeding and 
platelet disorder 
F Not known Bleeding and 
platelet disorder 
F Not known Not known 
F 40 Intrahepatic 
cholestasis of 
pregnancy 
M 34 Partial rod-cone 
dystrophy 










p.Arg302Ter 4 of 9 45.0 1 6.8 x 10-5 F 22 Bleeding and 
platelet disorder 





Two out of 37 reported COL4A1 mutations were identified in 11 unrelated controls, giving an 
overall diagnostic yield of 0.15%. p.Gln1316Glu, which has a CADD score of 11.3, was present 
in 8 individuals with an age range of 15 to 75 (allele frequency 5.4 x 10-4). p.Arg1238Cys, which 
has a CADD score of 34, was found in a similar allele frequency (2.0 x 10-4) to that in the ExAC 
database (2.1 x 10-4), but is not found in gnomAD. (Table 6-6) 
The heterozygous p.Gln1316Glu mutation was previously described in an infant with 
hydrocephalus, seizures, hypotonia and ocular abnormalities. MR imaging of the brain 
showed pronounced hydrocephalus, gyral abnormalities,  thinning of the corpus callosum and 
pontine hypoplasia, and was diagnosed as being on the spectrum between Walker-Warburg 
Syndrome and Muscle-Eye-Brain disease (MEB/WWS).268   MEB/WES is known in some cases 
to result from autosomal recessive mutations in genes encoding glycosyltransferases, 
however many other patients do not have mutations in these genes.  A relationship between 
these syndromes and the SVD spectrum has not been suggested in literature.  
The same variant, present in a low-complexity region of the protein (i.e. not affecting the Gly-
X-Y repeat of the triple helix) was not present in 286 control chromosomes in the same 
study.268 This variant thus has not specifically been described in cerebral small vessel disease 
manifesting as white matter hyperintensities, but has been identified in a related phenotype. 
As COL4A1 mutations are associated with familial porencephaly,331 anterior segment 
dysgenesis and other ocular abnormalities,332 muscle and renal disease,165 it is possible that 
this is one example of the disease spectrum seen in COL4A1-related disease. 
The association between the p.Arg1238Cys variant and familial SVD is also tenuous. This 
variant, which is also present in a low-complexity region of the protein, was reported in a child 
with congenital cataracts, epileptic seizures and spastic diplegia, showing bilateral white 
matter hyperintensities, a periventricular cyst and a focus of susceptibility on MRI.  The child 
also had muscle cramps with raised creatine phosphokinase levels, and microhaematuria 
without proteinuria.  The variant was inherited from the father, who had muscle cramps and 
Raynaud’s phenomenon, but no ocular or brain abnormalities apart from a dermoid cyst.  The 
child also carried a de novo splice site variant (c.2458 + 1G>A) of the COL4A1 gene, which is 




on real time PCR on the patient’s skin fibroblasts.  The authors hypothesized that the proband 
was a compound heterozygote, with each variant contributing to part of the phenotype as 
suggested by the presence of muscle cramps in both parent and child. No functional analyses 
were performed to investigate each variant in isolation,267 and it is not known if these controls 








Table 6-6: Frequency of COL4A1 variants associated with familial SVD in unrelated BRIDGE controls 

















p.Gln1316Glu 44 of 
52 
11.3 8 5.4 x 10-4  F 74.9 Pulmonary arterial 
hypertension 
9.1 x 10-5 1.3 x 10-4 268  
F Not known Not known  
F Not known Not known  
M 38.0 Pulmonary arterial 
hypertension 
M 14.9 Paediatric neurology 
F 64.6 Bleeding disorder 
F 35.4 Thrombocytopenia 
F 70.3 Membranoproliferative 
Glomerulonephritis 
 
p.Arg1238Cys 42 of 
52 


















F 37.4 Pulmonary arterial 
hypertension 






Of 10 reported COL4A2 mutations, three were identified in 175 unrelated controls, giving an 
overall diagnostic yield of 2.4%. The most common of these, p.Glu1123Gly, was identified in 
152 controls (allele frequency 1.1%), of which 4 were homozygous for this variant (diagnostic 
yield 2.1%). This variant was also present in 4 individuals with familial SVD. The allele 
frequency of this variant was similar in other control databases (0.78% in ExAC, 0.95% in 
gnomAD). Similarly, p.Gln1150Lys was present in a similar frequency in this control dataset 
when compared to ExAC and gnomAD, with an allele frequency of 0.14%. (Table 6-7) 
All 3 variants were first described in four singletons in a study of 96 patients with adult-onset 
intracerebral haemorrhage, and were absent in a dataset of 144 haemorrhage-free 
controls.159 None of these individuals were reported to have a family history of haemorrhage 
or stroke, and genetic analysis was not performed on any relatives. Two of these individuals 
carried the p.Glu1123Gly variant. p.Glu1123Gly and p.Gln1150Lys affect the ‘X’ residue in the 
triple-helix Gly-X-Y repeat region of COL4A2, while p.Ala1690Thr is found in the NC1 domain 
of the protein. The NC1 domain is thought to have roles in stabilising the collagen trimer using 
methionine-lysine covalent bonds. In vitro functional assays demonstrated that  these three 
variants impair the secretion of both COL4A1 and COL4A2 from the endoplasmic reticulum 
and trigger endoplasmic reticulum stress.159  
Although p.Glu1123Gly was subsequently identified in a six-month-old infant with 
porencephaly and focal cortical dysplasia, segregation was again not demonstrated. The 
variant was present in their asymptomatic father, in whom an MRI had not been performed.  
Hence, the evidence for the pathogenicity of all three variants is limited, and it is possible that 









Table 6-7: Frequency of COL4A2 variants associated with familial SVD in unrelated BRIDGE controls. p.Glu1123Gly is also present in 2 CSVD index cases. 












Disease phenotype ExAC gnomAD Ref Remarks 









Range 1.8 – 
80.8 
Mean ± SD 
42.7 ± 20.2 
Bleeding and platelet disorders 
(n=22) 
Hypertrophic cardiomyopathy (1) 
Intrahepatic cholestasis of 
pregnancy (2) 
Multiple primary malignant 
tumours (5) 
Pulmonary arterial hypertension 
(18) 
Primary immune disorder (18) 
Primary membranoproliferative 
glomerulonephritis (3) 
Paediatric neurology (21) 
Steroid resistant nephrotic 
syndrome (1) 
Not known (61) 
 





p.Gln1150Lys 37 of 
48 
20 20 0.0014 12 M 
11 F 
Range 6.6 – 
74.4 
Mean ± SD 
32.2 ± 22 
Bleeding and platelet disorders (3) 
Primary immune disorder (4, 2 
affected) 
Paediatric neurology (9) 
Steroid resistant nephrotic 
syndrome (3) 
Not known (1) 
 
0.0019 0.0026 159  
p.Ala1690Thr 48 of 
48 





M 10.6 Steroid resistant nephrotic 
syndrome 




6.4 Conclusions  
In this study we have investigated the frequency of known SVD-causing mutations in a control 
dataset of 7348 unrelated individuals, and demonstrated varying frequencies across different 
mutations, with some reaching levels seen in polymorphisms. Interpreted in the context of 
varying levels of evidence available for the pathogenicity of each variant, it is possible that 
some of these have been erroneously associated with disease. This study has also allowed us 
to glean several insights on the interpretation of known ‘disease-causing’ variants in the clinic.  
6.4.1 Milder forms of familial SVD 
We have shown the presence of mutations in a higher-than-expected frequency overall, with 
0.26% of controls carrying CADASIL-causing mutations, where the population prevalence of 
CADASIL is estimated at 2 to 4 per 100,000 population in the UK.40,41,334 Most of these 
cysteine-altering variants are also rare (less than 1 in 10 000) in ExAC and gnomAD. These 
variants may indeed be rare mutations which exist with a low background carrier rate in the 
control population, in which there may exist a number of undiagnosed individuals with 
CADASIL. These variants may also be incompletely penetrant, where another genetic or 
environmental factor, or both, are pre-requisites for the manifestation of early-onset disease.  
Two of these variants (p.Cys1222Gly and p.Arg1231Cys) are present in a greater number of 
controls in this study, as well as in ExAC and gnomAD, suggesting that these variants may 
indeed contribute to a milder disease phenotype as has previously been suggested of variants 
in this portion of the protein.59 These individuals may eventually have a later onset of 
symptoms, or milder symptoms that would not have warranted investigation for a familial 
disease. In a disease like CADASIL where the earliest feature (migraine with aura) is common 
in the population, and its more severe neurological features such as stroke and cognitive 
impairment arise relatively late (in the fourth and fifth decades) (Chapter 3), it would be 
reasonable to expect that such variants are not subject to the same selection pressures as 
those which result in diseases affecting reproductive ability, and thus may possibly be more 
common in the population than previously predicted. It is also possible that different variants 





These findings thus call into question the thresholds of allele frequency currently used as a 
filter in the diagnosis of rare disease in the era of high throughput sequencing. Disease causing 
variants within a single gene may exist at varying frequencies in the population, and at higher 
frequencies than expected.  Using arbitrary thresholds as a filtering strategy brings with it the 
risk of eliminating potentially causative mutations, or being over-inclusive resulting in large 
numbers of variants of uncertain significance.  
6.4.2 Evaluating the strength of evidence for pathogenicity: segregation in 
reported cases  
As illustrated with the example of two HTRA1 variants, there is significant variation in the 
quality of evidence available for different reported variants in the same gene. Initial 
associations of variants with disease were established through linkage analysis, 
demonstrating segregation of the variant with disease, and in vitro functional analyses 
showing a deleterious effect of the variant on normal gene function. Subsequent reports of 
variants in the same gene, identified through large screening studies of singletons with the 
same phenotype, may have been reported and accepted as disease-causing without being 
subjected to the same rigour. Variants reported in clinical genetic testing may have been 
based on some of these variants falsely associated with the disease, resulting in an erroneous 
genetic diagnosis being returned in the clinic.  
6.4.3 In vitro functional analyses alone are insufficient to demonstrate 
pathogenicity 
Despite the utility of in vitro assays of each variant, these may potentially also be misleading. 
As seen in CADASIL, loss- or gain-of-function mutations in the NOTCH3 gene are not 
associated with disease, and knock-outs of the gene do not result in CADASIL.335 Assays of 
protein function may thus show a deleterious effect of a mutation, but would not recapitulate 
the entire disease mechanism.  In this study, we have shown that the p.Gln1123Gly variant in 
COL4A2 is present in up to 2.1% of controls. This variant was previously reported in singletons 
with no clear evidence of familial disease, and functional studies suggested that this variant 




conclusions from these assays were thus incongruent with what would be expected for a 
common variant.  
6.4.4 Moving forward 
This study is limited by the fact that controls were from disease cohorts which may be related 
to SVD, such as paediatric neurology, and many were young patients who may not be disease-
free, but are instead pre-symptomatic affected cases. An ideal control dataset would 
comprise of age-matched, MRI-phenotyped, disease-free controls. This would allow us to 
determine the true background carrier rate of mutations, and help to determine a threshold 
which can serve as an effective filter when sifting through large numbers of variants identified 
on sequencing. However, a true disease-free dataset does not exist, and phenotyping controls 
to determine whether they have SVD remains a challenge in the absence of routine MR 
imaging for large numbers of potential controls.  
The high frequency of some known variants also calls into question the validity of previous 
reports of pathogenicity. Some of these variants have only been identified in singletons 
without segregation analysis, but have been reported as pathogenic by virtue of the fact that 
the same gene has previously been associated with the disease. The strength of evidence for 
each variant reported in literature should thus be weighed prior to their addition to clinical 
reports.  
It is possible that some rare variants may alone result in mild, late-onset disease which would 
normally be classified as sporadic disease, by contributing to risk in a complex, non-Mendelian 
pattern of inheritance. While studying extremes in phenotype is an approach to boost our 
understanding of the mechanisms of disease, our study has highlighted the possibility that 
the genetic basis of SVD is more likely a continuum between, rather than a dichotomy of 
monogenic and sporadic disease.   
Beyond isolated affected cases and functional assays, a more robust method of ascribing the 
pathogenicity of variants is to identify different pedigrees with the same phenotype and 
variant. This has been demonstrated in recent sequencing studies such as the Diagnosing 
Developmental Disorders project, which identified causative de novo variants for 




repositories of genotypic and phenotypic information such as Matchmaker Exchange 







Table 6-8: Cysteine-altering NOTCH3 variants reported as disease-causing, or identified in patients 
with CADASIL presenting to the UK National Referral Clinic for CADASIL. 
Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.127C>T p.Cys43Gly 2  257,258 
c.128G>T p.Cys43Phe 2  336 
c.128G>C p.Cys42Ser 2  337 
c.145T>C p.Cys49Arg 2  259 
c.145T>G p.Cys49Gly 2  338 
c.146G>A p.Cys49Tyr 2  339 
c.146G>T p.Cys49Phe 2  257–259 
c.157G>T p.Gly53Cys 2  150 
c.160C>T p.Arg54Cys 2  259,340,341 
Internal database 
c.179C>G p.Ser60Cys 2  257,258 
c.193T>G p.Cys65Gly 2  342 
c.194G>A p.Cys65Tyr 2  343 
c.194G>C p.Cys65Ser 2  257,258 
c.199T>A p.Cys67Ser 3  344 
c.200G>A p.Cys67Tyr 3  345 
c.213G>T p.Trp71Cys 3  57 
c.226T>C p.Cys76Arg 3  245 
Internal database 
c.227G>A p.Cys76Tyr 3  59 
c.228T>G p.Cys76Trp 3  257,258 
c.226_234del p.Cys76_Leu78del 3  346 
c.231_248del p.Gln77_Cys82del 3  258 
c.239_253del p.Asp80_Ser84del 3  347 
c.259T>C p.Cys87Arg 3  257,258 
c.260G>A p.Cys87Tyr 3  258 
c.265G>T p.Gly89Cys 3  348,349 
c.268C>T p.Arg90Cys 3  57,259 
Internal database 
c.277_279dup p.Cys93dup 3  350 
c.278G>A p.Cys93Tyr 3  351 
c.278G>T p.Cys93Phe 3  44 
c.316T>C p.Cys106Arg 3  352 
c.318C>G p.Cys106Trp 3  258 
c.322T>C p.Cys108Arg 3  150 
c.323G>A p.Cys108Tyr 3  257,258 
c.323G>C p.Cys108Ser 3  353 






Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.328C>T p.Arg110Cys 3  124,244 
Internal database 
c.341-2A>G p.Gly114_Pro120del Intron 
3 
 355 
c.349T>C p.Cys117Phe 4  150,356 
c.350G>A p.Cys117Tyr 4  263 
c.350G>C p.Cys117Ser 4  357 
c.350G>T p.Cys117Arg 4  44 
c.353C>G p.Ser118Cys 4  259,358 
c.368G>A p.Cys123Tyr 4  340 
c.368G>T p.Cys123Phe 4  44 
c.382T>G p.Cys128Gly 4  359 
c.383G>A p.Cys128Tyr 4  351 
c.383G>T p.Cys128Phe 4  LOVD 
Internal database 
c.391G>T p.Gly131Cys 4  326 
c.397C>T p.Arg133Cys 4 Yes 57,360,361 
Internal database 
c.401G>A p.Cys134Tyr 4  Internal database 
c.402C>G p.Cys134Trp 4  39 
c.421C>T p.Arg141Cys 4  39 
Internal database 
c.425T>G p.Phe142Cys 4  244,259,351 
c.431G>A p.Cys144Tyr 4  44 
Internal database 
c.431G>C p.Cys144Ser 4  44 
c.431G>T p.Cys144Phe 4  362 
c.434C>G p.Ser145Cys 4  258 
c.436T>C p.Cys146Arg 4  57 
c.437G>A p.Cys146Tyr 4  363 
c.437G>T p.Cys146Phe 4  57 
c.445G>T p.Gly149Cys 4  258,364 
c.449A>G p.Tyr150Cys 4  44 
c.457C>T p.Arg153Cys 4  57,244,259,365 
Internal database 
c.459_467del p.Arg153_Cys155del 4  347 
c.460A>T p.Ser154Cys 4  Internal database 
c.463T>A p.Cys155Ser 4  263 
c.464G>A p.Cys155Tyr 4  LOVD 
c.464G>C p.Cys155Ser 4  258 
c.484T>A p.Cys162Ser 4  340 
c.484T>C p.Cys162Arg 4  366 
c.485G>A p.Cys162Tyr 4  356 
c.486C>G p.Cys162Trp 4  336 






Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.505C>T p.Arg169Cys 4  57,259 
Internal database 
c.511G>T p.Gly171Cys 4  57 
c.520T>A p.Cys174Ser 4  344 
c.520T>C p.Cys174Arg 4  367 
c.521_522delinsTG p.Cys174Leu 4  368 
c.521G>A p.Cys174Tyr 4  44 
c.521G>T p.Cys174Phe 4  369 
c.539C>G p.Ser180Cys 4  340 
c.542T>G p.Phe181Cys 4  370 
c.544C>T p.Arg182Cys 4  57,244 
Internal database 
c.547T>A p.Cys183Ser 4 Yes 44,371 
c.547T>C p.Cys183Arg 4  44,372 
Internal database 
c.548G>T p.Cys183Phe 4  257,258 
c.553T>A p.Cys185Ser 4  43 
Internal database 
c.553T>C p.Cys185Arg 4  57 
c.553T>G p.Cys185Gly 4  339 
c.566A>G p.Tyr189Cys 4  244,336 
c.580T>A p.Cys194Ser 4  245 
Internal database 
c.580T>C p.Cys194Arg 4  351 
Internal database 
c.581G>A p.Cys194Tyr 4  340 
c.581G>C p.Cys194Ser 4  43 
Internal database 
c.581G>T p.Cys194Phe 4  44 
c.601T>C p.Cys201Arg 4  373 
c.602G>A p.Cys201Tyr 4  258 
c.616T>C p.Cys206Arg 4  374 
c.617G>A p.Cys206Tyr 4  340 
c.619C>T p.Arg207Cys 4  336 
c.634T>A p.Cys212Ser 4  244,356,375 
c.634T>C p.Cys212Arg 4  Internal database 
c.635G>A p.Cys212Tyr 4  356,376 
c.636C>G p.Cys212Trp 4  357 
c.659A>G p.Tyr220Cys 4  354 
c.664T>G p.Cys222Gly 4  57 
c.665G>A p.Cys222Tyr 4  351 
c.665G>C p.Cys222Ser 4  150,259 








Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.671G>A p.Cys224Tyr 4  57 
 
p.Cys194Gly 4  244 
 
p.Ser126Cys 4  Internal database 
c.697T>A p.Cys233Ser 5  339 
c.697T>C p.Cys233Arg 5  43 
Internal database 
c.698G>A p.Cys233Tyr 5  258,364 
c.699T>G p.Cys233Trp 5  260 
c.714_758del p.Asp239_Asp253del 5  377 
c.719G>C p.Cys240Ser 5  258 
c.733T>A p.Cys245Ser 5  40 
Internal database 
c.733T>C p.Cys245Arg 5  258,364 
c.751T>A p.Cys251Ser 5  260 
c.751T>C p.Cys251Arg 5  245 
Internal database 
c.751T>G p.Cys251Gly 5  378 
c.752G>A p.Cys251Tyr 5  344 
c.773A>G p.Tyr258Cys 5  57,244 
c.778T>G p.Cys260Gly 5  379 
c.779G>A p.Cys260Tyr 5  257,258 
c.1004C>G p.Ser335Cys 6  257,258 
c.1010A>G p.Tyr337Cys 6  260 
c.1012T>C p.Cys338Arg 6  380 
c.812G>T p.Cys271Phe 6  381 
c.886G>T p.Gly296Cys 6  382 
c.895A>T p.Ser299Cys 6  383 
c.955_956delGCinsTG p.Ala319Cys 6  258 
c.967C>A p.Cys323Ser 6  Internal database 
c.994C>T p.Arg332Cys 6  259,384–386 
Internal database 
c.1013G>T p.Cys338Phe 6  244 
c.1057_1071dup p.Asp353_Ser357dup 7  387 
c.1064G>C p.Cys355Ser 7  Internal database 
c.1078T>C p.Cys360Arg 7  388 
c.1096T>C p.Cys366Arg 7  HGMD 
c.1098T>G p.Cys366Trp 7  389 
c.1135T>C p.Cys379Arg 7  390 
c.1136G>C p.Cys379Ser 7  257,258 
c.1136G>T p.Cys379Phe 7  Internal database 
c.1144G>T p.Gly382Cys 7  260 
c.1163G>A p.Cys388Tyr 7  261 
c.1183T>C p.Cys395Arg 7  257,258 




Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.1222T>G p.Cys408Gly 8  Internal database 
c.1223G>A p.Cys408Tyr 8  259 
c.1241C>G p.Ser414Cys 8  262 
c.1257C>G p.Cys419Trp 8  259 
c.1258G>T p.Gly420Cys 8  339 
c.1261C>T p.Arg421Cys 8  257,258 
c.1279C>T p.Arg427Cys 8  259 
Internal database 
c.1282T>C p.Cys428Arg 8  380 
Internal database 
c.1283G>A p.Cys428Tyr 8  257,258 
c.1283G>C p.Cys428Ser 8  339 
c.1300_1308dup p.Glu434_Leu436dup 8  344 
c.1303T>C p.Cys435Arg 8  260 
c.1318T>A p.Cys440Ser 8  391 
c.1318T>C p.Cys440Arg 8  257,258 
c.1318T>G p.Cys440Gly 8  245 
Internal database 
c.1337G>C p.Cys446Ser 8  258 
c.1337G>T p.Cys446Phe 8  257 
c.1345C>T p.Arg449Cys 8  257,258 
c.1363T>C p.Cys455Arg 8  392 
c.1364G>A p.Cys455Tyr 8  262 
c.1364G>T p.Cys455Phe 8  ClinVar 
c.1370G>C p.Cys457Ser 8  43 
Internal database 
c.1394A>G p.Tyr465Cys 9  260,372 
c.1397G>A p.Cys466Tyr 9  244,393 
Internal database 
c.1426A>T p.Ser476Cys 9  Internal database 
c.1433G>A p.Cys478Tyr 9  394 
c.1450T>G p.Cys484Gly 9  244 
c.1451G>A p.Cys484Tyr 9  258 
c.1451G>T p.Cys484Phe 9  257 
c.1484G>A p.Cys495Tyr 9  257,258 
c.1510T>C p.Cys504Arg 10  395 
c.1531T>C p.Cys511Arg 10  257,258 
c.1532G>A p.Cys511Tyr 10  396 
c.1532G>T p.Cys511Phe 10  397 
c.1582G>T p.Gly528Cys 10 Yes 380,398 
c.1592G>C p.Cys531Ser 10  399 
c.1594C>T p.Arg532Cys 10  400 
c.1624T>C p.Cys542Arg 10  262 
c.1625G>A p.Cys542Tyr 11  57 




Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.1645T>C p.Cys549Arg 11  375 
c.1646G>A p.Cys549Tyr 11  257,258 
c.1672C>T p.Arg558Cys 11  57 
c.1703G>A p.Cys568Tyr 11  328 
c.1721A>G p.Tyr574Cys 11  399 
c.1732C>T p.Arg578Cys 11 Yes 57,403 
c.1735T>C p.Cys579Arg 11  404 
c.1759C>T p.Arg587Cys 11  259,262 
c.1771T>C p.Cys591Arg 11  LOVD 
c.1774C>T p.Arg592Cys 11  405 
Internal database 
c.1789C>T p.Cys597Arg 11  Internal database 
c.1790G>C p.Cys597Ser 11  406 
c.1791C>G p.Cys597Trp 11  372 
c.1816T>C p.Cys606Arg 11  353 
c.1819C>T p.Arg607Cys 11  340 
Internal 
c.1918C>T p.Arg640Cys 12  LOVD 
Internal database 
c.1999G>T p.Gly667Cys 13  LOVD 
c.2038C>T p.Arg680Cys 13  407 
c.2129A>G p.Tyr710Cys 13  408 
c.2149C>T p.Arg717Cys 14  259 
c.2182C>T p.Arg728Cys 14  57 
c.2324G>C p.Cys775Ser 15  257 
c.2411-1G>T p.Gly804_Asn856delinsAsp Intron 
15 
 409 
c.2815T>C p.Cys939Arg 18  353 
c.2857G>T p.Gly953Cys 18  245 
Internal database 
c.2898C>A p.Cys966Ter 18 Yes  410 
c.2923G>T p.Gly975Cys 18  369 
c.2929T>A p.Cys977Ser 18  259,395 
c.2951T>G p.Phe984Cys 18  244,340 
c.2953C>T p.Arg985Cys 18  57 
Internal database 
c.2963G>A p.Cys988Tyr 18  262 
c.2989T>G p.Cys997Gly 18  326,372 
c.3011G>A p.Cys1004Tyr 19  54 
c.3016C>T p.Arg1006Cys 19  57,411 
c.3037G>T p.Gly1013Cys 19  353 
c.3043T>C p.Cys1015Arg 19  53 
c.3062A>G p.Tyr1021Cys 19  351 
c.3065G>T p.Cys1022Phe 19  412 




Coding variant Protein variant Exon Reported in recessive 
cases 
References 
c.3091C>T p.Arg1031Cys 19  57 
c.3172G>T p.Gly1058Cys 20  351 
c.3182G>A p.Cys1061Tyr 20  LOVD 
c.3206A>G p.Tyr1069Cys 20  344 
c.3226C>T p.Arg1076Cys 20  53,259 
c.3296G>A p.Cys1099Tyr 20  328 
c.3317A>G p.Tyr1106Cys 20  372 
c.3356G>A p.Cys1119Thr 20  Internal database 
c.3356G>A p.Cys1119Tyr 20  Internal database 
c.3393C>G p.Cys1131Trp 21  414 
c.3427C>T p.Arg1143Cys 21  HGMD 
c.3471C>G p.Cys1157Trp 21  LOVD 
c.3664 T>G p.Cys1222Gly 22  256 
c.3691C>T p.Arg1231Cys 22 Yes 57,58,176,245,325,326 
Internal database 
c.3750C>G p.Cys1250Trp 23  390 
c.3748T>G p.Cys1250Gly 23  Internal database 
c.3781T>C p.Cys1261Arg 23  39 
c.3782G>A p.Cys1261Tyr 23  257,258 
c.3893G>T p.Cys1298Phe 24  415 
c.3944G>A p.Cys1315Tyr 24  416 
LOVD: Leiden Open Variation Database (www.lovd.nl).  





Table 6-9: Cysteine-sparing NOTCH3 variants previously associated with CADASIL. These variants do 
not lead to a gain or loss of a cysteine residue in the epidermal growth factor-like repeat region 
encoded by exons 2 to 24 of the gene, and are no longer considered pathogenic.  
Coding variant Protein variant  Exon Reference 
c.259C>T p.Arg61Trp 2 327 
c.224G>C p.Arg75Pro 3 417 
 p.Asp80Gly 3 315,319,320 
c.451C>G p.Gln151Glu 4 263 
c.509A>G P.His170Arg 4 263 
c.605C>T P.Ala202Val 4 418 
c.638G>A p.Arg213Lys 4 369 
c.709G>A p.Val237Met 5 419 
 p.Val252Met 5 420 
 p.Val322Met 6 420 
c.1729A>G p.Thr577Ala 11 328 
c.2932A>C p.Ser978Arg 18 328 
c.3058G>C p.Ala1020Pro 19 316 
c.3292A>T p.Tyr1098Ser 20 346 
 p.Gly1298Thr 24 421 





Table 6-10: HTRA1 variants reported in CARASIL or autosomal dominant SVD. 
Coding variant Protein variant CARASIL Autosomal dominant 
SVD 
References 
c.126delG p.Gly42fs Yes No 422 
c.161_162insAG p.Gly56Alafs*160 Yes No 423 
c.361A.C p.Ser121Arg No Yes 67 
c.367G>T p.Ala123Ser No Yes 67 
c.397C>G p.Arg133Gly No Yes 67 
 p.Gln151Lys No Yes 265 
 p.Ser163Gly No Yes 265 
c.496C>T p.Arg166Cys Yes No 66 
c.497G>T p.Arg166Leu No Yes 67 
c.517G>C p.Ala173Pro No Yes 67 
c.517G>A p.Ala173Thr Yes No 424 
 p.Val175Met No Yes 265 
 p.Gly206Glu No Yes 265 
c.616G>A p.Gly206Arg Yes No 425 
c.754G>A p.Ala252Thr Yes No 61 
c.821G>A p.Arg274Gln No Yes 426 
 
p.Gly283Glu No Yes 174 
c.850A>G p.Ser284Gly No Yes 67 
c.852C>A p.Ser284Arg No Yes 67 
c.854C>A p.Pro285Gln No Yes 67 
c.854C>T p.Pro285Leu No Yes 293 
c.856T>G p.Phe286Val No Yes 67 
c.883G>A p.Gly295Arg Yes No 65 
c.889G>A p.Val297Met Yes No 61 
 p.Arg302Gln No Yes 174 
c.904C>T p.Arg302Ter Yes Yes 61,264 
 p.Thr319Ile No Yes 174 
c.961G>A p.Ala321Thr Yes No 422 
c.973-1G>A p.Tyr325_Leu335del No Yes 67 
c.1091T>C p.Leu364Pro Yes No 427 
c.1108C>T p.Arg370Ter Yes No 
(see chapter 5) 
61 






Table 6-11: COL4A1 variants reported in familial disease, including paediatric porencephalyor 
schizencephaly, anterior segment dysgenesis, ophthalmological and renal abnormalities. All variants 
reported were in a heterozygous state.  
Coding variant Protein variant References 
c.*31G>T 3’UTR 208 
c.*32G>T 3’UTR 208 
c.*32G>A 3’UTR 209 
c.*32G>T 3’UTR 208 
c.*35C>A 3’UTR 208 
c.1A>T p.Met1Leu 162 
c.502G>A p.Gly168Arg 428 
 p.Gly188Glu 429 
c.1055C>T p.Pro352Leu 156 
c.1249G>C p.Gly417Arg 430 
c.1493G>A p.Gly498Asp 165 
c.1493G>T p.Gly498Val 431,432 
c.1528G>A p.Gly510Arg 165,433 
c.1537G>A p.Gly513Ser 434 
c.1555G>A p.Gly519Arg 85,435 
  
c.1573_1574GG>TT p.Gly525Leu 165 
c.1583G>A p.Gly528Glu 85,435 
 
c.1612C>G p.Arg538Gly 156 
c.1685G>A p.Gly562Glu 83,84 
c.1835G>A p.Gly612Asp 436 
c.1870G>T p.Gly624Ter 269 
c.1963G>A p.Gly655Arg 436 
c.1964G>A p.Gly655Glu 269 
c.1973G>A p.Gly658Asp 437 
c.2008G>A p.Gly670Arg 269 
c.2063G>A p.Gly688Asp 438 
c.2078G>A p.Gly693Glu 437 
c.2085del p.Gly696fs 294 
c.2086G>A p.Gly696Ser 439 
c.2122G>A p.Gly708Arg 440 
c.2123G>T p.Gly708Val 441 
c.2159G>A p.Gly720Asp 442–444 
c.2245G>A p.Gly749Ser 331 
c.2317G>A p.Gly773Arg 440,445,446 
c.2263G>A p.Gly755Arg 443,445,447,448 
c.2345G>C p.Gly782Ala 449 
 p.Gly785Glu 450 
c.2413G>A p.Gly805Arg 451 




Coding variant Protein variant References 
c.2424delT p.Pro810fs 269 
c.2581G>C p.Gly861Ser 269 
c.2608G>A p.Gly870Arg 436 
c.2636G>A p.Gly879Glu 269 
c.2645G>A p.Gly882Asp 445 
c.2662G>A p.Gly888Arg 269,430 
c.2689G>A p.Gly897Ser 436 
c.2903G>A p.Arg968Gln Internal database 
c.2931dupT p.Gly978TrpfsTer15 436 
c.2969G>A p.Gly990Glu 437 
c.2969G>T p.Gly990Val 453 
c.3005G>A p.Gly1002Asp 446 
c.3022G>A p.Gly1008Arg 452 
c.3046A>G p.Met1016Val 268 
c.3104G>T p.Gly1035Val 454 
c.3122G>A p.Gly1041Glu 436 
c.3130G>C p.Gly1044Arg 452 
c.3200G>C p.Gly1067Ala 269 
c.3245G>A p.Gly1082Glu 436 
c.3280G>A p.Gly1094Arg 269 
 p.Gly1103Arg 455 
c.3389G>A p.Gly1130Asp 162 
c.3706G>A p.Gly1236Arg 331,456 
c.3712C>A p.Arg1238Cys 267 
c.3715G>A p.Gly1239Arg 457 
c.3770G>A p.Gly1257Glu 269 
c.3796G>C p.Gly1266Arg 445 
c.3941G>T p.Gly1314Val 437 
c.3946C>G p.Gln1316Glu 268 
c.3976G>A p.Gly1326Arg 436 
c.3995G>A p.Gly1332Asp 436 
c.4031G>C p.Gly1344Ala 458 
c.4133G>A p.Gly1378Asp 437 
c.4150G>A p.Gly1384Ser 437 




c.4611_4612insG p.Thr1537fs 255 
c.4738G>C p.Gly1580Arg 296 
c.4738G>A p.Gly1580Ser 460 
c.4739G>C p.Gly1580Ala 269 
c.4814_4816insGGG p.ins1605Gly 461 
c.4843G>A p.Glu1615Lys 436 




Coding variant Protein variant References 
c.4887C>A p.Tyr1629Ter 436 
 
 
Table 6-12: COL4A2 variants reported in familial disease, including paediatric porencephaly or 
schizencephaly, anterior segment dysgenesis, ophthalmological and renal abnormalities. All variants 
reported were in a heterozygous state.  
Coding variant Protein variant Reference 
c.2105G>A p.Gly702Asp 164 
c.2399G>A p.Gly800Glu 463 
c.2821G>A p.Gly941Arg 464 
c.3110G>A p.Gly1037Glu 465 
c.3206delC p.Arg1069fs 86 
c.3368A>G p.Glu1123Gly 159,333 
c.3448C>A p.Gln1150Lys 159 
c.3455G>A p.Gly1152Asp 465 
c.4165G>A p.Gly1389Arg 86 
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7. Conclusions and future directions 
Recent advances in elucidating disease pathways in monogenic forms of SVD have 
transformed our understanding of the mechanisms of SVD in general (Chapter 1). In line with 
these findings, this thesis aimed to explore the genetic aetiology of cerebral SVD primarily 
from a monogenic disease perspective. Approaching SVD from both ends of the disease 
spectrum, we endeavoured to dissect the role of monogenic disease genes in both presumed 
familial and sporadic forms of SVD, and to explore the role of genes associated with sporadic 
SVD in suspected familial cases.  
We began by illustrating the variability of phenotypes and ages at onset of familial SVD 
(Chapter 1), particularly with CADASIL as an example (Chapter 3). We next investigated the 
prevalence of known and novel variants in the coding regions of candidate genes associated 
with monogenic disease in a cohort of patients with presumed sporadic SVD using a high 
throughput sequencing (HTS) gene panel (Chapter 4). In addition, a similar candidate gene 
approach was taken in a cohort of presumed familial SVD patients using whole genome 
sequencing data (Chapter 5). Finally, we examined the presence of previously reported 
disease-causing variants in a cohort of whole-genome sequenced controls (Chapter 6).  
Through this body of work, we have examined the phenotypes seen in familial SVD, and have 
explored not only the wealth of information provided by performing high throughput 
sequencing on families, but also the limitations faced when interpreting this data. This 






7.1 Key findings  
7.1.1 CADASIL: Migraine, encephalopathy and stroke (Chapter 3) 
CADASIL is the most well-described form of monogenic SVD. In a cohort of 300 symptomatic 
CADASIL patients we illustrated the variability in the ages at onset, and the broad range of 
presentations of the disease. We speculated a possible relationship between migraine with 
aura and a lower incidence of stroke, as well as between migraine with confusional aura and 
encephalopathy in CADASIL. The medical management of CADASIL symptoms has not been 
extensively investigated, hence we have also retrospectively reviewed patients’ responses to 
different medications used in the prevention of and relief of migraines in CADASIL. As a 
relatively well-understood prototype of monogenic SVD, we have used CADASIL to illustrate 
the heterogeneity of presentations of disease both within and between families, despite the 
simplicity of its pattern of inheritance.  
7.1.2 A candidate gene study in presumed sporadic SVD (Chapter 4) 
Using the ThromboGenomics sub-exome panel sequencing platform, we performed high 
throughput sequencing (HTS) of the coding regions of 15 candidate genes associated with 
familial SVD or its related phenotypes in 993 individuals with presumed early-onset (≤70 years) 
sporadic SVD. With this panel we achieved high coverage of the coding regions of each 
candidate gene. 
We show that a large number of rare variants can be identified using such a HTS technique, 
and also demonstrate that 1.1% of this cohort were found to have CADASIL-causing mutations, 
of which mutations in two individuals had not been identified on a previous screen using 
denaturing high-performance liquid chromatography (DHPLC) and Sanger sequencing. This 
suggests that a multi-gene HTS panel may be more sensitive and efficient in screening 
multiple genes simultaneously in patients with suspected familial SVD. 
We found that known disease-causing and novel variants in NOTCH3, HTRA1, FOXC1, TREX1, 
COL4A1 and COL4A2 may account for a few of these presumed-sporadic SVD cases, 
suggesting that this panel may also be useful for screening patients where there is a low index 
of suspicion for a single-gene disease.  However, clinical interpretation of the role of both 




The presence of known disease-causing variants in this cohort suggests that there may be a 
continuum between the between the phenotypes seen in presumed familial or sporadic 
disease, rather than a clear distinction. In this small sample of patients and relatively narrow 
selection of candidate genes we also found that each individual may have multiple variants 
identified in different genes, depending on the stringency of the filters used. This highlights 
the complexities of interpreting data produced using such techniques.   
7.1.3 Rare variants in suspected familial SVD: a candidate gene approach using 
whole genome sequencing (Chapter 5)  
We performed whole genome sequencing in 118 index cases with suspected familial SVD who 
did not have CADASIL-causing mutations identified on clinical genetic testing. As seen in 
Chapter 4 we similarly identified cases with CADASIL-causing mutations that had not 
previously been identified on Sanger sequencing or DHPLC.  
Using a candidate gene approach, we show that HTRA1 is the next most common gene 
affected in familial SVD, with rates in the UK being similar to those seen in Italy, France and 
Japan. We propose that some of the variants previously only seen in recessive disease 
(CARASIL) may in fact also be pathogenic in heterozygous individuals. We also report a third 
family with the only known mutation in the CTSA gene causing CARASAL.299 We also suggest 
a potential role for the CACNA1A gene, which has been implicated in multiple neurological 
diseases, in SVD. In several pedigrees we also found that genes associated with sporadic SVD 
may also act in a Mendelian fashion to cause familial disease.  
Finally, we demonstrate that the majority of patients have a large number of potentially 
causative variants identified through the filters we have used, which further illustrates how 
high throughput sequencing on the background of our current understanding of disease and 
genetics is a double-edged sword: while we can rapidly screen multiple genes simultaneously, 
we are also left with a deluge of data to interpret in a clinical context. This highlights the 
importance of developing additional strategies beyond predictive tools, in vitro functional 
analyses and minor allele frequency to establish the true causative mutation in each case. 
7.1.4 The frequency of known mutations in the general population (Chapter 6) 
As a critical evaluation of existing methods in literature, which we have employed when sifting 




frequency of known mutations in the general population – both in patients recruited in non-
SVD rare diseases, and in established exome and whole genome sequencing databases.  
We show that some variants exist in high frequencies in the population and may in fact be 
polymorphisms that have been erroneously reported as disease-causing due to the relatively 
small sample size of the control populations used in earlier studies. This highlights the 
importance of using large age- and ethnicity matched, well-phenotyped datasets in 
establishing the true background frequency of a variant, and hence its likelihood of 
pathogenicity.  
At the same time, however, our findings also cast doubt on the utility of an arbitrarily 
determined minor allele frequency cut-off as a filter for pathogenic variants. As the ‘general 
population’ or non-SVD patients are by no means disease-free controls, there may be milder 
forms of SVD that are undiagnosed in the population, thus resulting in the premature 
exclusion of potentially causative mutations. Truly pathogenic variants may in fact cause a 
spectrum of severity and symptoms as we have seen in CADASIL (Chapters 1 and 3).  
7.2  Moving forward: suggestions for future work 
7.2.1 Familial disease: linkage analysis using whole genome sequencing data 
Although linkage analysis was the main statistical genetic approach used in mapping 
Mendelian diseases, they were not always successful and were often limited by the size of 
families, with larger, cross-generational families and distantly related affected individuals 
being more likely to provide statistical power. On the other hand, genome-wide studies 
provided statistical power for studying complex traits on a population basis, but were found 
to have limited utility for Mendelian diseases. HTS approaches now offer cost- and time-
effective identification of rare variants in both complex and monogenic disease, however 
these techniques when applied in the rare disease context usually lack statistical power, and 
filtering approaches within families are likely to lead to multiple hits segregating with disease. 
A fundamental lesson learnt through our work is that rather than having hundreds of index 
cases which would never reach statistical power for proving causality in multiple rare variants 
through conventional Bonferroni-corrected testing, it may be more useful to have multiple 
affected and unaffected individuals across generations in a single family. In a pedigree of 4 




disease failed to pass our filters and was relegated to having a status as a ‘variant of uncertain 
significance’, whereas the variant was found to segregate in the same family when it was 
studied with 10 affected and 10 unaffected individuals. A genetic diagnosis was thus achieved 
through the combination of exome sequencing and linkage analysis.  
Methods in monogenic disease genetics have now, in some respects, come full circle. The 
combination of HTS and linkage analysis brings together the advantages from both 
approaches, and has led to the successful identification of disease-causing variants within 
families with suspected Mendelian inheritance of disease. Some other examples have been 
seen in a large pedigrees with SVD.208,209 Such a pedigree-based approach in the context of 
new sequencing technologies may well help us achieve genetic diagnoses in the remainder of 
unsolved cases. Ongoing work extending from that reported in this thesis involves the 
recruitment of additional relatives from each pedigree recruited, and the MR phenotyping of 
both symptomatic and asymptomatic relatives. This will provide us with the data required to 
perform robust linkage analyses.  
7.2.2 Familial disease: comparison of genotyped and phenotyped cases 
Recruiting multiple affected individuals across generations and branches of large pedigrees 
can be a challenge in genetic diseases, particularly in one with a late age at onset and with 
varying severity even within families. An alternative to validating the genotype for cases is to 
find similar pedigrees with the same phenotype and genotype. With deep phenotyping there 
may be a role for the use of online clinical genomics databases such as the DECIPHER project 
(https://decipher.sanger.ac.uk), where more than 18,000 cases have been uploaded with 
phenotypic and genotypic information, and with an option to contact referring clinicians for 
more information about reported cases.252  
Similarly, Matchmaker Exchange (http://www.matchmakerexchange.org/) is a web-based 
platform which serves as a bridge between clinicians who have cases with similar phenotypic 
or genotypic profiles. This may help to interpret variants of uncertain significance uncovered 





7.2.3 Familial disease: other candidate gene approaches 
In recent years the matrisome has taken centrestage in our growing understanding of the 
mechanisms of monogenic SVD.118 There are more than three hundred different proteins in 
the matrisome,467 and aberrations of each may well be associated with disease. This has been 
discussed in depth in Chapter 1. As part of an initial screen for mutations it would be worth 
considering genes encoding for key matrisome proteins. Variants arising in the same gene 
across multiple patients with similar phenotypes may point towards a novel disease gene, and 
by extension a novel disease pathway. Planned extensions of our whole genome sequencing 
work involves the screening of genes encoding matrisome proteins involved in the cerebral 
microvasculature.118,468  
As many of the variants identified in existing candidate genes were of uncertain significance, 
it may also be worth exploring the option of looking for enrichment of variants in a cohort of 
affected individuals as compared to controls. Again, this would require a large, well-
phenotyped and ethnicity-matched control cohort in order to provide any robust evidence.  
7.2.4 Familial disease: non-coding variation 
In this thesis we have focused mainly on the coding spaces, which at 2 to 3% of the genome 
is sufficiently large to raise more variants of uncertain significance than we can manage with 
our present knowledge. However, we have seen from COL4A1 that variants in the 3’ 
untranslated region can have an impact on the binding site of microRNAs, and that these 
variants are associated with familial SVD.208,295 Studies in other diseases have also illustrated 
that non-coding variants may introduce a new splice site, and thus affect the resulting 
protein.284 
 Candidate gene approaches may serve us well in the short term to exclude mutations in 
known genes, however with larger pedigrees and better curated control databases it will 
become necessary and fruitful to explore the non-coding genome. Functional analyses can 
also be performed, such as using RNA sequencing to establish the impact of a non-coding 




7.2.5 Sporadic disease: rare variant, common disease hypothesis 
GWAS studies capture the contribution of common variants to complex diseases such as 
SVD.29,469 However, there remains a proportion of missing heritability which may likely be 
explained by rare variants. These are only detectable by HTS techniques, and achieving a 
statistically significant result is challenging in the absence of a massive, robust set of controls. 
The definition of a ‘rare’ variant is also arbitrary and widely differs between studies.470  
One possible extension of GWAS studies is to deep-sequence the gene loci identified, as the 
lead single nucleotide polymorphism (SNP) may be tagging the causative rare variant in the 
same region. The downside of this is that variants may exert their effects in cis or trans, and 
a linear capture-sequencing approach that does not take into account the three-dimensional 
folding of chromosomes may potentially be an expensive gamble. A possible compromise 
would be to also consider expression quantitative trait loci (eQTL) and the folding of 
chromosomes in order to select regions to sequence. 
One other option is to perform burden association tests with a robust control data set. This 
essentially asks the question of whether there is a difference between the load of variants in 
cases as opposed to controls. Planned future work currently involves combining our data set 
of 993 individuals with that from other populations in Europe, which may lead to greater 
statistical power.  A fundamental component of such an analysis is a well-phenotyped, 
ethnicity-matched set of controls.  
7.3 Discussion  
7.3.1 SVD as a spectrum – fluid definitions of ‘monogenic’ or ‘sporadic’ disease 
Determining the true pathogenicity and penetrance of a variant requires a sound definition 
of the disease phenotype, which may be complicated in cases where patients do not have 
syndromic features of Mendelian disease. While earlier descriptions of familial disease are 
likely to have captured the most severe forms of the disease, it is probable that there exist 
milder forms in the population that have gone undiagnosed – as we have seen in Chapter 4.  
For example, classifying a 55-year-old patient with a history of hypertension, lacunar stroke 




suspected familial or sporadic case can be challenging. Is there a single gene mutation with 
low penetrance causing a milder form of disease that has presented relatively late in life? Or 
could multiple low impact variants in the context of a shared environment and/or existing 
cardiovascular risk factors be sufficient to explain the symptoms?  
In the same vein, assigning disease status to an individual in the context of a pedigree for 
segregation analysis is challenging. Phenotyping is often based on clinical judgment and can 
be subject to variation between clinicians. Is a relative with mild features of SVD on MRI and 
coexisting cardiovascular risk factors who becomes symptomatic at a later age affected or 
unaffected?  
Our definitions of disease and phenotyping of types of SVD are certainly called into question, 
and the decision remains a clinical one that will inevitably result in inter-rater variability. It 
may be the case that the phenotype assigned to each patient needs to be fluid between 
different studies involving the same patients, or that only the very extremes in phenotype 
such as those with syndromic features are studied.  
7.3.2 Variant interpretation in the age of sequencing 
In the context of HTS technology we are now burdened with more questions than answers. 
An important question to grapple with is whether SVD is in fact a spectrum, with familial 
disease at one end and hypertensive sporadic disease at the other. We have attempted to 
suggest a possible role for both ’Mendelian’ and ‘sporadic’ disease genes in the development 
of disease anywhere along this spectrum, where variants in either of these categories may 
have varying degrees of penetrance.  
As the cost of sequencing continues to fall and turnaround times shorten, it is important that 
we address the key challenge of interpreting the data generated. Predictive tools such as the 
Variant Effect Predictor or the CADD score can help to estimate likely impact of variants.  For 
example, loss-of-function variants introducing a premature termination codon are predicted 
to be of ‘high’ impact, while missense variants are thought to result in ‘moderate’ impact. 
Hence, such tools can help us give greater weight to nonsense and frameshift mutations 
which result in a significant change in protein function, as opposed to a synonymous variant. 
Yet, a key lesson learnt from studies in the pathogenesis of CADASIL is that disease is likely to 




variants resulting in a loss- or gain-of-function of the protein are not associated with 
disease.125 Furthermore, nonsense variants may not always result in a loss of function: in 
some proteins these may still permit the production of functional protein.471 Isolating a single 
causative genetic mutation where a particular inheritance pattern has been hypothesized is 
thus difficult when multiple variants have been identified, especially since a loss- or gain-of-
function variant may not necessarily result in disease.  
A sound understanding of the disease mechanism is thus inherent in our prediction of the 
impact of variants subsequently identified in a known disease-associated gene. It is of critical 
importance that subsequent variants reported in a known disease gene are subject to the 
same standards as those initially identified. In order to recognise a variant as disease-causing, 
it would be preferable to demonstrate segregation of the variant with disease in a large 
pedigree, alongside multiple functional in-vitro analyses and animal models to serve as 
convincing evidence of pathogenicity.  
It is also important to recognise that rare variants may not necessarily have high impact and 
common variants may not always have low impact. The context of an individual’s genetic and 
environmental factors, and the fact that rare forms of SVD do not affect survival before the 
reproductive years unfortunately muddy the waters, clouding our interpretation of the true 
impact of each variant.  
Other models of disease must also be considered: patients may require a ‘double hit’, or more 
than one mutation for the disease to develop. Patients may also have other rare variants that 
are ‘protective’ and prevent development of disease in context of presence of a disease-
causing mutation, further complicating our interpretation of the genetic picture. Mutations 
may not be as penetrant as expected, and individuals may require other genetic or 
environmental modulators in addition to the mutation in order to develop the disease.  
7.3.3 Controls, allele frequency and functional analyses 
In this thesis we have demonstrated the limitations of existing control databases. We have 
used patients with other rare diseases- which may or may not be related to one of these 





A truly ‘disease-free’ control cohort does not exist, and in the absence of a large set of age- 
and ethnicity-matched controls we run the risk of including pre-symptomatic individuals who 
are in fact affected. In Chapter 6 we also demonstrate how the ‘mutations’ shown to have 
deleterious effects on function in vitro may in fact simply be polymorphisms. Minor allele 
frequency or in-vitro functional studies alone are less helpful in the context of a rare disease 
with a later age at onset.  
In Chapters 4 and 6 we have also demonstrated that known disease-causing mutations may 
in fact be present in higher-than-expected frequencies in the general population. This 
highlights the importance of using different filtering strategies in addition to the minor allele 
frequency, which may inadvertently exclude disease-associated variants. As a corollary to this, 
we will also find ourselves reclassifying mutations as variants in light of more robust databases 
and functional analyses.  
We have also seen the limitations of in-vitro functional analyses used to illustrate the 
pathogenicity of variants identified in diseased individuals. Studies have shown clear evidence 
that the p.Gln1123Gly variant in COL4A2 is associated with impaired secretion of both 
COL4A1 and COL4A2 from the endoplasmic reticulum, as well as endoplasmic reticulum 
stress.159 With the availability of larger control databases this variant is now appearing to be 
a polymorphism rather than a rare, disease-causing mutation.  
7.4 Concluding Remarks 
In rare diseases we endeavour to discover a single rare variant to account for all of the 
features of disease, while GWAS studies examine the roles of common variants in common 
disease. It is likely that there also exist rare variants contributing to the heritability of common 
diseases, as well as variants with intermediate effect on disease at both ends of the spectrum. 
The involvement of genes such as COL4A1 and COL4A2 in both monogenic and sporadic 
SVD,157,166 and the presence of variants in genes associated with sporadic disease in pedigrees 
with familial disease highlights the possibility that the disease is not dichotomous. Instead, 
the lines between familial and sporadic disease are increasingly blurred and they may in fact 
belong to two ends of a single disease spectrum. This is in line with recent advancements in 
our understanding of the genetic basis of monogenic SVD, which points towards the 




phenotypes such as familial hemiplegic migraine may simply be different axes on a plane, 
along which patients lie at different positions manifesting each phenotype to different extents, 
depending on their genetic background and cardiovascular risk factors. It is likely that multiple 
distinct pathways lead to different manifestations SVD in different groups of patients.29 
In view of this changing landscape, a more flexible approach to phenotyping variants and 
sifting out variants identified on sequencing could be taken. For example, a family with 
‘familial disease’ may need to be assumed to have a multiple-gene disorder, while a middle-
aged patient with hypertension may in fact also have a monogenic disease. Examining the 
same pedigrees with different analytical approaches may thus allow us to better understand 
the true genetic basis of SVD. Arbitrary thresholds used in filtering large numbers of variants 
called may need to be adjusted in order not to be over-inclusive, or exclude true disease-
causing mutations. The same pedigree may thus need to be explored under multiple models 
or hypotheses. 
Despite the growing availability and falling costs of rapid sequencing approaches, our ability 
to make sense of the data produced has not kept up with the pace with which these 
technologies are becoming available to us in the clinic. Different approaches to phenotyping, 
sequencing, variant interpretation and validation, as well as the matching of phenotyped and 
genotyped cases from across the globe are needed in order for us to make further progress 
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